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Summary
Neurodegenerative diseases are common causes of dementia, which is defined
as a general decline in mental abilities severe enough to interfere with daily
life. The most common form of dementia is Alzheimer’s disease (AD), the most
common neurodegenerative movement disorder – also frequently accompanied by
dementia – is Parkinson’s disease (PD). Being age-related, progressive and up to
date incurable disorders, the global rise in life expectancy entails a strong rise
in case numbers, bringing along an enormous economical and emotional burden
for patients, their families and health systems.
On a molecular level, the cause for AD, PD and other neurodegenerative dis-
eases is reflected in the misfolding and aggregation of certain usually monomeric
proteins of the brain. Two examples of such proteins, described in detail in this
work are α-synuclein, a small presynaptic protein and tau, a group of proteins
involved in cytoskeleton dynamics. Several extrinsic and intrinsic factors can
contribute to the conformational templating of these proteins, leading to pro-
gressive aggregation, inflammatory reactions, cellular transport deficits, synap-
tic dysfunction and ultimately to cell death, the structural basis of symptoms in
neurodegenerative diseases.
Apart from transgenic mouse models, which have been used widely for the
study of neurodegeneration, a recent development involves the injection of patho-
genic protein aggregates directly into (brain) tissue, termed seeding and triggers
the molecular cascade of conformational templating and progressive protein ag-
gregation.
In the present work, two publications and one unpublished manuscript are
included which investigate to role of the pathogenic proteins α-synuclein and
tau in the light of structural brain plasticity and network function. The primary
method used was in vivo two-photon microscopy that enabled the chronic follow-
up of small neuronal structures like dendritic spines or the activity of single
neurons in the brain network over prolonged periods of time in living mice.
xix
Summary
The recently published study by Blumenstock et al. investigated the effects
of α-syn overexpression and α-syn seeding on dendritic spines, which are small
protrusions from neuronal dendrites corresponding to the postsynaptic compart-
ment of glutamatergic synapses. Chronic in vivo two-photon microscopy and ex
vivo confocal laser scanning microscopy was performed in mice expressing trans-
genic eGFP in a subset of neurons of the neocortex. In one part of the study,
dendritic spines on apical dendrites of the somatosensory cortex were analyzed
in vivo in mice overexpressing human α-synuclein. Compared to controls, these
mice showed reduced spine density, altered spine morphology and changes in
spine dynamics in an age-dependent manner. After progressive spine loss due
to a decreased fraction of gained spines in young mice, older mice showed no
further net spine loss over time at an overall reduced spine density compared to
mice expressing endogenous levels of α-syn. Spine morphology was found to be
changed accordingly. Another part of this study investigated for the first time
the impact of α-syn seeding on dendritic structures. The histochemical proper-
ties of α-syn inclusions developing predominantly in layer IV of the cortex after
seeding were found to resemble Lewy inclusions, as they were phosphorylated,
ubiquitinated and amyloid. Five months after intracerebral inoculation with
preformed fibrils, spine density was reduced on layer V apical dendrites of the
somatosensory cortex and spine morphology was changed towards relatively less
thin spines. Apical tuft dendrites were furthermore found to develop dystrophic
swellings following α-syn seeding. Summarized, these results provide new in-
sights about the dynamic changes in synaptic plasticity linked to the pathologic
accumulation of α-synuclein.
The study published by Hoffmann et al. investigated the impact of the tau
protein, which is implicated in several neurodegenerative tauopathies, includ-
ing Alzheimer’s disease and frontotemporal dementia (FTD). Mice overexpress-
ing human tau carrying the FTDP-17-linked mutation P301S were subjected to
chronic in vivo microscopy. The experiments revealed a reduced spine density
compared to controls, which was due to a decrease in the formation of new spines.
Spines showed morphological changes like an increased spine head volume, which
could represent a compensatory mechanism for spine loss to strengthen the re-
maining synaptic contacts. Moreover, the absence of detectable amounts of tau
xx
Summary
in dendritic spines indicate that axonal pathology and local network dysfunction
might cause spine impairments.
In the study by Marinković et al., the functional consequences of different
species of tau protein were investigated. As the exact nature of tau species
causing neuronal malfunction and degeneration are still not known, tau seeding
was used to induce the formation of neurofibrillary tangles in in a portion of
cortical neurons of P301S mice that normally don’t show prominent fibrillary tau
aggregation. By using chronic in vivo two photon microscopy, network activity
was measured in transgenic P301S mice with and without neurofibrillary tangles
formed after seeding. This approach also enabled intrinsically comparing the
activity of tangle-bearing neurons with the activity of their tangle-free neighbors.
It was shown that P301S cortical neurons are less active than WT neurons and
that this effect is independent of NFT presence.
In conclusion, the studies combined in this thesis provide new insights into
toxic role of misfolded, hyperphosphorylated and aggregated protein species that
are linked to the progression of neurodegenerative diseases. Dendritic spine
loss was demonstrated in two mouse models expressing high levels of soluble
α-syn or Lewy Body-like structures. Both studies on tau indicate that soluble
oligomeric species of tau are most likely linked to the malfunction and structural
degeneration of neurons. The chronic studies on synaptic plasticity furthermore
add important knowledge on synapse dynamics in α-synuclein and tau related
disorders, as they provide a link to the pathophysiology underlying dementia.
xxi
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Introduction
1
1. Introduction
1.1 Neurodegenerative diseases
Speaking in terms of global health, mankind in the 21. century has benefited
from growing wealth, improved hygiene and advanced medical care, all of which
contributes to population growth and the rise in life expectancy — especially in
developing countries [3]. On the other hand stands a considerable increase in
cases of neurodegenerative diseases like Alzheimer’s Disease (AD) and Parkin-
son’s Disease (PD), for which advanced age is the major risk factor. Pathological
changes of the nervous system lead to a certain dissociation of body and mind in
form of motor and mental impairments and present great personal hardship for
affected individuals and their families. Medical treatment is frequently hampered
by the lack of a correct diagnosis and even if such exists, only symptomatic treat-
ments are available on the market up to date. In order to regulate the enormous
financial, societal and emotional burden of these brain disorders, the thorough
scientific understanding of neurodegenerative diseases is of utmost importance
for the development of preventive measures and curative therapies.
Neurodegenerative diseases are commonly sporadic and, less frequently, ge-
netic pathological events which can affect a population of neuronal cells or the en-
tire central nervous system (CNS). The slow progressive loss of neuronal function
ranges from initial synaptic dysfunction to extensive neuron death with resulting
brain atrophy and the according implications for the patient. This heterogeneous
group of disorders can be roughly categorized according to their symptoms into
dementias and movement disorders or alternatively according to their molecu-
lar biology into proteinopathies like α-synucleinopathies, tauopathies, Aβ pro-
teinopathies, polyglutamine repeat diseases, TDP-43 proteinopathies, and prion
diseases, as outlined in Table 1.1 (adapted from [4]).
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Toxic Protein Familial Linked Sporadic Genetic
protein deposit disease gene disease risk factor
α-synuclein Lewy bodies Familial PD SNCA PD SNCA polymprphism
Lewy neurites DLB MAPT haplotype
Glial cytoplasmic Not identified Not MSA Not identified
inclusions applicable
Tau Neuronal and FTDP-17 MAPT AD and MAPT haplotype
glial inclusions tauopathies
β-amyloid Senile Familial AD APP AD Apoe4
(Aβ) plaques PS1
PS2
Polyglutamine Nuclear and Huntingon’s HD Not applicable Not identified
repeat cytoplasmic Disease
expansion inclusions
TDP-43 TDP-43 inclusions Autosomal TARDBP Sporadic Not identified
SOD Hyaline inclusions dominant SOD1 ALS
FUS FUS inclusions familial ALS FUS
PrPSC Protease- Familial prion PRNP Sporadic prion PRNP polymorphism
resistant PrPe protein disease protein disease
Table 1.1. Neurodegenerative diseases grouped by the deposition of aggregated proteins
1.2 Parkinson’s Disease as the most common
synucleinopathy
200 years after James Parkinson’s essay on the shaking palsy [5], which was
the initial formal description of the disorder now bearing his name, Parkinson’s
Disease (PD) has received an enormous and increasing amount of attention.
Together with dementia with Lewy Bodies (DLB) and multiple system atro-
phy (MSA), these diseases are classified as synucleinopathies. Today, PD is the
second most common neurodegenerative disorder [6] after Alzheimers disease,
affecting over 1.5% of the world population over 65 years of age (reviewed by
[7]). The predominant sporadic form of PD also called idiopathic PD usually
commences at an age between 50 and 60 years and is foreshadowed by a consid-
erable preclinical period, estimated to last 5 up to 20 years before the first onset
of motor symptoms [8, 9, 10]. In contrast, the rarer genetic forms of PD make
up 2-3% of the late-onset cases and about 50% of the early-onset cases (reviewed
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by [11, 12]).
In his essay based on the study of six cases, James Parkinson described the
major motor symptoms characterizing this disease [5], including rest tremor,
slowness of movement (bradykinesia), rigidity, postural and gait impairment,
festination, falls, soft speech, dysphagia and saliva trickling from the mouth. As
motor networks are not the only parts of the brain affected by the progressive
neurodegeneration, there is a great spectrum of non-motor symptoms [13] as
well, including sleep disturbances [14], olfactory dysfunction [15], psychiatric
disorders [16] and digestive disturbances [17]. Cognitive dysfunction is also a
very common occurrence, its severity ranging from mild cognitive impairment
to dementia. In fact, dementia is a frequent symptom in the terminal stages of
PD [18]. One of the largest prospectively followed PD autopsy series found that
80% of patients with PD develop dementia after 20 years [19].
After Parkinsons initial description, it took 150 years until the underlying
biochemical changes in the brain – the loss of striatal and nigral dopamine –
were identified [20, 21] and the first effective treatment, i.e. the introduction of
high-dosage levodopa, was developed [22]. The cellular basis of the dopamine
neurotransmitter deficiency was determined to be the loss of neurons in the
basal ganglia and more precisely, in the substantia nigra pars compacta (SNpc)
[23, 24] (Figure 1.1 A). Apart from SNpc neuron loss, the gold standard for
the post mortem diagnosis of many synucleinopathies is the presence of dense
proteinaceous aggregates called Lewy bodies. They consist of abnormal accu-
mulations of the protein alpha-synuclein (α-syn), neurofilament, ubiquitin and
other proteins and form round cytoplasmic inclusions (Lewy bodies, LBs) and
elongated neuritic inclusions (Lewy neurites, LNs) [25, 26] (Figure 1.1 B-D).
The ultrastructure of these intracellular accumulations with a dense eosinophilic
center and a pale halo was described as early as 1865 by Duffy and Tennyson;
the connection to PD, however, originates from the German neurophathologist
Friedrich Lewy [27]. LBs display a dense network of fibrillary, amyloid polymers
with a typical β-sheet protein structure, which can be stained specifically with
congo red derivatives and Thioflavin S and are resistant against proteinaceous
digestion [28, 29]. Additionally, pale bodies are considered precursors of LBs and
represent another neuropathological hallmark in PD brains. They are pallid cy-
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toplasmic inclusions with a less eosinophilic structure than LBs and are without
a halo [30].
Dopaminergic neuron loss has functional consequences on two efferent net-
works which control the fine tuning of motor function (see Figure 1.1 E, reviewed
by [31]) and this gives rise to the motor symptoms: (1) the direct pathway via the
internal globus pallidus, facilitating movement and (2) the indirect pathway via
the external globus pallidus and the subthalamic nucleus, which repress motor
action. Dopamine release in a healthy individual increases the contribution of
the direct over the indirect pathway, thereby facilitating movement. The balance
between the two efferences was thought to be controlled through feedback from
the SNpc and the ventral tegmental area to the striatum via differential expres-
sion of dopaminergic receptors of the D1 or the D2 type. The degeneration of
dopaminergic neurons in the SNpc leads to a superfluous inhibitory contribution
of the basal ganglia to the thalamus, which in turn causes a diminished thalamic
activation of neocortical motor neurons. Their reduced activity finally results
in the attenuated motoric abilities (hypokinesia) [32]. The precise reasons for
the increased vulnerability and selective loss of dopaminergic neurons are not
entirely clear, but there is reason to believe that oxidative stress and toxic pro-
tein aggregation are mechanisms that lead to neuronal damage and, ultimately,
neuronal death [33, 34, 35].
Based on the topographical extent of lesions in the brains from PD patients,
the course of pathology can be traced and categorized into six stages according to
Braak et al. and is illustrated in Figure 1.1 F. The stages describe the histologi-
cal state of the brain from incidental to symptomatic PD. Lesions initially occur
in the brainstem, the anterior olfactory nucleus and in the enteric nervous sys-
tem, during the pre-symptomatic phase of the disease. The spread of pathology
gradually follows an ascending course to the midbrain in stage 3 where it gives
rise to the prominent motor phenotype and later involves associative cortical
regions [38]. In the recent years, evidence has pointed out that the presence of
LBs might likely just be the tip of the iceberg rather than the cause of neurode-
generation. In fact, Kramer and Schulz-Schäffer showed that presynaptic α-syn
oligomers and micro-aggregates might be responsible for neurodegeneration as
well as for synapse loss observed in post-mortem DLB brains rather than LBs,
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Figure 1.1. The Parkinson’s Disease brain. A. The midbrain from a PD patient (left) shows
depigmentation due to the loss of melanin-containing neurons in the substantia nigra pars com-
pacta compared to a healthy control (right) [36]. B-D. The typical microscopic pathology in PD
brains contains Lewy Bodies (B), pale bodies (C) and Lewy neurites (D) [37]. E. Left: The in-
put from two efferent pathways determines the output of the basal ganglia and the fine-tuning of
movement. Right: Recent anatomical studies have drawn a more complex picture of connections in
the midbrain, which complicates the prediction of how the transformation of inputs generates out-
puts. GPe/i, globus pallidus externa/interna; SNpc/r, substantia nigra pars compacta/reticulata;
STN, subthalamic nucleus (adapted from [31]). F. The staging of Parkinson’s Disease according
to Braak [38]. dm, dorsal motor nucleus of the glossopharyngeal and vagal nerves; co, coeruleus-
subcoeruleus complex; sn, substantia nigra; mc, anteromedial temporal mesocortex; hc, high order
sensory association areas and prefrontal fields; fc, first order sensory association areas, premotor
areas, primary sensory and motor fields.
which might represent a protective mechanism to sequester smaller and more
toxic α-syn aggregates [39].
With the latest addition from 2016 [40], 23 so-called PARK loci have been
identified that have been shown to be related to genetically linked parkinson-
ism. Mutations and deletions in these genes can lead to dysfunctions of synapses,
mitochondria, intracellular signal cascades or lysosomal or proteasomal degrada-
tion mechanisms, thereby paving the way for synaptic and neuronal degeneration
(reviewed by [41]).
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1.2 Parkinson’s Disease as the most common synucleinopathy
1.2.1 The alpha-synuclein protein
The SNCA gene encodes for the 140 amino acid alpha-synuclein (α-syn) protein,
which is highly conserved in the central nervous system. Along with its discovery
in the pacific electric ray (Torpedo californica) [42], α-synuclein was named after
its presence at both the synapse and nucleus [43, 44].
The protein sequence of α-syn can be divided into three overlapping regions:
(1) the N-terminal region (aa 1 – 95) comprises seven imperfect 11 amino acid re-
peats (XKTKEGVXXXX) which can form an amphiphatic alpha-helix for mem-
brane interaction, (2) the central hydrophobic NAC domain (non-amyloid beta
component of AD amyloid plaques, aa 61 – 95) which confers the beta-sheet po-
tential and (3) the acidic and amphipathic C-terminal region (aa 96 – 140) with
an unfolded conformation (reviewed by [45, 46]). The α-syn protein sequence
subdivision is illustrated in Figure 1.2. Among the three identified members
of the synuclein family (alpha, beta and gamma-synuclein), α-syn structurally
stands out by its NAC domain. Apart from that, all three synucleins are neu-
ronal proteins that localize preferentially to presynaptic terminals [43, 47].
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Figure 1.2. Structure of α-synuclein. α-syn is a 140 amino acid, 14.5 kDa protein devided into
three domains: the amphipatic N-terminal region; the hydrophobic and aggregation-prone NAC
domain; and the acidic C-terminal region. All pathogenic missense mutations described up to date
are localized to the N-terminal region, while most disease-related phosphorylation sites are in the
C-terminal region. Both mutations and posttranslational modificataions may interfere with the
physiological conformation of α-syn and facilitate fibrillization. Adapted from [48].
α-syn can adopt a great variety of conformations, exhibiting dynamic changes
depending on its environment. In solution, α-syn is present as a natively unfolded
monomer, lacking a uniform tertiary structure [49]. In the presence of acidic lipid
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membranes [50] or membranes with a high curvature [51], the N-terminal domain
of α-syn folds into an α-helical structure for membrane interaction. Therefore, it
seems that α-syn conforms to its physiological structure and function primarily
in the presence of its molecular interacting partners. Beyond that, α-syn can
interact with other α-syn molecules to form multimers. It is currently controver-
sially debated whether α-syn physiologically also exists as a tetramer [52] and
whether this conformation might represent a molecular strategy for ”safe” stor-
age prior to its biological functions. Moreover — and relevant for the pathologic
state — there is α-syn self-assembly into β-pleated sheets and the formation of
insoluble aggregates [53]. The aspects of protein aggregation are introduced in
detail in section 1.4
Around the turn of the millenium, studies led to the notion that α-syn func-
tions as a modulator of synaptic transmission. The expression of the protein is
induced during development and lags behind proteins involved in the establish-
ment of synaptic structure [54, 55]. Furthermore, α-synuclein expression levels
are changed in conditions with altered synaptic plasticity or neuronal injury
[56, 47]. In the presynaptic terminal, α-syn was shown to move away from vesi-
cles upon repeated neuronal firing, to gradually return later. It was therefore
suggested that α-syn acts as a negative regulator for neurotransmitter release
[57] through transient binding to synaptic vesicles [58] and regulating the read-
ily releasable synaptic vesicle pool [59]. Other studies suggest a direct inter-
action between α-syn and SNARE (soluble NSF attachment protein receptor)
proteins. These receptors are — together with Sec1/Munc-18-like proteins —
crucial for controlling the membrane fusion mechanism during neurotransmit-
ter release [60]. The role of α-syn includes vesicular trafficking to, and docking
with, the presynaptic membrane [61, 62], as well as vesicular endocytosis [63].
It is believed that α-syn acts in synergy with CSPα in a chaperone-like fashion
for SNARE-complex assembly [64] and that this process involves its binding to
synaptobrevin-2 [61]. These functional aspects are illustrated in Figure 1.6. The
interaction of α-syn with a vast number of proteins involved in dopamine biosyn-
thesis and handling furthermore strongly suggests a specialized role of α-syn in
the dopaminergic synapse (reviewed by [65]).
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1.3 Tauopathies by the example of Alzheimer’s
Disease
Most prominent among this heterogenous group of dementias — which are
termed tauopathies — stands Alzheimer’s Disease (AD), being diagnosed in 50-
75% of patients. Another 5-10% of dementia patients suffer from Frontotemporal
lobar dementia (FTLD), but many other diseases may also be accompanied by
tauopathy, including Down Syndrome, Pick’s Disease, ALS and parkinsonism
linked to chromosome 17 (FTDP-17) (reviewed by [66, 67]).
The recognition of Alzheimer’s Disease as a disorder originates back to the
German psychiatrist and neuropathologist Alois Alzheimer and his patient Au-
guste Deter, who presented herself with cognitive impairment and disorientation
in time and space [68]. Today we know that dementia associated with Mor-
bus Alzheimer typically starts as mild cognitive impairment slowly progresses
over several years, making patients dependent on care in the late stages [69].
After Auguste Deter’s death at 55, Alzheimer was also the first to describe
the two neuropathological characteristics found in the brains of AD patients:
amyloid plaques and neurofibrillary tangles (NFTs) (Figure 1.3 A-D). Plaques
consist mainly of aggregated Aβ amyloid peptides being cleavage products of
the amyloid precurser protein (APP). NFTs are intracellular aggregates of the
microtubule-associated protein tau, which is hyper-phosphorylated and forms
so-called paired helical filaments. NFTs are also typical for other tauopathies,
including Down’s syndrome, progressive supranuclear palsy, Pick’s disease and
several disorders with parkinsonism [70].
Furthermore, the loss of neurons and synapses can be observed in the AD
brain. In combination with the degeneration of neurites, these pathogenic pro-
cesses are responsible for the macroscopic brain atrophy present in AD (reviewed
by [72]). Neurons of the hippocampus, the connected entorhinal cortex and the
frontal, parietal and temporal neocortex degenerate in particularly great measure
[73, 74, 75]. Accordingly, synaptic loss can be observed both for the presynaptic
and the postsynaptic compartments in AD brains and highly correlates with the
severity of cognitive impairment [76, 77].
9
1. Introduction
A B C
D
E stages I-II
stages III-IV
stages V-VI
Figure 1.3. The Alzheimer’s Disease brain. A. Histological brain section from Auguste Deter,
which was kindly provided by Prof. Dr. h.c. Hans Kretzschmar for microscopic imaging, as depicted
in B-D at the Center for Neuropathology and Prion Research. B. Bielschowsky silver staining to
show the neuropathological characteristics in AD brains. C. Amyloid plaques and D. Neurofibrillary
tangles. E.The staging of AD according to Braak. Adapted from [71].
The sequence of events which lead to the deposition of Aβ amyloid plaques
and tau NFTs can be summarized with the amyloid cascade hypothesis. At
its beginning stands the proteolytic processing of the amyloid precurser protein
(APP), which is an ubiquitously expressed integral membrane protein and can be
cleaved in one of two pathways. Non-amyloidogenic cleavage involves the metal-
loprotease ADAM10 (a disintegrin and metalloprotease 10) and γ-secretase and
produces the APP intracellular domain and a short extracellular fragment called
p3. The amyloidogenic pathway in contrast involves cleavage by the β-secretase
BACE1 (β-site APP cleaving enzyme 1) followed by γ-secretase and yields the
APP intracellular domain and the longer extracellular Aβ peptide. Especially
the 42-amino-acid long Aβ42 peptide is prone for aggregation, if produced ex-
cessively (reviewed by [78, 79]). Successive Aβ aggregation over time can then
cause synapse damage, immune reaction in form microglial and astrocytic acti-
vation and phosphorylation of tau, which in turn aggregates over several toxic
intermediate forms to finally form NFTs [80, 81].
Similar to the staging of Parkinson’s disease, the tau pathology follows a de-
fined pattern of spatial development across brain regions which are grouped into
six Braak Stages. The first tau aggregates are formed in the entorhinal and trans-
entorhinal cortex (stages I and II), followed by the hippocampus (stages III and
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IV) and the neocortex (stages V and VI), as illustrated in Figure 1.3 E [82, 83].
The involvement of tau in the onset and the progression of Alzheimer’s disease
in not entirely clarified. Nevertheless, there is strong evidence of a causative
relation between insoluble tau aggregates and neurodegeneration (reviewed by
[84]). The extent of tau pathology usually correlates better to cognitive decline
than the extent of amyloid plaque deposition (reviewed by [85]). This is the
reason why tau pathology is routinely assessed for staging in post mortem AD
brains.
1.3.1 The tau protein
Tau (from: tubulin associated unit) is a microtubule (MT)-binding protein and
localized particularly to axons of the CNS [86]. Alternative splicing of the MAPT
gene (from: microtubule associated protein tau [87]) localized on chromosome
17q21 and containing 16 exons results in 6 isoforms of the tau protein [88].
These consist of 3 or 4 C-terminal repeat regions for MT binding (3/4R tau)
and a certain number of N-terminal regions (0/1/2N tau), as shown in Figure
1.4. The adult human brain expresses all six isoforms at approximately a one-
to-one ratio of 4R to 3R tau [89]. Natively unfolded tau protein binds to MTs
through interaction between amino acids within its repeat domains and α- and
β-tubulin molecules. This interplay promotes MT formation and stability [90].
Consequently, 4R tau has a higher affinity for binding to microtubules than 3R
tau, owing to the additional repeat domain [91].
The MT-binding ability of tau is also regulated by posttranslational modifi-
cations, primarily through phosphorylation, but other modifications of tau have
been reported as well (reviewed by [92]). Phosphorylation of tau leads to its de-
tachment from MTs and is controlled by a balance in phosphorylase and kinase
activities. Although tau-binding stabilizes MTs and is essential for their in-
tegrity, it also represents a physical obstacle for vesicles and other forms of cargo
transported along the MT. Therefore, frequent cycles of tau phosphorylation,
leading to its detachment from the MT and dephosphorylation, and, promot-
ing its binding, occur to enable efficient cellular transport and rearrangement
of MTs (reviewed by [93]). Particularly when detached from MTs, tau can also
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Figure 1.4. Structure of tau. Alternative splicing of the N1, N2 and R2 regions yields 6 different
tau isoforms, which contain an acidic N-terminal region and a tubulin binding region. The majority
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Adapted from [48, 67].
bind to a heterogeneous population of other structures and enzymes, including
RNA, presenilin 1 (PS1) and the plasma membrane [94, 95, 96] which ultimately
might lead to protein misfolding and aggregation [97].
With its ability to modulate MT-dynamics, tau therefore directly or indi-
rectly contributes to cellular structure and function. In vitro experiments have
shown that tau-mediated axonal transport is necessary for synapse maintenance
as the mislocalization of tau to the somatodendritic compartment causes synapse
degeneration [98, 99].
1.4 Misfolded proteins in neurodegenerative dis-
eases
Growing evidence reveals a common pathogenic mechanism underlying many
neurodegenerative disorders: the misfolding of distinct proteins and their aggre-
gation and deposition in nervous tissue is associated with progressive CNS amy-
loidosis. Generally speaking, soluble or natively unfolded proteins change their
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conformation, adopt a β-sheet-rich structure and form growing disease-specific
fibrillar aggregates which are deposited extracellularly, in the cytoplasm, in the
nucleus or in neurites (Figure 1.5). In most cases, this process develops over
an entire lifetime and doesn’t manifest clinically before middle or late life. In
healthy individuals, refined cellular quality-control measures like molecular chap-
erones promote proper protein folding and the ubiquitin-proteasome system or
the autophagy-lysosomal system degrade any proteins that remain misfolded
[100]. It is still not entirely understood what ultimately causes the defect of
these control measures, but mutations in certain disease-related genes can speed
up the process of protein aggregation, by directly facilitating the propensity of
resulting proteins to aggregate or by interfering with the physiological processing
of amyloidogenic proteins.
Intranuclear inclusion
(polyQ expansion)
Intracytoplasmic inclusion
(NFTs, Lewy bodies)
Extracellular aggregate
(senile plaques)PeptidesAutophagy
Native protein
(random coil)
Misfolded 
proteins
Oligomers
(ß-pleated sheet)
Fibrils
(ß-pleated sheet)
Ubiquitination
ProteasomePhagosomes/
lysosomes
Genetic and 
environmental factors
Molecular
chaperones
Figure 1.5. Misfolded proteins in neurodegenerative diseases. Native proteins can misfold,
aggregate and fibrillize, leading to the formation of protein aggregates in the nucleus, the cytoplasm
or the extracellular space. Genetic and environmental factors may facilitate this process, whereas
cellular quality-control measures like molecular chaperones, autophagy or the ubiquitin-proteasome
system act as a counterbalance and limit the accumulation of misfolded protein. Adapted from [4].
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1.4.1 Contributors for the misfolding of proteins
Familial forms of parkinsonism can be caused by point mutations in the SNCA
gene that lead to pathogenic amino acid substitutions in the protein (A30P,
E46K, H50Q, G51D, A53E or A53T) [101, 102, 103, 104, 105, 106] (see 1.2).
Duplication or triplication of the SNCA gene [107, 108] can also result in PD
or DLB, which indicates that a 50 % increase in protein expression suffices to
trigger the disease [109]. This is consistent with the notion described above that
the conformational templating of α-syn is initially an energetically unfavorable
process with a long lag-phase, which can be however overcome by a higher abun-
dance of α-syn leading to a greater stochastic formation of aggregates. α-syn
protein with the A30P, A53T, H50Q and E46K mutations have been reported to
increase the rate of aggregation and to more readily form protofibrils and fibrils
than the WT protein [28, 110, 111]. The A30P mutation has also been shown to
directly disrupt the association of α-syn with membranes as well as its synaptic
localization [112]. Furthermore, environmental factors such as the exposure to
the complex I inhibitor rotenone induces oxidative stress, which causes nigros-
triatal dopaminergic degeneration and promotes the formation of Lewy bodies
[113]. On the contrary, both the A53E and G51D mutations were described
to reduce the intrinsic propensity of α-syn to aggregate [114, 115], despite still
causing early-onset PD with α-syn pathology [104, 106].
The neuropathology of AD is characterized by two types of lesions. NFTs
form in the cytoplasm and consist of aberrantly phosphorylated tau, whereas
senile plaques are extracellular depositions consisting largely of β-amyloid (Aβ).
Mutations of both the amyloid precursor protein (APP) and presenilin (PS1 or
PS2) ultimately lead to an increased production of the amyloidogenic Aβ42 cleav-
age product of APP, which readily fibrillizes to gradually form senile plaques, as
outlined in the amyloid cascade hypothesis of AD [81].
The number of pathogenic mutations known for tau are somewhat larger
than for the α-syn protein. Although the deposition of tau is secondary after
Aβ accumulation in the amyloid cascade, it has a stronger causal relationship
to neurodegeneration [84]. Under pathologic conditions, the balance of the MT-
tau protein binding is disturbed, leading to an increase in the level of unbound
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tau, which is prone to aggregate with further tau molecules and other proteins.
This significantly affects the control of MT-dynamics and impairs axonal trans-
port. Tau hyperphosphorylation, misfolding and progressive aggregation can
be triggered by several pathogenic events, including over 30 known mutations
in the MAPT gene (see Figure 1.4). A direct relationship between splice-site
and missense mutations such as G272V, P301L and R406W and filamentous,
hyper-phosphorylated tau inclusions were initially reported for cases of FTD
with parkinsonism linked to chromosome-17 (FTDP-17) [116, 117]. Mutations
in exon 10 also often perturb the balanced one-to-one ratio of the 4R and 3R tau
isoforms, favoring the expression of the 4R isoform in most cases and thereby
affecting MT-binding affinities and increasing the propensity to aggregate [89].
Finally, the ability of many cofactors promoting the misfolding and fibrilliza-
tion of tau may explain in part the presence of tau deposits in many different
neurodegenerative diseases.
Despite their clinically distinct features, there is increasing evidence for the
considerable overlap of synucleinopathies and tauopathies, which might share a
mechanistic link. On the one hand, 50-60 % of AD patients with NFTs also have
α-syn-containing Lewy bodies [118, 119, 120]. Moreover, 50 % of AD patients
displaying extrapyramidal signs show considerable co-localization of α-syn and
phospho-tau pathology in the substantia nigra [121, 122]. On the other hand,
a co-staining of phospho-tau with α-syn has been observed in 30-40 % of the
Lewy bodies in the nucleus basalis of Meynert and the locus coeruleus [123],
and in 10-30 % of LBs in the medulla [124] of PD and DLB patients. Other
studies showed the overlap of phospho-tau with α-syn pathology in FTLD and
progressive aphasia [125], in the Parkinsonism-Dementia complex of Guam [29]
and in PD patients with the A53T α-syn mutation [126]. Furthermore, axonal
deficits are not a unique feature of tauopathies, but have been described in
numerous neurodegenerative diseases including synucleinopathies (reviewed by
[127]). So there is ample reason to believe that no simplistic linear pathways lead
to the one or the other neurodegenerative disorder, but that multiple intrinsic
and extrinsic factors contribute to the individual disease process of patients. In
fact, a regression model considering cortical Aβ, tau and α-syn pathologies more
accurately predicted dementia than any one of the single markers alone [128].
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1.4.2 Cell-to-cell propagation and spreading of misfolded
proteins
The spatiotemporal sequence of LB and NFT pathology in PD and AD has lead
to the hypothesis that progression is related to the cell-to-cell propagation of
pathogenic proteins like α-syn and tau and their templated misfolding. Sup-
port for this idea came from observations in patients with PD who received
implants of fetal graft neurons into the striatum to compensate for the degener-
ated dopaminergic neurons of the SNpc [129]. The post mortem analysis of these
brains showed α-syn pathology in the transplanted neurons, which indicated a
spread of pathology from other neurons. Furthermore, the ascending distribu-
tion of α-syn and tau pathology in patient brains as described by Braak [38, 82]
can be interpreted as representing the dissemination of α-syn and tau across
connected brain regions. Further support comes from the case of a woman who
died from AD at the age of 85 and whose cortex was partly disconnected from
the rest of the brain during surgery 20 years earlier [130]. In contrast to other
brain areas, this isolated brain region contained no amyloid plaques or NFTs,
which highlights that the spread of pathology requires connection.
The cell-to-cell propagation hypothesis was experimentally challenged in a
number of cell culture studies. Using transfection reagents driving membrane
permeability, the addition of a small amount of exogenous α-syn preformed fibrils
(PFFs) provokes cells expressing endogenous α-syn to develop amyloid inclusions
[131, 132, 133]. Thereafter, a study on α-syn demonstrated that the sole addi-
tion of PFFs to primary neurons is sufficient to induce inclusion formation [134].
The first cellular experiments on the influence of extracellular tau on intracellu-
lar tau exposed human fetal cortical cultures to brain extracts from AD patients
to show that the cells developed inclusions similar to paired helical filaments
(PHFs) [135]. Later, cultured cells were described to take up aggregated, but
not monomeric, tau and to develop intracellular fibrils, which in turn were com-
petent to seed fibril formation in vitro [136]. Intracellular tau inclusions were
furthermore demonstrated to molecularly resemble tau in human NFTs [137]
and also that pathologic inclusions can be nucleated by PFFs in primary neu-
rons [138]. Apart from cellular models, animal models are widely used to study
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the spreading of α-syn and tau pathology and are outlined in section 1.6.1.
Although the misfolded proteins characteristic of neurodegenerative diseases
do not reach the infectiousness of prions, they share some features and molec-
ular modes of behavior. On top of being able to propagate, there is increasing
evidence for the existence of strains. This implicates that pathologic aggregates
featuring specific molecular traits can be recovered from host cells or organisms
and reintroduced into näıve cells where they re-establish identical pathology.
α-synuclein, for instance, was shown to adopt distinct conformations produc-
ing characteristic fibril shapes depending on the physical conditions during fib-
ril production [139]. Injected into rat brains, these strains display differential
seeding capacities and cause distinct histopathological phenotypes [140]. In a
recent study from the tauopathy field, tau aggregates from 5 different human
tauopathies were also associated with different sets of strains. The introduction
of these strains into cells bearing aggregation-prone mutated tau lead to the for-
mation of inclusions with unique morphologies, which could also be successfully
passaged over 6 months [141]. From this evidence it is tempting to believe that
the unique conformations of α-syn or the tau proteins might also be responsible
for the varied types of synucleinopathies and tauopathies, but this remains the
subject of further study.
1.5 The glutamatergic synapse
The human brain is one of the most complex structures known and it contains
almost one hundred billion neurons and an estimated hundred trillion (1014) spe-
cialized junctions called synapses (reviewed by [142, 143]). Synapses are local
sites for signal transduction and plasticity within the brain and the majority
form at contacts between presynaptic axons and postsynaptic dendrites and
use glutamate as neurotransmitter, making glutamatergic neurons the princi-
pal excitatory system in the brain. The architecture of glutamatergic synapses
comprises a presynaptic compartment, the synaptic cleft, and a postsynaptic
compartment, typically a dendritic spine. The structure and function of a glu-
tamatergic synapse and the involvement of tau and α-syn proteins is illustrated
in Figure 1.6.
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1.5.1 The presynapse
The presynapse is the point of arrival for action potentials originating in the
neuronal cell body and traveling along the axon. It contains mitochondria and
numerous synaptic vesicles, often bound to the presynaptic cytoskeleton. Their
life-cycle at the synapse includes various proteins that mediate their transport,
interaction with the cytoskeleton, uptake and storage of neurotransmitter, reg-
ulated interaction and fusion with the plasma membrane at the presynaptic
active zone and finally their recycling (reviewed by [144]). In functionally ma-
ture glutamatergic synapses, the presynaptic compartments are enriched with
glutamate-filled synaptic vesicles and specialized active zones that reinforce the
release of glutamate into the synaptic cleft (reviewed by [145]). Glutamate is
released from the presynaptic terminal upon the arrival of an action potential.
The opening of voltage-gated Ca2+ channels cause a local increase of Ca2+ ions
in the presynapse, leading to a cascade of events that finally cause vesicles of the
presynaptic active zone carrying glutamate to fuse with the presynaptic mem-
brane and release glutamate into the synaptic cleft. At the postsynaptic mem-
brane, glutamate acts upon postsynaptic glutamate receptor channels, mainly of
the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and NMDA
(N-methyl-D-aspartate) type (reviewed by [145]).
Parallel pre- and postsynaptic intracellular signaling cascades can trigger
protein synthesis and simultaneous control of synaptic plasticity. The isolation
and molecular analysis of the synaptic compartment has naturally been of great
interest for researchers. Half a century of research using subcellular fractionation
of brain tissue and protein identification has led to a certain understanding of
the synaptic proteome [144].
1.5.2 The postsynapse and structural plasticity
”...the surface...appears bristling with points or short spines” [146]. These words
from 1888 by the legendary spanish neuroanatomist Ramón y Cajal refer to the
first description of dendritic spines on a Purkinje neuron. Since then, technical
advances have broadened our knowledge of the structure and function of these
small protrusions from the dendritic shaft. Today we know that most excitatory
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synapses in the mature mammalian brain occur on dendritic spines and that
a spine head typically contains the input of a single synapse. Dendritic spines
protrude from the dendritic shaft and are typically 0.5 – 3 μm in length and up
to 0.8 μm3 in volume (reviewed by [147]).
On the ultrastuctural level, an electron-dense structure called the postsynap-
tic density (PSD) is associated with the spine membrane facing the synaptic cleft.
It consists of structural proteins, neurotransmitter receptors of the AMPA and
NMDA types and proteins for signal transduction. Additionally, spines contain
a cytoskeleton, polyribosomes and smooth endoplasmatic reticulum which can
fold into a structure known as the spine apparatus [148, 147]. Spine morphol-
ogy displays great heterogeneity; apparent even on single dendrites [151, 152].
Based on detailed anatomical analysis of fixed tissue, the morphological subtypes
mushroom, stubby and thin have been defined [153, 154]. Mushroom spines have
a large, bulbous head that is connected to the dendrite through a narrow spine
neck, whereas thin spines have a smaller head. Stubby spines lack the spine neck
and appear as round elevations from the dendritic shaft. In addition, filopodia
are very long and thin structures that lack a spine head. They are considered
precursors of dendritic spines and are the most dynamic of dendritic structures,
which protrude and retract rapidly from the dendritic shaft and only sometimes
develop into one of the other spine types [152, 155]. Importantly, dendritic spine
density, shape and size are remarkably dynamic and known as structural plas-
ticity. Changes occur over timescales ranging from seconds to minutes and from
hours to days [156] but tend to become increasingly stable in mature neurons
[157]. Morphological changes of spines are also tightly linked to their content of
organelles and specific molecules. As the size of the spine head correlates with
the size of the PSD, it also correlates with the amount of postsynaptic receptors
[158], the number of docked presynaptic vesicles [159] and therefore the strength
of synaptic transmission.
The spine head represents a biochemically and electrically isolated compart-
ment, in which reactions and electric potentials occur. Ex vivo studies have
shown that high-frequency stimulation of the presynapse inducing long-term po-
tentiation (LTP) leads to an increase in spine volume [160, 161] as well as to the
de novo formation of spines [162, 163, 164]. 15-19 hours after LTP, newly formed
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Figure 1.6. The glutamatergic synapse. A. Microtubules are composed of α- and β-tubulin
arranged into cylindrical polymers and provide structural support to neurons. The protein tau can
bind to MTs via its tubulin-binding motifs in the 3 or 4 repeat domains. Phosphorylation of Tau by
kinases at a number of serine or threonine residues attenuates its binding to microtubules as well
as their stability. Adapted from [93]. B. Overview of the function of α-syn for SNARE-complex
assembly. α-syn binds to synaptobrevin on synaptic vesicles. Munc18-1 is bound in a closed
conformation to the membrane-anchored syntaxin-1. SNAP-25 remains in a state competent for
membrane fusion by interacting with its co-chaperones CSPα, Hsc70 and SGT. Upon vesicle fusion
with the plasma membrane, the full SNARE complex is assembled, which is orchestrated in parts by
the Munc proteins and assisted by α-syn through yet to be determined interactions. After fusion,
the SNARE complex is disassembled by SNAPs and NSF and synaptobrevin is recycled back to vesi-
cle membranes. CSP, cysteine string protein; NSF, N-ethylmaleimide sensitive factor; SGT, small
glutamine-rich protein; SNAPs, soluble NSF adaptor proteins; SNARE, SNAP receptor; SNAP-25
synaptosomal associated protein of 25 kDa. Adapted from [149]. C. Synaptic components impor-
tant for signal transmission and plasticity. Action potentials arriving at the presynaptic terminal
cause Ca2+ influx through voltage-gated calcium channels, which mediates glutamate release. At
the postsynaptic side, ionotropic AMPA receptors anchored in the structural support of the PSD
convert the chemical glutamatergic signal back to an electric signal, activating NMDA receptors
and causing postsynaptic Ca2+ influx. This activates signal cascades enabling the synapse to adapt
its reactivity and plasticity in the long term. This is also mediated by local translation and dynamic
trafficking of receptors to and from the membrane facing the synaptic cleft. Adapted from [150].
D. Spine morphology classes as seen with confocal microscopy.
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spines also have developed ultrastructural features of mature synapses, such as
an attached and vesicle filled presynaptic bouton and a synaptic cleft [165]. In
contrast, low-frequency presynaptic stimulation inducing long-term depression
(LTD) results in spine shrinkage [166, 161] and reduced neuronal activity causes
a loss of spines [162]. Being the first postsynaptic element encountered by the ex-
citatory neurotransmitter, spines play a pivotal role in the integration of synaptic
input and by their plasticity in learning and memory [167]. In disorders like PD
or AD, in which synapses degenerate with and even before neurons [168, 169],
the study of synaptic plasticity can therefore give import insights about the
pathophysiology of these diseases.
1.6 In vivo two-photon imaging
As life is inherently dynamic, the microscopy of living tissue (in vivo) enabling
the detailed description of cells, tissues and biological processes in their natural
surrounding has enormous value for the understanding of organisms in health
and disease. Unfortunately, the optical properties of living tissue make it ill-
suited for direct microscopic measurements by itself, owing to the scattering of
visible light and its light-protective mechanisms to prevent photodamage by sun-
light. Fluorescence microscopy techniques were developed to enable the specific
and selective detection of molecules at low concentration and with a high signal-
to-noise ratio (reviewed by [170]). One drawback with conventional fluorescence
microscopy, however, is the restriction on its use to thin samples, as the entire
sample is excited indiscriminately of the focal plane. In order to avoid the ob-
scuration of the image by out-of-focus light, confocal laser scanning microscopes
(CLSM) [171, 172] prevent it from reaching the detector using a pinhole and
thus enable optical sectioning of specimens. At the same time, the rejection of
out-of-focus light means the rejection of a large proportion of emitted photons.
Increasing excitation increases the emission signal but also can induce photo-
damage and photobleaching, which can be considered the Achilles heel of this
otherwise superior technique [170].
Two developments of the last two decades have revolutionized fluorescence
microscopy: the introduction of genetically encoded fluorophores like the green
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fluorescent protein (GFP) [173, 174] and the invention of two-photon micro-
scopes [175]. Unlike traditional optical microscopy techniques including confo-
cal microscopy, which use linear (one-photon) excitation, nonlinear absorption
requires two photons for the excitation of a fluorophore. The nonlinear optical
effect was originally proposed by the physicist Maria Göppert-Mayer in 1931 and
states that a fluorophore can be stimulated by effectively simultaneous absorp-
tion of two photons, if the sum of their energies equals the required energy of
excitation [176, 177]. The probability of excitation under nonlinear conditions
is extremely low, but increases proportionally to the square of light intensity
[178]. The development of ultrafast lasers [179] allowed the efficient multipho-
ton excitation of fluorescence, which requires extremely short pulses and high
repetition frequencies (typically 100-fs pulses at 100 MHz) of mode-locked lasers
and generates extremely high photon densities (several kW/cm3) [175, 178, 180].
The light source of choice most commonly has been the Ti:sapphire laser [181],
which can be tuned to wavelengths between 670 and 1070 nm. The principles of
one- and two-photon microscopy are illustrated in Figure 1.7.
Nonlinear excitation holds a number of advantages over linear excitation for
the imaging of biological specimens [182]: (1) the infrared light used for excita-
tion is absorbed and reflected to a lesser extent by tissue, which increases the
penetration of light into the tissue and enables the examination of fluorophores
deep (up to 1 mm) in living samples; (2) as the nonlinear optical effect is depen-
dent on a high local concentration of photons, excitation essentially only occurs
at the focal point, leading to an inherent optical sectioning. Without any out-
of-focus excitation, photodamage and photobleaching are likewise reduced. (3)
Especially deep in tissue, the efficiency of detection is substantially higher, as
emitted fluorescence scattered by tissue also contributes to the signal, as long as
they reach the detector.
For in vivo studies using 2-photon-microscopy, the biological structures of in-
terest have to fluoresce. Some metabolic products like NAD(P)H [nicotinamide
adenine dinucleotide (phosphate)] [183], flavines [184] and indolamines [185] have
an intrinsic fluorescence which can be used to measure the metabolic state of
a cell. In addition, second harmonic generation (SHG) enables direct imag-
ing of anisotropic biological structures which can be hyperpolarized, such as
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Figure 1.7. Principles of one- and two-photon microscopy. A. Simplified Jablonski-diagram
to illustrate linear one-photon (blue) and nonlinear two-photon (red) excitation. Valence electrons
of a fluorophore can be excited to an energetically higher state by the absorbance of one or two
photons. Relaxation to the ground state can occur through non-radiative transitions or through
emission of light — shown here as green fluorescence. B. One-photon linear excitation generates an
entire cone of fluorescent light, whereas two-photon nonlinear excitation creates spatially confined
signal in the vicinity of the focal spot. C. Schematic of a two-photon microscope and the generation
of three-dimensional image stacks. A Ti:Sa laser generates photon pulses in femtosecond-cycles
and can be tuned to wavelengths between 670 and 1070 nm. An acousto-optic modulator (AOM)
regulates light intensity and a telescope increases the light ray width. A system of X-Y scan
mirrors and an array of lenses guide the focused beam of light grid-type across the specimen.
The emitted fluorescence wavelengths are separated using dichroic mirrors. Photomultiplier tubes
(PMTs) convert the arriving photons into electric signal, which is processed using imaging software.
Combining optical sectioning with X-Y scanning enables the creation of three-dimensional image
stacks or videos longitudinally over time. Shown here exemplarily are the reconstruction of a
dendritic tree from a cortical neuron (c1) and an activity profile of layer II cortical neurons (c2).
Adapted from [180].
collagen [186, 187, 188]. Another approach involves the direct injection of fluo-
rophores. Angiography visualizes the vasculature [189] whereas fluorophores able
to cross the blood-brain-barrier can be used to label certain structures within the
brain tissue. Thioflavin S [190] and FSB [191] [(trans,trans)-1-fluoro-2,5-bis(3-
hydroxycarbonyl-4-hydroxy)styrylbenzene] are two examples of amyloid-binding
fluorophores that can be used to label neurofibrillary tangles in vivo.
As mentioned above, genetically encoded fluorophores are a very elegant way
to visualize structures of interest. GFP is a naturally fluorescent protein orig-
inally isolated in 1962 by biochemist Osamu Shimomura et al. [192] from the
jellyfish, Aequoria Victoria. It can be expressed fused to a protein of interest
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in a specific tissue and in any species in which genetic engineering is possible
[173, 193]. Spectral color variants (XFPs) have been generated by introducing
mutations into the GFP gene and create great experimental flexibility for the
microscopist [194]. For in vivo imaging of neuronal structure including den-
drites and spines, transgenic mice expressing XFPs under the control of the
pan-neuronal promotor Thy1.2 have been generated. GFP-M and the YFP-H
are two examples of mouse lines in which the random expression of the Thy1.2
promotor drives sparse labeling including a subset of pyramidal neurons in the
neocortex [195], making them and their dendritic trees optically distinguishable
and depictable.
The use of fluorophores to pick up neuronal function on the cellular level
is among the great advances in neuroscience of the last few decades. Calcium
indicators respond to the binding of calcium ions (Ca2+) by changing their flu-
orescent properties and consequently give an immediate measure of neuronal
activity. Here one can distinguish between bioluminescent proteins, chemical
and genetically encoded calcium indicators (reviewed by [196]). Bioluminescent
proteins like aequorin were the first Ca2+ indicators [192] rely on oxidation for the
emission of photons, whereas chemical Ca2+ indicators like fura-2 [197] or Ore-
gon Green 488 BAPTA-1 (1,2-bis(o-aminophenoxy)ethane-N,N,N’,N’-tetraacetic
acid) [198] change their fluorescence upon the chelation of Ca2+ ions. Geneti-
cally encoded Ca2+ indicators (GECI) come in two flavors. FRET-based indi-
cators use the conformational change of a protein upon Ca2+ binding to induce
Förster resonance energy transfer (FRET), leading to a shift in the primarily
emitted fluorescence wavelength [199]. Single-fluorophore GECIs increase their
emitted fluorescence upon Ca2+ binding due to intramolecular conformational
changes. Prime representatives from this family, which experience frequent use
in in vivo conditions and were also used for this work are the GCaMP indicators,
which consist of an enhanced GFP protein, flanked by the Ca2+ binding protein
calmodulin and the calmodulin-binding peptide M13 on the other side [200].
The in vivo imaging of neuronal structures requires optical access to the
brain. In order to achieve this, two approaches have been described and used:
(1) the open skull preparation and (2) the thinned skull preparation. The open
skull preparation implicates the removal of a typically round piece of skull with
24
1.6 In vivo two-photon imaging
a diameter of 3 to 8 mm [201, 202]. In the case of a chronic experiment, it is
replaced by a round piece of glass of the same size that is fixed permanently to
the skull. Applying this approach, the experimenter profits of a large and optical
perfectly transparent area to study and allows imaging up to 800 μm deep into
the tissue. Depending on the skill of the surgeon and biological factors (such
as bone regrowth), this preparation can stay optically accessible for weeks up
to months and enables any desired number of imaging time points. It has to
be noted that the invasive nature of this type of surgery provokes an immune
reaction of glial cells, which however subsides during a recovery period of three
to four weeks [201]. The thinned skull preparation is less invasive, as the bone
is not fully perforated but thinned down to a 20 μm transparent layer [203, 204,
205]. The superior transparency of a glass window cannot be reached by this
approach, which limits the penetration depth of the 2-photon laser and enables
imaging only in superficial tissue. Moreover, with a diameter of about 200 μm,
the accessible area is significantly smaller than in the open skull preparation.
Repetitive imaging is possible, but bone regrowth requires a new preparation
if imaging time points are further apart than 24 h which is typically successful
only three to four times. An advantage of this method is that very long time
periods between imaging sessions can be used. Overall, both preparations have
their benefits and depend on an experienced surgeon for an optimal result.
1.6.1 Alpha-synucleinopathy and Tauopathy mouse mod-
els
The study of human neurodegenerative diseases is complicated by several factors.
Patient studies are subject to multitudinous restrictions and due to a continuing
lack of safe and reliable biomarkers, the definite diagnosis into a disease category
can commonly only be made post mortem. Brain tissue is often not available
until hours after the time of death, and is thus unsuitable for sensitive biochem-
ical analysis and in any case only gives information about the pathological state
at that time point, but not about the pathogenesis or the etiology. Histological
analysis of brain tissue extracted through biopsy is possible only in rare cases.
The heterogeneity across patient groups is large due to the presence of concomi-
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tant diseases, which diminishes the ability to make generally valid statements.
Along with the major efforts in medical research to develop symptomatic and
reversive treatments, the intervention in the early pre-clinical stages to prevent
disease could be crucial (reviewed by [206]).
Complementary to human studies, animal models constitute a great potential
in modern neuroscience. The utilized model organisms range from invertebrates
like nematodes (Caenorhabditis elegans) or fruit flies (Drosophila melanogaster),
which are widely used to investigate molecular pathways, over zebra fish (Danio
rerio) to mammals like mice (Mus musculus) or rats (Rattus norvegicus forma
domestica) and less commonly primates. Several reasons make mice one of the
most widely used model organisms. They are relatively easy to breed and to
house, their genome has a great similarity with the human genome, and there
are refined tools for genetic modifications (reviewed by [207]). The introduction
of transgenes, for instance, allows the expression of genes like the mutant human
MAPT- or SNCA genes. Promotors that drive expression in the brain can be
selected to be cell-type- or tissue-specific and drug-based genetic switches enable
the temporal conditional expression of a transgene (reviewed by [208]). One can
also knock in (KI) discrete mutations by homologous recombination or knock
out (KO) a gene to abolish its expression altogether [209]. Furthermore, the
availability of inbred strains with a common genetic background facilitate the
comparison between cohorts and the life span of around 2 years enables studies
over prolonged periods of time [210].
There is a great variety in available transgenic mouse lines for the study of
α-synucleinopathies and tauopathies, which are extensively reviewed elsewhere
[210, 211, 207]. Here, the focus shall be on two lines in which in vivo experiments
were performed — one for modeling tauopathy and one for modeling synucle-
inopathy. PDGF-h-α-syn mice express wild-type human α-syn under the control
of the pan-neuronal platelet-derived growth factor-β (PDGFβ) promotor. In the
brain of these mice, granular inclusions of α-syn in neuronal cell bodies and neu-
rites can be found chiefly in the cortex, the hippocampus and the olfactory bulb.
A slight reduction in the density of dopaminergic terminals can be observed in
the striatum and aged transgenic mice display mild motor impairments [212].
The P301S mouse model expresses the shortest human four-repeat isoform of
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tau (0N4R) with the P301S mutation. In humans, this mutation causes FTDP-17
and is associated with early-onset dementia with parkinsonism [213]. The Thy1.2
promotor drives expression in CNS-neurons, leading to intraneuronal inclusions
of hyper-phosphorylated tau and to age-dependent neuron loss in the cortex
and the spinal cord [214]. As a consequence, a pronounced motor phenotype
including muscle weakness, tremor and hindlimb paraparesis is present in 5-
month-old homozygous P301S mice.
In order to study the induction and spread of α-syn and tau inclusion pathol-
ogy, more options than transgenic mouse models are available. The method
of injecting pre-existing proteinaceous aggregates (the ”seed”) into the brain,
which have the ability to induce further misfolding among endogenous protein
and propagate from cell to cell, has become known as seeding. The induction of
α-syn pathology has been achieved in several ways: (1) the intracerebral injec-
tion of brain lysates from aged, motor-impaired transgenic mice or human MSA
patients can induce pathology in α-syn overexpressing mice [215, 216]; (2) the
intracerebral injection of in vitro preformed fibrils (PFFs) of α-syn into trans-
genic α-syn mice causes a similar phenotype, providing more direct evidence that
the induction and spread of pathology is specifically caused by misfolded α-syn
and not by other potential inducers — like glial factors or cellular injury re-
sponse activators — present in brain extracts [217, 218, 219]; (3) the peripheral
injection of PFFs into the hindlimb muscle [220] of PD mouse models was suf-
ficient to induce α-syn pathology; (4) for α-syn there is also evidence for seeded
conformational templating in WT mice. The injection of LB-enriched extracts
from the SNpc from post mortem PD or DLB brains into WT mice or monkeys
resulted in progressive nigrostriatal neurodegeneration and α-syn inclusion for-
mation [221, 222]. Finally, the intracerebral injection of α-syn PFFs also induces
LB-like pathology in WT mice [223].
The first evidence that tau propagates in vivo was provided in 2009 using the
ALZ17 mouse line expressing the wild-type human 2N4R tau isoform under the
control of the Thy1.2 promotor. Brain extracts were prepared from the P301S
mice described above [214], which develop abundant tau pathology primarily
in the brainstem and the spinal cord by 6 months of age. Injection of brain
extracts containing 0N4R P301S tau aggregates into the hippocampus and cortex
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of ALZ17 mice resulted in fibrillary hippocampal inclusions that included the
2N4R tau isoform, indicating that at least some of the tau within the inclusions
was recruited from wild-type tau protein expressed in the ALZ17 mice [224].
Since then, several other studies have shown the seeding and spreading abilities
of tau with preparations from human tauopathies [225, 226] and PFFs [227, 228,
229].
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2.1 Seeding and transgenic overexpression of
alpha-synuclein triggers dendritic spine pathol-
ogy in the neocortex [1]
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Abstract
Although misfolded and aggregated a-synuclein (a-syn) is recog-
nized in the disease progression of synucleinopathies, its role in
the impairment of cortical circuitries and synaptic plasticity
remains incompletely understood. We investigated how a-synu-
clein accumulation affects synaptic plasticity in the mouse
somatosensory cortex using two distinct approaches. Long-term
in vivo imaging of apical dendrites was performed in mice overex-
pressing wild-type human a-synuclein. Additionally, intracranial
injection of preformed a-synuclein fibrils was performed to induce
cortical a-syn pathology. We find that a-synuclein overexpressing
mice show decreased spine density and abnormalities in spine
dynamics in an age-dependent manner. We also provide evidence
for the detrimental effects of seeded a-synuclein aggregates on
dendritic architecture. We observed spine loss as well as
dystrophic deformation of dendritic shafts in layer V pyramidal
neurons. Our results provide a link to the pathophysiology underly-
ing dementia associated with synucleinopathies and may enable
the evaluation of potential drug candidates on dendritic spine
pathology in vivo.
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Introduction
The mammalian brain contains a complex network of billions of
neurons communicating through different types of synapses that
can be severely and irreversibly disturbed by neurodegeneration. In
synucleinopathies like Parkinson’s disease (PD) or dementia with
Lewy bodies (DLB), progressive neurodegeneration is linked to
misfolding and intracellular aggregation of the synaptic protein
a-synuclein (a-syn; Clayton & George, 1999; Lücking & Brice, 2000)
and leads to motor as well as cognitive deficits and ultimately to
dementia (Spillantini et al, 1997; Burn, 2004; Aarsland et al, 2008).
Familial cases of PD or DLB can be caused by mutations in the
a-syn gene (Polymeropoulos et al, 1997; Krüger et al, 1998; Zarranz
et al, 2004) or overexpression of a-syn (Simón-Sánchez et al, 2009)
and strengthen the association between protein load/aggregation
and the onset of disease. Although the filamentous, cytosolic a-syn
inclusions called Lewy bodies (Spillantini et al, 1998) are a prereq-
uisite for the histopathological diagnosis of PD and DLB, only an
imperfect correlation between the Lewy body load and severity of
cognitive impairment is known (Hughes et al, 1992; Parkkinen et al,
2005). Several studies rather support synaptic failure as the predom-
inant pathophysiological mechanism. Presynaptic neurotransmitter
release has been proven to be unbalanced in PD (Nikolaus et al,
2009). Moreover, presynaptic a-syn oligomers and micro-aggregates
are thought to be responsible for neurodegeneration as well as for
dendritic spine loss observed in postmortem DLB brains (Kramer &
Schulz-Schaeffer, 2007).
Over the past few years, an increasing body of evidence supports
the concept of the propagation of misfolded a-syn species from
neuron to neuron, where they are transported along axons and trig-
ger the conversion of endogenous a-syn into a pathologic form in
culture and in vivo (Luk et al, 2012a,b). Aspects of progressive
a-syn aggregation—namely the spread along synaptically connected
brain regions and the maturing of Lewy-like inclusions—can be
recapitulated in model systems by exogenous introduction of
in vitro-generated, preformed fibrils (PFFs) of a-syn, which under
certain conditions is even possible in non-transgenic animals (Luk
et al, 2012a,b; Masuda-Suzukake et al, 2013; Osterberg et al, 2015).
Dendritic spines are small protrusions from the dendritic shaft
which are highly regulated and have been shown to be altered in
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several neurological disorders including neurodegenerative diseases
(Fiala et al, 2002; Penzes et al, 2011; Murmu et al, 2013). Various
studies in the field of a-syn-related disorders have addressed the
impairment of dendritic spines in brain areas like the striatum
(McNeill et al, 1988; Day et al, 2006; Zaja-Milatovic et al, 2006;
Finkelstein et al, 2016), the hippocampus (Winner et al, 2012), the
olfactory bulb (Neuner et al, 2014), and naturally the substantia
nigra (Patt et al, 1991). However, chronic effects of cortical a-syn
have not been studied extensively, even though it is becoming more
and more evident that the cortical involvement in the pathophysiol-
ogy of PD and DLB cannot be neglected.
This study aims to extend the understanding of the structural
consequences of neocortical a-syn accumulation on dendritic spines
in a time-resolved manner. To address this question, we used
chronic two-photon in vivo imaging to monitor spine dynamics over
time, in young and aged transgenic mice overexpressing human
wild-type a-synuclein (PDGF-h-a-syn) (Masliah, 2000). Further-
more, we used PFFs as a tool to induce cortical a-syn accumulation
in mice expressing only the reporter transgene eGFP in order to
study the structural consequences of a-syn seeding on dendritic
architecture and spines.
Here, we report detrimental effects on dendrites and dendritic
spines due to a-syn overexpression as well as seeding. Accumula-
tion of a-syn in the neocortex triggers the loss of dendritic spines,
interferes with spine dynamics, and leads to dystrophic malforma-
tion of dendritic branches. Our combination of a transgenic and a
PFF-seeding mouse model provides new insights on the a-syn-
dependent mechanisms that lead to dendritic spine decay in the
cortex and therefore might create a better understanding of cogni-
tive decline in synucleinopathies.
Results
Overexpression of wild-type human a-synuclein leads to changes
in dendritic spine density and dynamics in aged mice
In vivo two-photon imaging was performed in three age groups of
mice (3, 6, and 12 months), which were chosen according to previ-
ously published data on the progression of a-syn accumulation and
its corresponding behavioral phenotype (Masliah, 2000; Rockenstein
et al, 2002; Amschl et al, 2013). We consider the 3-month-old
cohort as “presymptomatic”, whereas the 6- and 12-month-old
cohorts show a developing and fully fledged phenotype,
respectively.
Previous long-term in vivo imaging studies have shown that
spines are highly dynamic structural elements and can be classified
accordingly: Persistent spines are long lasting and stable for weeks
up to the entire life span, whereas transient spines are newly formed
and lost within days (Grutzendler et al, 2002; Trachtenberg et al,
2002; Holtmaat et al, 2005). In both h-a-syn transgenic and control
mice, dendritic images were analyzed for spine density and dynam-
ics. Newly appeared and disappeared spines relative to the previous
imaging session were marked as “gained” or “lost”, respectively.
Spines that were gained at a certain time point and persisted for
< 7 days were considered as being “transient” (Fig 1A).
Our image analysis in the 6- and 12-month-old cohorts revealed
that the number of spines per lm was significantly lowered in mice
overexpressing h-a-syn. The ANOVA genotype main factor was
significantly changed (6 M: F(1,7) = 27.11; P = 0.0012 and 12 M:
F(1,7) = 55.78; P = 0.0001), denoting that h-a-syn mice exhibit
considerably less (30%) dendritic spines on apical tuft dendrites
but show no increase or decrease in spine density over the imaging
time period relative to controls (Fig 1B).
Concerning spine dynamics, the fractions of both gained and lost
spines were found to be elevated; however, only the comparison of
the lost fractions reached statistical significance (6 M: F(1,7)= 5.85;
P = 0.0461 and 12 M: F(1,7) = 8.86; P = 0.0206). As newly gained
spines were disproportionally more often lost again, the fraction of
transient spines showed a significant increase in both 6- and 12-
month-old h-a-syn mice (6 M: F(1,7) = 7.19; P = 0.0315 and 12 M:
F(1,7) = 24.25; P = 0.0017; Fig 1C).
As a consequence of the change in spine dynamics, the daily
turnover ratios were found to be significantly elevated in h-a-syn
mice (6 M: F(1,7) = 5.65; P = 0.0491 and 12 M: F(1,7) = 6.93;
P = 0.0338; Fig 1D). In summary, we could show that spine
density is significantly reduced and does not further change over
the imaging interval of 35 days. Moreover, parameters of spine
dynamics were profoundly changed in mice overexpressing a-syn
compared to controls. The significant increase in transient spine
fraction both in 6 and 12 months of age indicates that compen-
satory mechanisms may take place. Since there are no significant
differences between 6 and 12 months of age, spine pathology does
not further progress after 6 months of age but has reached a stable
equilibrium.
Young adult a-synuclein overexpressing mice exhibit a different
dynamic phenotype than aged mice
In order to reveal when the spine loss starts leading to reduced spine
density in 6- and 12- month-old h-a-syn mice, we analyzed a
3-month-old cohort over 6 weeks. Different to the older cohort, we
observed a progressive decrease in spine density, with a significant
interaction between genotype and time in Bonferroni’s post hoc test
(F(5,30) = 15.18; P < 0.001). Compared to controls, spine density in
h-a-syn mice was reduced 12% on average at the first imaging time
point (age of mice: 3 months) and 30% at the last imaging time
point (age of mice: 4.5 months; Fig 2A).
Moreover, the dynamic fractions of spines show a somewhat
contradictory picture compared to the 6- and 12-month-old mice.
Our data revealed a significant impairment in the formation of new
spines in h-a-syn mice (F(1,6) = 8.71; P = 0.0256), while the fraction
of lost spines was unaffected, which accounts for the progressive
decrease in spine density. By implication, stable spines represent a
significantly larger fraction in these mice (F(1,6) = 8.71; P = 0.0256),
while the fraction of transient spines is not significantly different
from controls (Fig 2B). We also observed no significant change of
the daily turnover ratio (TOR) between the groups at 3 months of
age (Fig 2C).
Our results demonstrate that overexpression of human a-syn
leads to structural alterations of dendritic spines in the cerebral
cortex. The alterations develop already in young adults at the age
of 3–4.5 months, significantly before behavioral or motoric pheno-
types become apparent (Amschl et al, 2013), but reach a state of
dynamic equilibrium later and do not progress further until
12 months of age.
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Alterations in spine density and morphology in young adult and
aged PDGF-h-a-syn mice
The progressive decrease in spine density seen in young adult mice
could be monitored in vivo between 3 and 4.5 months of age.
Extrapolation of the data curve (Fig 2A) of a-syn overexpressing
animals to an earlier age would yield a time point at which no dif-
ference in synaptic spine densities between the groups is present. As
chronic in vivo imaging in younger mice is technically not possible
(bone growth in mice until 6–8 weeks of age, 4 weeks postsurgery
necessary for chronic window clearing/healing), we addressed this
question with a single time point ex vivo approach. Confocal
A
C D
B
Figure 1. a-Synuclein overexpression alters spine density and dynamics in vivo.
A Representative in vivo two-photon recordings of eGFP-labeled apical tuft dendrites in the somatosensory cortex in h-a-syn and control animals. Arrowheads mark
representative spines that were stable (white, present > 7 days), newly formed (green), or lost (magenta). Gained spines that do not stabilize (yellow/green, present
< 7 days) are defined as transient. Scale bar, 5 lm.
B Spine density is reduced in both 6- (**P = 0.0012) and 12-month-old (***P = 0.0001) h-a-syn animals.
C The fractions of both gained (P6 months = 0.0527; P12 months = 0.0678) and lost spines (*P6 months = 0.0461; *P12 months = 0.0206) are elevated in h-a-syn mice
compared to controls; the fraction of transient spines is significantly higher (*P6 months = 0.0315; **P12 months = 0.0017).
D Consequently, the daily turnover ratio (TOR) is significantly increased in both 6- and 12-month-old h-a-syn mice (*P6 months = 0.0491; *P12 months = 0.0338).
Data information: n = 5 (h-a-syn), n = 4 (control) animals, mean with s.e.m.; two-way ANOVA genotype main factor, *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 2.
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imaging of apical tuft dendrites (layer I) was performed in brain
slices of control as well as h-a-syn mice that were 2 and 4.5 months
old. Note that the higher resolution of confocal microscopy in brain
slices leads to an overall increased detection of spine density and a
better ability to judge spine morphology. Two remarkable dif-
ferences concerning the age and the genotype of the animal were
observed. Firstly, at 2 months of age, there was no difference in
spine density between control and transgenic animals, whereas at
4.5 months, spine density in h-a-syn mice showed a ~40% decrease
(t(6) = 5.770; P = 0.0012) relative to age-matched controls.
Secondly, there was a significant difference in the spine densities of
the h-a-syn mice (t(6) = 4.097; P = 0.0064; ~30% reduction at
4.5 months) depending on their age, whereas this had no impact on
the spine densities of control animals (Fig 2D).
In order to clarify whether the progressive spine loss in h-a-syn
mice is reflected by changes in spine morphology, we furthermore
analyzed spine shape for which three morphological subtypes have
been defined (Rochefort & Konnerth, 2012). Thin spines have an
elongated appearance, with a long neck and a small spine head.
Mushroom spines have the largest, round head, while stubby spines
are devoid of a neck and appear as round elevation from the
dendritic shaft. In addition, filopodia are very long and thin struc-
tures that lack a spine head and are considered the most dynamic of
dendritic structures, which appear and disappear rapidly and only
sometimes develop into one of the other spine types. In the morpho-
logical analysis of our confocal data, the absolute numbers
(Appendix Fig S1A) as well as the fractions of mushroom, stubby
and thin spines as well as filopodia, were comparable in 2-month-
old mice independent of the expression of human a-syn (Fig 2D).
In 4.5-month-old h-a-syn mice, the density of all morphological
spine types is decreased (Appendix Fig S1A); however, not all types
are lost to the same extent. The normalized fractions reveal a slight
increase in the fraction of stubby spines (t(6) = 2.579; P = 0.0418),
whereas thin spines clearly represent a smaller fraction compared
both to age-matched controls (t(6) = 3.346; P = 0.0155) and to
younger h-a-syn mice (t(6) = 4.443; P = 0.0044) (Fig 2D).
The confocal imaging data from aged mice confirmed the reduc-
tion in spine density of ~30% in both 7.5- and 13.5-month-old h-a-
syn brains. Compared to controls, the fractions of mushroom spines
were decreased, while the fractions of thin spines were increased
(Fig 2E and Appendix Fig S1B).
Taken together, our data confirmed our hypothesis that struc-
tural changes of dendritic spines develop within a certain time frame
in young a-syn overexpressing mice. This time frame was deter-
mined to be approximately between 2 and 4.5 months of age.
Before, the dendritic appearance in these mice is indistinguishable
from healthy controls. Later, a-syn overexpression causes changes
in dendritic spines toward an overall lower spine density and a shift
in spine morphology.
Intrastriatal injection of preformed a-synuclein fibrils triggers a
progressive spread of endogenous protein aggregation
a-syn pathology can be induced in wild-type mice by injecting
preformed fibrils (PFFs) (Luk et al, 2012a). Using this as a tool
to investigate whether seeded pathology of disease-associated
a-syn will lead to structural alterations in synapses, we injected
healthy 2-month-old GFP-M mice with PFFs prepared in vitro.
Prior to injection, the quality of the injection material was
controlled. The amyloid nature of PFFs was confirmed in a thio-
flavin T (ThT) assay, as ThT changes its fluorescent properties
upon binding to amyloid b-sheet structures (Fig 3A). Differential
centrifugation through a sucrose gradient confirmed the strongly
increased sedimentation coefficient and thus the increased molec-
ular density of PFFs compared to a-syn monomers (Fig 3B).
Finally, an electron micrograph visualized the fibrillary structure
of PFFs (Fig 3C).
Sonicated PFFs were stereotactically injected into the striatum
(Fig 3D), an area which contains extensive efferent and afferent
projections to other brain regions and is affected in PD (Shepherd,
2013). As cortical neurons are the targets of interest in this study,
the time-course and extent of a-syn pathology progression into dif-
ferent layers of the neocortex was monitored at different days
postinjection (dpi). The phosphorylation of a-syn at S129 (pS129) is
widely considered as a pathologic posttranslational modification
(Tenreiro et al, 2014; Oueslati, 2016) and was used in this study to
identify pathologic inclusions.
Striatal injection of PFFs resulted in intraneuronal aggregation of
phosphorylated a-syn (pS129-immunopositive) in the neocortex, at
first confined to layer IV and V neurons (30–150 dpi), developing
later to spread over all cortical layers (9 months postinjection;
Fig 3E). pS129-a-syn inclusions appeared as cytoplasmic fibrillary
forms (Fig 3F), which could also be stained by anti-ubiquitin
(Fig 3G) and thioflavin S (Fig 3H and I), thereby presenting Lewy-
body-like traits. Inclusions were also observed in the contralateral
cortex relative to the injection site and the amygdala (Appendix Fig
S2B). Due to a reported cross-reactivity between the pS129 antibody
and phosphorylated neurofilament subunit L (NFL; Sacino et al,
2014b), we confirmed the presence of phosphorylated a-synuclein
inclusions with a costaining for NFL (Appendix Fig S2B and C). The
◀ Figure 2. a-Synuclein overexpression alters spine density, dynamics, and morphology differently depending on age.A In young, 3-month-old h-a-syn mice, progressive decrease in spine density is observed in vivo.
B The loss of spines in young h-a-syn animals is driven by a reduced fraction of newly gained spines, while the fraction of lost spines remains unchanged and the
fraction of stable spines is increased (*Pgained/stable = 0.0256).
C The daily turnover of spines shows no significant difference between groups (P = 0.4062).
D Ex vivo confocal data in young mice confirm synapse loss in h-a-syn mice between 2 and 4.5 months of age (**Psyn 2/4.5 months = 0.0064; **Pctrl/syn 4.5 months = 0.0012)
and show a shift in spine morphology toward relatively more stubby (*pstubby = 0.0418) and less thin spines (**Ph-a-syn 2/4.5 months = 0.0044; *Pctrl/syn 4.5 months =
0.0155).
E Ex vivo confocal data in aged h-a-syn mice show a decrease in total spine density (***P7.5 months = 0.0005; **P13.5 months = 0.0039) as well as in the fraction of
mushroom spines (***P7.5 months = 0.0004; *P13.5 months = 0.0298), whereas the fraction of thin spines is increased (**P7.5 months = 0.0097; *P13.5 months = 0.0155).
Data information: (A–C) n = 4 animals per group; (D, E) n = 3–4 animals per group as illustrated; mean with s.e.m.; Bonferroni’s post hoc test (A): #P < 0.05, ##P < 0.01;
two-way ANOVA genotype main factor (B, C): *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test (D, E): *P < 0.05, **P < 0.01, ***P < 0.001.
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presence of pS129-a-syn inclusions across different brain regions is
shown in Appendix Fig S2D.
Control brains injected with PBS did not show comparable
immunopositive inclusions (Fig 3E). Importantly, also monomeric
a-syn injected into GFP-M mice as well as PFFs injected into a-syn
knock-out mice (SNCA KO) failed to induce the phenotype as
observed after injection of PFFs (Appendix Fig S2E).
In order to further examine whether the effect can be attributed
to templated conversion of endogenous mouse a-syn into misfolded
and aggregated species rather than just the uptake of PFFs by cells,
control injections of fluorescently labeled PFFs into the striatum
were performed. Twenty-four hours after the injection, the injection
material was prominently detectable in the striatum, corpus callo-
sum, and the injection canal (Appendix Fig S3B and C). At 6 dpi,
however, the fluorescent material was removed from the injection
site (Appendix Fig S3D) and later showed very little colocalization
with developing pS129-a-syn-positive aggregates at 30 dpi
(Appendix Fig S3E and F). We therefore conclude that the spreading
of intracellular a-syn aggregation in our model is dependent on the
introduction of fibrillary a-syn as a molecular template on top of
endogenous a-syn expression and not simply due to a cellular
uptake of injected PFFs.
Considering inflammation as a contributor in neurodegenerative
diseases (Perry et al, 2010) and synaptic plasticity (Morris et al,
2013) and as PFF-induced a-syn accumulations have been associ-
ated with microglia (Sacino et al, 2014a), we assessed the presence
and activation of microglia in the neocortex with two markers. Anti-
Iba-1 marks all microglial cells including their processes, CD68 is a
marker associated with active phagocytosis. We find that at the time
point of spine analysis (5 months postinjection), the cortical area
covered by microglia shows a tendency toward higher coverage,
especially in layer IV (Appendix Fig S4A and B). We also observed a
tendency for an increase in the coverage with activated microglia
(Appendix Fig S4C and D) as well as occasional colocalization of
CD8-positive microglia and pS129-positive aggregates (Appendix Fig
S4E). However, variation between samples is high and the effect is
not significant.
Seeded a-synuclein aggregates have detrimental effects on
dendrites and spines
Advantageous to other mouse models, the seeding model does not
require a disease-related transgene to induce a pathologic pheno-
type. In this way, we wanted to investigate structural alterations
that might be the consequence of dose- and time-controlled molecu-
lar templating of a-syn aggregates. Five months after the injection of
PFFs or PBS (control) into the dorsal striatum, brain slices were
stained for pS129-positive a-syn aggregates, which were most abun-
dant in layer IV and upper layer V of the cortex, including pyramidal
eGFP-expressing neurons (Appendix Fig S3A). In order to study
whether structural changes might be solely attributed to a local
effect of intracellular aggregates on neighboring dendrites or due to
a more global disturbance in the synaptic network, we imaged
apical dendrites located in two different layers (Fig 4A). Dendrites
imaged in layer IV or V were spatially close to cells bearing an intra-
neuronal a-syn accumulation, while tuft dendrites of layer I were
distal to these cells (Fig 4B).
Indeed, we found alterations in spine density irrespective of the
cortical location of the dendrites. In both layer IV/V (t(11) = 3.628;
P = 0.004) and layer I (t(11) = 3.838; P = 0.0028), spine density was
found to be lowered in brains which had been injected with PFFs
and contained a-syn aggregates (Fig 4C).
We next investigated how vulnerable the morphological spine
types are in response to seeded a-syn. In the layer IV/V dendrites,
all types were lost to the same extent, leaving the fractions of mush-
room, stubby, and thin spines comparable in controls and seeded
animals (Appendix Fig S5B and Fig 4C). Contrarily, in apical tuft
dendrites (layer I), thin spines proved to be more and stubby spines
less vulnerable to seeded a-syn. The fraction of thin spines was
therefore decreased (t(11) = 2.350; P = 0.0385), while the fraction
of stubby spines was increased (t(11) = 2.599; P = 0.0247)
(Appendix Fig S5A and Fig 4C). This phenotype was already
observed in our ex vivo spine data of young transgenic h-a-syn mice
(see Fig 2) and could be reproduced here. On the presynaptic side,
no overt change in the density of excitatory boutons could be
detected in both the transgenic and the seeding mouse model
(Appendix Fig S6I–L).
The irregular form of the tuft dendritic shafts in PFF-seeded
brains was an additional observation. In controls, injected only with
PBS, the diameter of dendritic shafts was found to be relatively
uniform. In contrast, apical tuft dendrites of PFF-seeded mice
showed an irregular appearance of the dendritic shaft. Over the
length of the dendrites, large swellings could be observed as well as
segments with an extremely narrow diameter (Fig 4D). In a histo-
gram plotting the frequency of diameter values, dendritic shaft
diameters follow a normal distribution (R2 = 0.9263) for the control
animals. For the seeded mice, the variety of values is broader and
the values are best described with two distributions: one at very low
dendritic diameter (R2 = 0.9250) and one comparable to the control
distribution (R2 = 0.9664), with the exception of the presence of
abnormally high values (Fig 4E). As a consequence of the high vari-
ation, the mean standard deviation of the dendritic shaft diameter
was found to be significantly increased (t(11) = 3.054; P = 0.011) in
mice that were seeded with a-syn PFFs (Fig 4F). Note that this
phenotype was only observed in our seeding, but not in the trans-
genic model.
With our approach, we could show that the introduction of
a-synuclein seeds and the consecutive accumulation in the cerebral
◀ Figure 3. Injection of PFFs into the dorsal striatum triggers cortical a-synuclein aggregation.A–C The quality of the injection material was verified using ThT fluorescence assay (A), sucrose-gradient fractionation (B), and electron microscopy (C).
Scale bar: 0.2 lm.
D Injection site, 0.2 mm anterior of the bregma (star) and imaging area (box) as depicted in (E).
E–I Representative images of the cortical layers I–VI in the somatosensory cortex of mice at different time points postinjection. Controls were injected with sterile PBS.
Neurons in the layers IV and V of the somatosensory cortex contain aggregates of a-synuclein phosphorylated at S129 (F), which are ubiquitin-positive (G) as well
as thioflavin S-positive (H, I). Image stacks (E–I) are depicted as maximum intensity projections. Scale bars: 50 lm (E), 10 lm (F, G), 20 lm (H), 5 lm (I).
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cortex triggers structural changes both at the level of the dendritic
spine and the dendritic shaft.
Discussion
This study presents converging evidence from two distinct
approaches for the adverse effects of a-syn accumulation for the
density and structural plasticity of dendritic spines in the cerebral
cortex. Dendritic spines are excitatory postsynapses, and their loss
has been described repeatedly as a structural correlate for cognitive
impairment and dementia (Terry et al, 1991; Dickson et al, 1995;
Bellucci et al, 2012; Picconi et al, 2012). Moreover, the effects of
mutated and accumulated a-syn have been studied in several brain
regions. Striatal spine loss has been reported in various animal
models of PD and in PD and DLB patients (McNeill et al, 1988;
Zaja-Milatovic et al, 2006). In a mouse model overexpressing the
human A53T a-syn mutation, spine loss has been observed in the
A C
D E F
B
Figure 4. The presence of accumulated a-synuclein induced by seeding 5 months prior to analysis causes spine loss and malformation in layer V apical
dendrites.
A a-Synuclein aggregates occur as intrasomal (arrowheads) and neuritic (arrows) accumulations and are present predominantly in upper layer V and layer IV of the
cortex. In layer I, pS129-positive structures are much less dense. Lines exemplarily mark dendrites used for analysis.
B Spine analysis was performed on apical dendrites located in the cortical layers IV/V and I.
C In layer I, spine density is reduced relative to PBS-injected controls (**P = 0.0028), with the fraction of stubby spines being increased (*P = 0.0247) and the fraction of
thin spines being decreased (*P = 0.0385). In layer IV/V, spine density is reduced as well (**P = 0.004), without a significant effect on spine morphology.
D In apical tuft dendrites of PFF-injected mice, dendrites display dystrophic swellings and parts of very small diameter; white lines: measurement positions.
E Histograms of the dendritic shaft diameter.
F Variation in the diameter of single dendrites in seeded mice compared to controls (*P = 0.011).
Data information: n = 6 (control), n = 7 (PFF) animals, mean with s.e.m.; Student’s t-test: *P < 0.05, **P < 0.01. Scale bars: 20 lm (A), 2 lm (B, D).
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striatum and in the hippocampus (Finkelstein et al, 2016). Some
authors report that D2R striatopallidal neurons in reserpine and
6-OHDA-treated mice selectively lose spines (Day et al, 2006), while
others found spine loss on both direct and indirect pathway neurons
in 6-OHDA- or MPTP-treated models (Suárez et al, 2014). In
contrast, another study failed to detect striatal spine loss in A53T
mice, despite a decrease in the number of SNpc neurons (Oaks et al,
2013). a-syn was also demonstrated to have negative impact on
newly generated neurons of the hippocampus (Winner et al, 2012)
and the olfactory bulb (Neuner et al, 2014), particularly on their
dendrite outgrowth and spine development.
In our current study, we aimed to extend this knowledge with a
chronic examination of spines in the cortex. As the chronic effects
of a-syn on cortical spine plasticity remain incompletely understood,
we used two different mouse models which exhibit a-syn accumula-
tion in the cortex. In our transgenic model, wild-type human a-syn
was expressed under the PDGF promoter, leading to neocortical
accumulation of mostly soluble protein located as inclusions in
neuronal cell bodies as well as synaptic terminals (Masliah, 2000;
Rockenstein et al, 2002; Amschl et al, 2013). Our seeding model
was based on the striatal injection of preformed wild-type mouse a-
syn fibrils and caused a slowly progressing phenotype of phosphory-
lated a-syn-positive neuronal inclusions, which first developed in
the deeper layers of the neocortex and condensed over time to
mature into fibrillary Lewy-like inclusions.
Our study also provides in vivo evidence that accumulation of
wild-type a-syn interferes with cortical spine plasticity and spine
density which declined in young adult mice starting from about
3 months of age and stabilized at a reduced overall density in older
mice (30%). This spine loss occurs well before behavioral impair-
ments become apparent in these mice (Masliah, 2000; Amschl et al,
2013) and may be the result of a presymptomatic change in pre- and
postsynaptic function.
While numerous studies have made great effort to unravel the
molecular mechanism behind a-syn toxicity, it remains to be clari-
fied whether a toxic gain-of-function or a loss-of-function or both is
responsible for synapse and cell loss. Among the toxic gain-of func-
tion effects of a-syn are the impairment of lysosomal and proteaso-
mal protein degradation, induction of endoplasmic reticulum (ER)
stress, Golgi fragmentation, and active formation of pores on cellu-
lar membranes (reviewed by Cookson & van der Brug, 2008). For
instance, it was shown that the acute application of a-synuclein
oligomers onto autaptic hippocampal cultures as well as onto
hippocampal slices significantly enhances basal NMDA receptor
activation and the amplitude of AMPA-receptor-mediated synaptic
currents (Hüls et al, 2011; Diogenes et al, 2012). This augmented
excitatory transmission could be explained by (i) a-syn oligomer-
mediated pore formation in the postsynaptic membrane
(Volles et al, 2001; Furukawa et al, 2006; Schmidt et al, 2012),
(ii) enhancement of voltage-operated Ca2+ channel activity
(Hettiarachchi et al, 2009), or (iii) inefficient membrane repolariza-
tion (Shrivastava et al, 2015), all causing increased calcium influx
which in turn results in AMPA-receptor recruitment to the dendritic
spine membrane (Byth, 2014). The resulting postsynapse is
saturated with receptors and therefore unable to recruit extra AMPA
receptors upon theta-burst stimulation which causes a long-term
potentiation (LTP) decline and overall excitotoxicity (Yuste &
Bonhoeffer, 2001; Diogenes et al, 2012). On the long term—as we
analyzed the structural impact of transgenic and seeded a-synuclein
during and after several months—this proposed mechanism based
on a slightly but chronically enhanced calcium influx may disturb
the tightly controlled, calcium-dependent machinery of synaptic
plasticity. Likewise, a primary presynaptic pathology might alter
synaptic vesicle release which as a long-term consequence may alter
dendritic spine plasticity. Excessive a-synuclein has been shown to
inhibit neurotransmitter release via specifically reducing the size of
the synaptic vesicle recycling pool (Nemani et al, 2010) as well as
to regulate SNARE-driven membrane fusion (Garcia-Reitbock et al,
2010; Burre et al, 2015). A study in DLB brain tissue showed
massive deposits of diffuse aggregates in the cortical and subcortical
gray matter, which were located at synaptic terminals and were
linked to dendritic spine loss. This suggests that the subcellular
presynaptic location of a-syn is important for its neurodegenerative
effect (Kramer & Schulz-Schaeffer, 2007) and although our models
show no overt presynaptic loss, an alteration in function seems
likely. The functional roles of a-synuclein, in conjunction with regu-
lating actin dynamics and chaperoning the polymerization of micro-
tubule-associated proteins (Sousa et al, 2009), would certainly
impair spine stability and dendritic plasticity (Tsaneva-Atanasova
et al, 2009).
The a-syn loss-of-function hypothesis comprises that with
progressing aggregation, endogenous a-syn becomes sequestered
into inclusions; be they oligomers, protofibrils, or mature LBs and
LNs, leaving less functional protein to perform normal cellular func-
tions (reviewed by Benskey et al, 2016). Particularly the changes
seen after seeding with PFFs are supportive of this hypothesis. As
previously shown and confirmed in this study through seeding of
fluorescently tagged a-syn fibrils, the aggregates formed are chiefly
composed of endogenous a-syn, with very little of the initial PFF
seed being part of the developed inclusions (Luk et al, 2009). The
concept of sequestration is further reinforced by the complete
absence of inclusions and toxicity in a-syn null mice seeded with
PFFs (Volpicelli-Daley et al, 2011; Luk et al, 2012a). To complicate
things even further, recent evidence suggests that microglial activity
can contribute to both detrimental and protective mechanisms in
neurodegenerative diseases (Morris et al, 2013; Miyamoto et al,
2016; Tang & Le, 2016). In our model, the infusion of PFFs did not
cause overt and chronic microglial activation at the observed time
point, but additional experiments might be necessary to gain a
broader picture about the glial involvement in a-syn-affected
synapse dynamics.
From our imaging data, we cannot pin down which of these
described mechanisms exactly are involved in the loss of spines,
which emphasizes the need for further studies for clarification.
Furthermore, as our in vivo data suggest, the mechanism underlying
synapse loss and the shift in morphology may not even be uniform
throughout the course of disease. Spine dynamics were found to be
changed remarkably depending on the age of the animal upon
observation. The decrease in gained spines observed in 3-month-old
animals caused a progressive spine loss and is morphologically
reflected in the diminished fraction of thin spines, which are known
to correspond to non-synaptic transient precursors of the larger
stabilized spines (Holtmaat et al, 2005; Arellano et al, 2007).
Contrarily, in the two older groups (6 and 12 months), further spine
loss was restrained by an elevation of the daily turnover ratios. This
was in turn reflected by an increase in the fraction of thin spines.
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Thus, we propose that the observed spine remodeling in these
animals represents a compensatory mechanism for the loss of abso-
lute spine number, thereby strengthening the remaining synaptic
contacts.
In both our seeding and transgenic model, proteinaceous aggre-
gates are present in the neocortex, albeit in two histopathological
variances: while the PDGF promoter in the transgenic model drives
a more or less uniform accumulation of non-fibrillary (Masliah,
2000) a-syn in cortical neurons and synapses, seeding of PFFs leads
to the formation and maturation of fibrillary Lewy-like structures in
neurons connected to the dorsal striatum. Our results from our
in vivo study in young transgenic mice are in line with the dendritic
spine phenotype which can be induced through inoculation with
PFFs. Dendritic spine loss in layer V pyramidal neurons as well as a
redistribution of spine morphologies toward less thin spines can be
observed 5 months after inoculation with PFFs. The observed spine
loss was independent of whether the respective dendrite was
spatially close to the cortical layer V, in which neuronal a-syn
inclusions were most pronounced. Interestingly, dystrophic defor-
mation of apical tuft dendrites was present in PFF-seeded brains.
Dendritic varicosities have been described in other progressive
neurodegenerative diseases and have been linked to dendritic spine
loss in scrapie-injected rodents (Fuhrmann et al, 2007) and an
Alzheimer’s disease model (Bittner et al, 2010). The presence of
axonal varicosities caused by a-synuclein seeding has been reported
(Rockenstein et al, 2005); furthermore, it has been shown that
inclusions mature and condense over time and that aggregate bear-
ing neurons selectively degenerate (Osterberg et al, 2015). There-
fore, it seems likely that the degeneration of the respective cell body
and the accompanying transport deficits are the cause for
dystrophies and contribute to spine loss in our PFF-seeded brains.
For answering scientific questions, animal models in principle
comprise advantages as well as drawbacks (Bezard et al, 2013).
For example, all available genetic mouse models of synucle-
inopathies are able to model only a subset of symptoms known in
the human disease cases. Promoter-driven protein expression is
A
CB
Figure 5. Cortical a-synuclein accumulation and long-term in vivo imaging of PDGF-h-a-syn × GFP-M mice.
A Immunostaining with 15G7 antibody shows cortical layer V overexpression of a-synuclein (magenta) including accumulation in cell bodies (arrows).
B Experimental timeline: 4 weeks after window implantation (white arrowhead), imaging was performed over 6 weeks, once every 7 days (gray arrowheads) and finally
followed by perfusion and tissue fixation directly after the last imaging session (black arrowhead).
C Overview and detailed projections of eGFP-labeled layer V apical dendrites in the somatosensory cortex, imaged through a chronic cranial window.
Data information: Scale bars: 20 lm (A), 50 lm (C), 5 lm (C, inset).
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limited to a cell population in which the promoter is active and is
even complicated through the fact that background strain might
affect the expression pattern (Chesselet et al, 2008). Apart from
that, a-synuclein pathology induced by seeding of PFFs can be
induced in wild-type animals (Luk et al, 2012a) in a dose- and
region-specific manner. Here, however, the unphysiologically large
protein amount used for “planting the seed” should be considered.
One strong point of our combined approach was to apply and
compare both models, in order to best break down the actual
structural impact of a-syn accumulation on cortical neurons.
Collectively, our results support the idea that a-syn homeostasis is
constantly balanced on a knife-edge and that perturbations that
change its expression produces neurotoxicity with a common
mechanism in which the critical events are protein misfolding,
aggregate deposition, aggregate propagation, and synaptic dysfunc-
tion (Jucker & Walker, 2011; Guo & Lee, 2014; Luna & Luk, 2015).
Our data provide evidence for the harmful structural consequences
of excessive wild-type a-synuclein on cortical dendrites throughout
different pathological stages and may pave the way toward new
therapeutic strategies for PD and DLB that focus on the mainte-
nance of synaptic function.
Materials and Methods
Animals
PDGF-h-a-syn animals were obtained from QPS Austria Neurophar-
macology (Grambach, Austria) and bred on a C57Bl/6 background.
These transgenic mice overexpress human a-synuclein (h-a-syn)
under the regulatory control of the human platelet-derived growth
factor-b (PDGF-b) promoter (Masliah, 2000). Expression is strongest
in the neocortex, hippocampus, olfactory bulb, and limbic system,
leading to intraneuronal and synaptic a-syn accumulation as early
as 3 months of age (Fig 5A and Appendix Fig S6A–D) as well as
progressive motor deficits (Masliah, 2000; Amschl et al, 2013).
Furthermore, C57Bl/6 wild type, Thy1-eGFP transgenic mice (GFP-
M) (Jackson Laboratory, Bar Harbor, ME, USA), and a-syn knock-
out (SNCA KO) mice (Abeliovich et al, 2000) were used. For in vivo
imaging, the heterozygous PDGF-h-a-syn × GFP-M (termed h-a-syn
in this paper) line was created by interbreeding and the experiment
involved three age cohorts of both male and female mice, in which
mice were 3, 6 or 12 months old at the first imaging time point. All
animals were housed in groups under pathogen-free conditions and
bred in the animal housing facility at the Center for Neuropatho-
logy and Prion Research of the Ludwig Maximilians University of
Munich, with food and water provided ad libitum (21  2°C, at
12/12-h light/dark cycle). After cranial window implantation, mice
were housed separately. All experiments were approved by the
Bavarian government (Az. 55.2-1-54-2532-163-13) and performed
according to the animal protection law.
Injection material and stereotactic injection
Recombinant wild-type mouse a-synuclein was expressed in BL21
(DE3) E. coli using a pRK172 plasmid (kind gift from Kelvin Luk
and Virginia Lee, University of Pennsylvania, USA) as previously
described (Nuscher et al, 2004; Kostka et al, 2008). Briefly,
Escherichia coli BL21(DE3) (Invitrogen, MA, USA) were trans-
formed with the plasmid, and expression was induced with
isopropyl b-D-1-thiogalactopyranoside (IPTG, Peqlab, Erlangen,
Germany). Cells were lysed by boiling after heat-inactivation of
proteases. After centrifugation, the supernatant was filtered
through Filtropur S 0.2 filters (Sarstedt, Nümbrecht, Germany),
loaded on a HiTrap Q HP anion-exchange column (5 ml, GE
Healthcare, Munich, Germany) and eluted with a linear 25 mM to
500 mM NaCl gradient. Synuclein containing fractions were
concentrated using VivaSpin 2 columns (Sartorius, Göttingen,
Germany). Protein concentration was assessed to 5 mg/ml in
50 mM Tris–HCl, pH = 7.0. After freezing in liquid nitrogen, the
protein was stored at 80°C. Appendix Fig S2A shows blots from
the monomer preparation. Preformed fibrils (PFFs) were assem-
bled from purified a-synuclein monomer (5 mg/ml) by incubation
at 37°C with constant agitation (1,400 rpm) in an orbital mixer
(Eppendorf, Hamburg, Germany) for 96 h and stored at 80°C
(Conway et al, 2000; Deeg et al, 2015). For fluorescent labeling,
purified a-synuclein monomer (3.75 mg/ml, containing 100 mM
NaHCO3) was incubated with 0.34 mg/ml Alexa Fluor
 488 NHS
Ester (Life Technologies, Darmstadt, Germany) for 18 h at 4°C.
The remaining free fluorophore was removed from the solution
using PD-10 columns (GE Healthcare, PA, USA) according to the
manufacturer’s recommendations prior to fibril assembly as
described above. Directly before injection, an aliquot of PFFs was
sonicated four times with a handheld probe (SonoPuls Mini 20,
MS1.5, Bandelin, Berlin, Germany) according to the following
protocol: amplitude 30%; time 15 s (pulse on 3 s, pulse off 6 s).
Two-month-old mice (male or female) were anesthetized with
ketamine/xylazine (0.13/0.01 mg/g body weight; WDT/Bayer
Health Care, Garbsen/Leverkusen, Germany) and stereotactically
injected with 5 ll (25 lg) of PFFs into the dorsal striatum (coordi-
nates relative to the bregma: +0.2 mm anterior, +2.0 mm from
midline, +2.6 mm beneath the dura) of the right hemisphere using
a 5-ll Hamilton syringe. Injections were performed at 400 nl/min
with the needle in place after injection for at least 5 min. Control
animals received sterile PBS or 5 ll of 5 mg/ml monomeric
a-synuclein. Animals were monitored regularly after the surgery
and sacrificed at different predetermined time points (30 days,
60 days, 90 days, 5 months, and 9 months after injections) for
perfusion and tissue fixation with 4% paraformaldehyde.
Thioflavin T binding and sucrose gradient
For in vitro measurement of thioflavin T (ThT) binding, 10 lM ThT
was added to 100 lg/ml monomeric a-synuclein or PFFs and incu-
bated at 30°C for 10 min. Fluorescence signal was excited at 420–
460 nm and emission detected at 460–500 nm with a spectrofluorometer
(FluoStar Optima, BMG Lab Tech, Jena, Germany). Continuous
sucrose-gradient assay was performed as described previously
(Friedlander et al, 2002; Wagner et al, 2013). Briefly, six layers of
solutions with decreasing sucrose concentration (50 mM Tris pH
7.5, 0.1% NP-40, 10–60% D(+)-sucrose, respectively) were filled
into a 4 ml 11 × 60 mm polyallomer tube (Beckman Coulter, CA,
USA). Finally, 200 ll of 5 lM protein in 1× TBS (pH 7.5) containing
0.1% NP-40 was loaded on the top of the gradient. Ultracentrifuga-
tion with 100,000 g at 4°C for 1 h was performed using a Sw60Ti
rotor (Beckman Coulter, USA). Resulting continuous gradients were
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fractionated in volumes of 200 ll. 20 ll per fraction was analyzed
by denaturing Western blot using a monoclonal antibody against
mouse-a-synuclein (New England Biolabs, Frankfurt, Germany).
Electron microscopy
a-Synuclein fibrils diluted to 5 lM in H2O were adsorbed onto a
Formvar-coated, carbon-stabilized copper grid. The grid was then
rinsed briefly with H2O and stained with uranyl acetate and lead
citrate. Digital images were captured at different magnifications on a
Jeol JEM-1011 TEM (JEOL Inc., MA, USA) equipped with an 11
megapixel Orius CCD digital camera (Gatan Inc. CA, USA).
Cranial window
A cranial window was implanted over the right cortical hemisphere
as previously reported (Fuhrmann et al, 2007). In short, the mice
were given an intraperitoneal injection of ketamine/xylazine to
reach surgical anesthesia. Additionally, dexamethasone (0.01 mg/g
body weight; CP Pharma, Burgdorf, Germany) was intraperitoneally
administered immediately before surgery (Holtmaat et al, 2009). A
circular piece of the skull (4 mm in diameter) over the right hemi-
sphere (centered over the parietal bone, approx. 5.5 mm caudal
from the bregma and 5.5 mm lateral from midline) was removed
using a dental drill (Schick-Technikmaster C1; Pluradent; Offen-
bach, Germany). The craniotomy was closed immediately with a
round coverslip (4 mm in diameter), held with dental acrylic. A
small z-shaped titan bar was glued next to the coverslip to allow
repositioning of the mouse during subsequent imaging sessions.
After surgery, mice received subcutaneous analgesic treatment with
carprofen (5 mg/kg body weight; Rimadyl; Pfizer, NY, USA) and
antibiotic treatment with cefotaxime (0.06 mg/kg body weight;
Sanofi-Aventis, Frankfurt, Germany).
Long-term in vivo imaging
Imaging started 4 weeks after the cranial window preparation to
allow the animals to recover from surgery. After 6 weekly 2-photon
in vivo imaging sessions, mice were sacrificed and their brains were
fixed for further analyses (Fig 5B). Two-photon imaging was
performed on a LSM 7 MP (Zeiss, Jena, Germany) equipped with
GaAsP detectors and a 20× water-immersion objective (W Plan-
Apochromat 20×/1.0 DIC, 1.0 NA, Zeiss, Jena, Germany). eGFP was
excited at 880 nm by a Ti:Sa laser (MaiTai DeepSee, Spectra-
Physics, Darmstadt, Germany), and emission was collected from
440 to 500 nm. Image stacks of 425 × 425 × 249 lm3 were acquired
using the “z-stack” mode of the microscope control software
(ZEN 2012/ZEN 2010 64-bit) with a lateral resolution of 0.83 and
3 lm separation distance between consecutive images. Mice were
anesthetized with isoflurane (CP Pharma, Burgdorf, Germany) for
imaging and fixed to a custom-made head holder using the attached
metal bar. In subsequent imaging sessions, previously imaged
volumes were identified by eye using the unique blood vessel
pattern and fine adjusted by the position of previously imaged
dendrites. This method enabled precise alignment of the same imag-
ing volume over a period of 6 weeks (Fig 5C; Helmchen & Denk,
2005). In order to maintain stable fluorescence emission levels, the
laser power was adjusted relative to imaging depth.
Image processing and analysis of in vivo and ex vivo data
For image analysis, only microscope image data with sufficient
eGFP expression and good signal-to-noise ratio over time were
included and the experimenter was blinded to the genotype of the
mice by assigning a random number to each animal. From each
mouse (male or female, n = 4–5 in vivo, n = 6–7 seeding experi-
ment, without randomization), 9–10 dendrites from at least three
different positions underneath the cranial window or in slices were
analyzed. The length of individual dendrites was measured in ZEN
2012 (Zeiss). Spines identified along the dendrite were marked as
gained, lost, or stable. The mean density of dendritic spines was
estimated for each time point and expressed over 1 lm of dendrite
length. The stability of spines was calculated based on the amount
of spines that remained unaltered for at least two subsequent imag-
ing sessions. The spine turnover rate (TOR) was assessed based on
gain and loss of spines over each day of imaging, calculated as
follows: TOR = (Ngained + Nlost)/(2 × Npresent)/It, where Ngained,
Nlost, and Npresent represent the number of gained, lost, or total
spines at time points of interest, respectively, while It is the number
of days between consecutive imaging sessions. Ex vivo image anal-
ysis measurements were performed manually from maximal projec-
tion images of deconvoluted (AutoQuantX3, Media Cybernetics)
confocal stacks. All spines along the dendrite were marked and
categorized into three morphologically different classes, according
to established criteria (Jung et al, 2011). For analysis of the
dendritic diameter, length measurements were taken every 40
pixels along the dendritic shaft (control: 756 measurements,
n = 6, PFF-seeded: 840 measurements, n = 7) using ImageJ. To
quantify the density of glutamatergic presynaptic boutons VGLUT1-
positive Imaris 7.7.2 software was applied to detect VGLUT1-
positive puncta. In detail, the spots detection algorithm was applied
using an estimated diameter of 0.5 lm in xy and an 1.5 lm in z.
Background subtraction was enabled, and region-growing type was
set to local contrast with a manual threshold of 30 defined for all
datasets. Only spots with a xy diameter greater than 0.4 lm were
counted as boutons. The data were compiled in MATLAB using
ImarisXT interface.
Statistical analysis
The sample size of animals and imaged dendrites per animal
were chosen according to our previous experience in long-term
imaging (Neuner et al, 2014; Filser et al, 2015). Graphs were
created, and statistics were calculated in Prism v 5.04 (GraphPad
Software, San Diego, CA, USA). For in vivo time series data, two-
way ANOVA followed by the Bonferroni’s post hoc test was used
to compare the variance of spine parameters assessed over time
in control and h-a-syn animals. For assessment of inter-group dif-
ferences at single time points, Student’s t-test (unpaired, two-
sided) was applied. Normal distribution was assumed according
to the central limit theorem, as spine densities were calculated as
the means of means for every mouse. For t-tests, the variance
between groups was tested (F-test) and not found to be signifi-
cantly different. Data are expressed as mean  SEM unless other-
wise indicated, with P < 0.05 defining differences as statistically
significant (*P < 0.05; **P < 0.01; ***P < 0.001; for post hoc test:
#P < 0.05; ##P < 0.01).
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Immunohistochemistry and confocal microscopy
Animals in deep ketamine/xylazine anesthesia were killed by tran-
scardiac perfusion with 1× phosphate-buffered saline (PBS)
followed by 4% paraformaldehyde (w/v). The brains were postfixed
in PBS containing 4% paraformaldehyde overnight before cutting
60-lm-thick coronal sections on a vibratome (VT 1000S from Leica,
Wetzlar, Germany). Immunofluorescence staining was performed
on free-floating sections. Primary antibody incubation (overnight or
48 h (anti-VGLUT1), 4°C) was followed by 2 h of secondary anti-
body incubation at room temperature. Appendix Table S1 lists the
antibodies used in this study. For unambiguous analysis of GFP-
labeled neurons in eGFP-M mice, slices for spine analysis were
re-stained with anti-GFP Alexa Fluor 488 antibody (Invitrogen, Life
Technologies GmbH). Sections for the study of neuronal a-syn
accumulation were incubated with a fluorescent Nissl stain (Neuro-
traceTM 435/455, Thermo Fisher Scientific, USA). For mounting on
glass coverslips, VECTASHIELD Mounting Medium (Vector Labo-
ratories) was used. Laser wavelengths used for excitation and
collection range of emitted signals were as follows: Alexa Fluor
488/eGFP—488 nm/500–550 nm; Alexa Fluor 594—561 nm/585–743;
Alexa Fluor 647—633 nm/long-pass 650 nm; Nissl—750 nm/
435–485 nm. Analysis of dendritic spines was limited to cortical
apical dendrites from layer V neurons, cropped, and imaged at high
resolution. For imaging of presynaptic boutons, three-dimensional
16-bit data stacks of 1,024 × 1,024 × 26 pixels were acquired from
four different positions in the somatosensory cortex at a lateral reso-
lution of 0.1 lm/pixel and an axial resolution of 0.4 lm/pixel.
Appendix Fig S6E–H illustrates the automatic bouton detection
applying the algorithm.
Expanded View for this article is available online.
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Appendix Table S1. Antibodies used in this study 
Antibody Source Host Dilution 
Mouse α-syn New England Biolabs 
(4179 S) 
rabbit monoclonal 1:1000 (WB) 
15G7 human α-syn (Neumann et al, 2002) rat monoclonal 1:500 (IF) 
pS129 α-syn Abcam (ab59264) rabbit polyclonal 1:200 (IF) 
Ubiquitin Abcam (ab7780) rabbit polyclonal 1:500 (IF) 
Neurofilament-L (DA2) Cell Signaling (2835 S) mouse monoclonal 1:200 (IF) 
Iba-1 Wako (019-19741) rabbit polyclonal 1:500 (IF) 
CD68 BioRad (MCA 1957) rat monoclonal 1:1000 (IF) 
VGLUT1 Millipore (AB5905) guinea pig polyclonal 1:200 (IF) 
anti-GFP Alexa488  Invitrogen (A21311) rabbit polyclonal 1:500 (IF) 
anti-rabbit Alexa 647   Invitrogen (A21245) goat polyclonal 1:200 (IF) 
anti-rat Alexa 647 Invitrogen (A21247) goat polyclonal 1:200 (IF) 
 
Reference:  
1. Neumann, M. et al. Misfolded proteinase K–resistant hyperphosphorylated α-synuclein in aged 
transgenic mice with locomotor deterioration and in human α-synucleinopathies. J. Clin. Invest. 110, 
1429–1439 (2002). 
 
  
48
Blumenstock et al.: alpha-synuclein mediates spine pathology 
 
3 
 
 
Appendix Figure S1. Spine morphology changes in α-syn transgenic mice. Absolute 
densities of mushroom, stubby and thin spines in apical tuft dendrites of PDGF-h-a-syn mice 
compared to controls. (A) In young adult (2 and 4.5 months old) mice, the densites of 
mushroom (psyn 2/4.5mo = 0.0326; pctrl/syn 4.5mo = 0.0255), stubby (psyn 2/4.5mo  = 0.025) and thin 
spines (psyn 2/4.5mo = 0.0107; pctrl/syn 4.5mo = 0.0012) are decreased.  (B) In aged (7.5 and 13.5 
months old) mice, the densities of mushroom (p7.5mo < 0.0001; p13.5mo = 0.0005) and stubby 
spines (p7.5mo = 0.0009; p13.5mo = 0.008) are decreased in h-a-syn mice compared to controls. 
A: n = 3 (control 2 mo), n = 4 animals per group. B: n = 4 animals per group, mean with 
s.e.m; *p<0.05, **p<0.01. Student‘s t-test. 
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Appendix Figure S2. Distribution of phosphorylated α-syn aggregates in the mouse 
brain. (A) Full coomassie blot and western blot against mouse α-syn (14 kDa) from the initial 
momomer preparation of mouse α-syn, demonstrating the purity of the sample before PFF 
production. (B) 5 months after striatal injection, dense neuronal pS129-immunopositive 
inclusions are present most prominent in the ipsilateral cortex (layer IV and V) of the injection 
site and in the amygdala. Due to known cross-reactivity of the pS129 α-synuclein antibody 
with phosphorylated neurofilament subunit L (NFL), white matter tracts are stained as well 
(C) Double staining (in the amygdala) distinguishes between false positive staining of white 
matter and pathological α-synuclein aggregates in cell bodies and neurites. (D) Spread of α-
syn aggregates 5 months after seeding. Magenta dots mark the position of intracellular 
aggregates. Am: amygdala, SNpc: substantia nigra pars compacta, SNpr: substantia nigra 
pars reticulata. (E) Injection with monomeric α-synuclein into mice expressing endogenous α-
syn or PFFs into SNCA KO mice does not lead to the spreading of α-syn aggregates. Image 
stacks (B,C,E) are depicted as maximum intensity projections.  Scale bars: B = 500 μm; C = 
20 μm; E = 50 μm. 
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Appendix Figure S3: Templated misfolding of α-synuclein. (A) Neocortical layer V 
pyramidal neuron containing a phosphorylated α-synuclein inclusion. (B) Brain overview at 1 
day post-injection (dpi) with fluorescently labeled PFFs. (C) Injection site in the striatum at 1 
dpi. White arrowheads mark cells that have internalized fluorescent PFFs. (D) Brain overview 
at 6 dpi shows that fluorescently labeled PFFs have been removed from the injection site 
(asterisk). (E, F) At 30 dpi, small puncta of fluorescent PFFs locate to the injection canal 
(asterisk) and to some cortical cell bodies (arrows). The developing phospho-α-syn 
inclusions (arrowheads) however, consist largely of non-fluorescent α-synuclein (F). Scale 
bars: B,D = 500 μm; E = 100 μm; C = 50 μm; A,F = 5 μm. 
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Appendix Figure S4. Presence of microglia in the neocortex. 5 months post-injection with 
PFFs or PBS (ctrl), staining across cortical layers II-VI were performed against (A) Iba1, 
marking the total number of microglia (layer IV is indicated as a dashed line, as no double 
staining with pS129 could be performed) and (C) CD68, marking actively phagocytic 
microglia. (B,D) area coverage of microglia in % in maximum intensity projections of 10µm of 
cortical thickness (scaling Z = 2 µm). (E) occasional colocalization of CD68 positive microglia 
and pS129 positive aggregates (white arrows) is present in layer IV. n = 5 animals per group, 
mean with s.e.m; Student‘s t-test. Scale bars: A,C = 50 µm; E = 10 µm. 
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Appendix Figure S5. Spine morphology changes in PFF-seeded mice (5 mo post-
injection). Absolute densities of mushroom, stubby and thin spines in (A) apical tuft 
dendrites of layer I (pmushroom= 0.0029, pstubby= 0.0179, pthin= 0.0058) and (B) layer IV/V apical 
dendrites (pmushroom= 0.0046) in PFF seeded mice compared to controls. n = 6 (control), n = 7 
(PFF) animals, mean with s.e.m; *p<0.05, **p<0.01. Student‘s t-test. 
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Appendix Figure S6. Presynaptic glutamatergic bouton density does not differ in 
seeded or transgenic mice. (A) Transgenic α-syn expression and (B) glutamatergic 
presynapses (C) show overlapping confocal signal. White arrows exemplarily mark double-
stained boutons. (D) The expression level of α-syn does not differ significantly across age 
groups. (E) VGLUT1 immunosignal in green exhibiting a spot-like pattern. (F) The same 
image is shown after local background subtraction to diminish intensity variations among 
different stacks and Gaussian filtering to reduce image noise. (G) VGLUT1-positive puncta 
representing single boutons are shown in magenta as detected by automatic spot detection 
using Imaris software. (H) Overlay of VGLUT1 immunosignal (green) and the detected 
boutons (magenta). Cyan color highlights regions that were automatically detected as blood 
vessels and were excluded from the analyzed volume. (I) The bouton density between 
control and PFF mice does not differ. n=6-7 animals per group, Mann-Whitney-U-Test, 
P>0.05. (K) The bouton density does not show a change with age nor between the groups. 
Two-way analysis of variance “age” F(2)=1.32, p>0.05 and “interaction” F(2)=1.5, p>0.05; n = 4 
animals per group. (L) Since age had no effect on bouton density mice of all three age 
cohorts were pooled and the groups were compared using the unpaired t-test; p > 0.05, n = 
12 animals per group, mean with s.e.m. Scale bars: 15 µm. 
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Impaired plasticity of cortical dendritic spines in
P301S tau transgenic mice
Nadine A Hoffmann1,2, Mario M Dorostkar1,2, Sonja Blumenstock2, Michel Goedert3 and Jochen Herms2,4*
Abstract
Background: Illuminating the role of the microtubule-associated protein tau in neurodegenerative diseases is of
increasing importance, supported by recent studies establishing novel functions of tau in synaptic signalling and
cytoskeletal organization. In severe dementias like Alzheimer’s disease (AD), synaptic failure and cognitive decline
correlate best with the grade of tau-pathology. To address synaptic alterations in tauopathies, we analyzed the
effects of mutant tau expression on excitatory postsynapses in vivo.
Results: Here we followed the fate of single dendritic spines in the neocortex of a tauopathy mouse model,
expressing human P301S mutated tau, for a period of two weeks. We observed a continuous decrease in spine
density during disease progression, which we could ascribe to a diminished fraction of gained spines. Remaining
spines were enlarged and elongated, thus providing evidence for morphological reorganization in compensation
for synaptic dysfunction. Remarkably, loss of dendritic spines in cortical pyramidal neurons occurred in the
absence of neurofibrillary tangles (NFTs). Therefore, we consider prefibrillar tau species as causative for the
observed impairment in spine plasticity.
Conclusions: Dendritic spine plasticity and morphology are altered in layer V cortical neurons of P301S tau
transgenic mice in vivo. This does not coincide with the detection of hyperphosphorylated tau in dendritic spines.
Keywords: Tau, P301S mutation, Dendritic spines, Synaptic plasticity, Two photon in vivo imaging
Background
Intracellular aggregates of the microtubule-associated
protein tau are found in a large number of neurodegenera-
tive diseases, including AD and frontotemporal dementia
and parkinsonism linked to chromosome 17 (FTDP-17)
[1,2]. In these so-called tauopathies, hyperphosphorylation
of tau promotes its detachment from microtubules, result-
ing in tau mislocalization to the somatodendritic compart-
ment, where it forms oligomers, neuropil threads and
NFTs. The pathological mechanisms triggered by abnormal
tau remain largely unknown, especially with regard to syn-
aptic failure. In sporadic AD, tau-pathology precedes de-
position of extracellular amyloid-β and correlates best with
the grade of dementia [3]. Moreover, synaptic dysfunction
is believed to be the primary cause of cognitive decline in
AD and other dementias [4]. Thus, for understanding the
pathological mechanisms causing tauopathies, as well as
for the development of therapies, illuminating the effects
of tau on synapses is indispensable.
Recently, Hoover et al. showed that dendritic spines
are the locus of early synaptic malfunction caused by
tau. Thereby, mistargeting of hyperphosphorylated tau
to intact spines mediates synaptic dysfunction independ-
ently of neurodegeneration [5]. This detrimental role of
hyperphosphorylated and misdistributed tau is further
supported by the finding that dendritic tau mediates
amyloid-β toxicity [6] and tau knockout prevents early
lethality and behavioural deficits in an AD mouse model
[7]. Dendritic spines and synaptic pathology in tauopathy
mouse models have also been analyzed by other groups,
obtaining divergent results: rTg4510 mice, transgenic for
human tau with the FTDP-17 mutation P301L, show re-
duced spine density and impaired dendritic complexity
of pyramidal neurons in the cortex, both in the absence
and presence of NFTs [8,9]. Synapse loss in the hippo-
campus before the emergence of fibrillary tangles was
described for a mouse line expressing P301S mutated
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human tau under the murine prion promoter [10]. A re-
duced hippocampal spine density was also found in
TauRD/ΔK280 mice, expressing proaggregation mutant
tau [11]. Conversely, an age-dependent increased spine
density in cortical layer III, but no alterations in the
hippocampus were reported for transgenic mice express-
ing human P301L or wildtype tau [12]. In cortical layer
III pyramidal neurons of mice expressing all six human
tau isoforms instead of murine tau, the spine volume de-
creases with advancing age, while spine density stays un-
affected [13]. Since these studies were based on fixed
brain tissue, so far, dendritic spine plasticity has not been
analyzed in a tauopathy mouse model in vivo. Therefore,
alterations in the total number of spines could not be
attributed to changes in spine kinetics.
In this study, we investigated the effects of mutant tau
expression on the structural plasticity of dendritic spines
in P301S Tau mice [14]. They express human tau protein
bearing an FTDP-17 mutation [15] under the control of
the murine thy1-promoter. FTDP-17 patients carrying
this mutation suffer from an early onset, rapidly progres-
sive frontotemporal dementia and parkinsonism in com-
bination with epileptic seizures [16]. Homozygous P301S
Tau mice similarly exhibit severe tau-pathology already
at 5–6 months of age: Abundant intracellular filaments
composed of hyperphosphorylated tau deposit in several
regions of the central nervous system (CNS), especially
the brain stem and spinal cord [14,17-20]. Progressive
neuron loss, accompanied by neuroinflammation, can be
found in cortical layers I/II [21], but early behavioral
abnormalities have been reported well before the onset
of neurodegeneration [22].
By means of long-term two-photon in vivo imaging,
we found a progressive spine loss on apical tuft den-
drites of cortical layer V neurons in 4-month-old P301S
Tau mice. The remaining spines were enlarged in head
volume and increased in length. Immunohistochemical
characterization of the analyzed pyramidal neurons re-
vealed them to be bare of NFTs or hyperphosphorylated
tau. In contrast to other brain regions like hippocampal
CA3 pyramidal neurons, where abundant deposits of
hyperphosphorylated tau can be found in dendritic
spines, these were absent in the cerebral cortex. This
observation is in line with what is seen in the brain tissue
of AD patients [23,24].
Methods
Transgenic mice
For two-photon in vivo imaging, homozygous mice
transgenic for the 383 amino acid isoform of human tau
protein with the familial FTDP-17 mutation P301S [14]
were crossbred with mice of the YFP-H line [25] (obtained
from The Jackson Laboratory, Bar Harbor, ME, USA).
Mice homozygous for tau (P301S Tau x YFP-H mice) were
used in experiments, while mice lacking mutant tau served
as wildtype controls. The mice were exclusively male and
the offspring of the same founder animals. Tau homozy-
gosity was determined by real time PCR. Mice were group
housed under pathogen-free conditions until surgery from
which on they were singly housed. All procedures were
performed in accordance with an animal protocol ap-
proved by the Ludwig Maximilian University of Munich
and the Government of Upper Bavaria (ref. num. 55.2-
1.54-2531-110-06).
Cranial window surgery
A chronic cranial glass window was implanted over the
right hemisphere of the cerebral cortex (Figure 1a), ap-
plying the open skull preparation as previously described
[26,27]: The mice were anesthetized by an intraperitoneal
injection of ketamine/xylazine (130 and 10 μg/g body
weight, respectively). Additionally, anti-inflammatory dexa-
methasone (6 μg/g body weight) was administered intra-
peritoneally and body temperature was maintained by
a heating pad. A circular piece of the skull, 4 mm in
diameter, was removed above the somatosensory cortex
(centered at the right parietal bone, approximately 2 mm
caudal of the bregma and 2.5 mm lateral of the midline),
using a dental drill (Schick-Technikmaster C1; Pluradent;
Offenbach, Germany). To close the craniotomy, a round
coverslip (5 mm in diameter) was glued to the skull using
dental acrylic (Cyano-Veneer fast; Heinrich Schein Dental
Depot, Munich, Germany). A small metal bar, containing
a screw thread, was mounted next to the coverslip to allow
fixation and precise repositioning of the mouse head dur-
ing subsequent imaging sessions. After surgery, mice re-
ceived a subcutaneous analgesic dose of carprophen
(7.5 μg/g body weight Rimadyl; Pfizer, New York, USA).
Long-term two-photon in vivo imaging
To avoid neuroinflammatory responses, in vivo imaging
was performed after a 3 week recovery period. Each im-
aging session lasted for no longer than 60 min during
which mice were anesthetized by an intraperitoneal in-
jection of ketamine/xylazine (130/10 μg/g body weight)
and body temperature was maintained by a heating pad.
YFP was excited by a titanium-sapphire laser (MaiTai,
Spectra-Physics, Darmstadt, Germany) at 880 nm and
the emission was collected using a 500–550 nm band-
pass filter (LSM 5MP, Carl Zeiss MicroImaging GmbH,
Jena, Germany). Less than 50 mW laser power was de-
livered to the tissue to prevent laser-induced phototoxic-
ity. A 20x water-immersion objective (1.0 NA; Carl Zeiss
MicroImaging GmbH) was used to acquire overview
stacks of 425 × 425 × 350 μm3, starting at the brain sur-
face, with 0.41 × 0.41 × 3.00 μm3 xyz-scaling. Subse-
quently, single spiny dendritic elements at a depth of 50–
120 μm of this volume were imaged at high resolution
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Figure 1 Decreased dendritic spine density and impaired spine kinetics in P301S Tau mice. a Location of the chronic cranial glass
window, as implanted for long-term in vivo imaging of YFP-expressing neurons. b Example of an isolated, volume rendered layer V neuron in a
425 × 425 × 550 μm3 xyz-stack of the somatosensory cortex. A section of an apical tufted dendrite, stretching in parallel to the brain surface, is
shown in higher magnification (maximum intensity projection; scale bar: 5 μm). c-c’ Dendritic elements in 4-month-old wildtype (c) and P301S
Tau mice (c’) were analyzed by high-resolution two-photon in vivo imaging over a time period of two weeks (d: day). Repetitive imaging allows
discrimination of stable, gained, and lost spines (black, green, and red arrowheads respectively; maximum intensity projections; scale bars: 2 μm).
d Spine density was reduced in P301S Tau mice at the first in vivo imaging session. Presented are means per animal of 8 mice; 61–82 dendrites
per group; 14–22 dendrites per mouse; means ± SD per group in red. e During the following 14 days, the spine density stayed stable in wildtype
mice but further declined in P301S Tau mice. Presented are means ± SEM of 28–41 dendrites in 3–4 mice per group, 8–12 dendrites per mouse;
normalized to the first imaging day. Line, linear fit. p <0.01 (F test of means). f-h In P301S Tau mice, the densities of persistent (f) and lost spines
(g) was not significantly impaired, while the density of gained spines was decreased (h). Presented are means ± SD of 3–4 mice per group; 28–41
dendrites; 8–12 dendrites per mouse. b, c, e, f & g: Unpaired t test; * p < 0.05.
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(0.16 × 0.16 × 1.00 μm3 xyz-scaling). To ensure that these
apical tuft dendrites arose from layer V neurons, and ex-
clude YFP-expressing layer II/III neurons, only dendrites
protruding a depth of 350 μm were chosen (Figure 1b). In
subsequent imaging sessions, previously imaged regions
were relocalized and precisely aligned based on the unique
pattern of blood vessels, neuronal cell bodies, and their
processes. Laser intensity was adjusted to keep the emitted
YFP fluorescence stable.
Immunohistochemistry
Brains of 4- and 6-month-old P301S Tau x YFP-H mice
of mixed sex were processed for immunohistochemistry.
Following transcardial perfusion of the mice with phos-
phate buffered saline (PBS) and 4% paraformaldehyde
(PFA) in PBS at 4°C, brains were removed and fixed in
4% PFA in PBS over night at°C. In an attempt to im-
prove tissue preservation for tau detection in dendritic
spines, as described by Kremer et al. (2011), some mice
were alternatively perfused with PBS at 4°C, brains were
removed and hemispheres were fixed over night at 4°C
in either 4% PFA in PBS or in Bouin solution (71.4% sat-
urated picric acid, 23.8% formaldehyde, 4.8% glacial
acidic acid). 100 μm free-floating frontal sections of the
somatosensory cortex were cut on a vibratome (VT1000S,
Leica Microsystems GmbH, Wetzlar, Germany). During all
following steps, the sections were kept on a shaker at room
temperature. To permeabilize the tissue, the sections were
incubated over night in 2% Triton X-100 in PBS.
For AT8-, AT180-, and HT7-stainings, background
signal was reduced using Endogenous Biotin-Blocking
Kit E-21390 (Molecular Probes, Eugene, OR, USA). Sec-
tions were incubated in 10% normal goat serum (NGS),
1% bovine serum albumin (BSA), and 0.1% Triton X-100
in PBS before primary antibody incubation in 5% BSA
and 0.1% Triton X-100 in PBS over night. The following
monoclonal antibodies, conjugated to biotin, were used
in 1:200 dilutions: HT7 recognizing human tau, AT8
recognizing human and murine tau phosphorylated
at S202 and T205, and AT180 recognizing human
and murine tau phosphorylated at T231 and S235 (all
from Thermo Scientific Pierce Protein Research Products,
Rockford, IL, USA). Enzyme-mediated antibody-detection
was performed using TSA™ kit #26 (Invitrogen, Carlsbad,
CA, USA) with HRP-streptavidin (1:200) in 1% BSA in
PBS and Alexa Fluor 647 tyramide (1:200), according to
the manufacturers’ instructions.
For AT100-stainings, non-specific epitopes were blocked
with Casein I-Block (Invitrogen) for 1 hour. AT100
(Thermo Scientific Pierce Protein Research Products),
recognizing human and murine tau phosphorylated at
Alzheimer-specific epitopes S212 and T214, was ap-
plied for 4 hours, diluted 1:200 in PBS. Detection was
performed by incubating the sections with secondary
anti-mouse antibody conjugated to Alexa Fluor 647
(1:200 in PBS; Invitrogen) for 4 hours.
For all stainings, sections were finally washed 5x10 min
with PBS before mounting on glass coverslips using fluor-
escence mounting medium (Dako, Glostrup, Denmark).
Confocal microscopy
Fluorescence images were acquired with a confocal laser
scanning microscope, mounted on an inverted micro-
scope support (LSM 510 and AxioVert 200, Carl Zeiss
MicroImaging GmbH). Alexa Fluor 488 was excited by
an argon laser at 488 nm and emission was collected
using a 500–550 nm bandpass filter. Alexa Fluor 647
was excited by a helium-neon laser at 633 nm and emis-
sion was collected using a 650 nm longpass filter.
For the AT8-YFP-correlation, a 40x oil-immersion ob-
jective (Plan-Apochromat, NA 1.3; Carl Zeiss MicroIma-
ging GmbH) was used to obtain 360 × 360 × 50 μm3
stacks with 0.35 × 0.35 × 2.00 μm3 xyz-scaling. Per ani-
mal 10 stacks of layer V neurons were analyzed.
Image processing and data analysis
Dendritic spine density was determined using ZEN
2011 Light Edition software (version 7.0, Carl Zeiss
MicroImaging GmbH). Images were corrected with a
gamma of 0.45 and spines were counted manually by
scrolling through the z-stacks. In time-series, a den-
dritic spine was defined as the same if its location did
not change within a range of 1 μm along the dendrite.
Since z-scaling was limited to 1 μm, only protrusions em-
anating laterally from the dendritic shaft were analyzed.
For morphological spine analysis, the three-dimensional
in vivo images were deconvolved (AutoQuant, version
X2.0.1, Media Cybernetics, Bethesda, USA) and semi-
automatically remodelled (Imaris 6.1.5, Bitplane, Zurich,
Switzerland). Spine subtypes were identified using the
Imaris XT spine classification module, based on the follow-
ing hierarchical algorithms (adapted from [28]): mushroom
spine: “max_width(head)/min_width(neck) > 1.4 and max_
width(head) > 0.4 μm and min_width(neck) > 0 μm”;
stubby spine: “length(spine)/mean_width(neck) ≤ 3 or
min_width(neck) = 0 μm or > 0.5 μm”; thin spine: length
(spine)/mean_width(neck) > 3.
Analysis was performed blinded in respect to mouse
genotype.
YFP- and / or AT8-positive layer V pyramidal neurons
were counted manually using ZEN 2011 Light Edition
software (version 7.0; Carl Zeiss MicroImaging GmbH).
All data are presented as mean ± SD or ± SEM, as
stated in the figure legends. Statistical differences be-
tween two groups were determined using unpaired t test.
Since spine head volumes had a log-normal distribution,
in this exceptional case the t test was done on log-
transformed data. All other measurements represent
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means of means, which according to the central limit the-
orem approximate a normal distribution. Therefore, we
used a parametric test. The slope from a linear regression
was tested for statistical difference from zero by F test.
Statistical analysis and graphs were done using Prism soft-
ware (version 5.04, GraphPad Software Inc., La Jolla, CA,
USA). Figures were arranged using Adobe Illustrator CS4
Extended software (version 11.0.2, Adobe Systems, San
Jose, CA, USA).
Results
In order to analyze the effects of cortical tau-pathology
on dendritic spines, we performed long-term two-
photon in vivo imaging of P301S Tau mice (Figure 1a).
The line was crossbred with mice of the YFP-H line,
expressing yellow fluorescent protein in a subset of cor-
tical neurons, i.e. layer II/III and V pyramidal neurons
(Figure 1b). Thus, we were able to follow the fate of in-
dividual dendritic spines in 4-month-old homozygous
P301S Tau mice and age-matched wildtype mice through
a chronic cranial window (Figure 1c-c’).
Decreased cortical spine density in P301S tau mice
The spine densities of apical tuft dendrites of layer V
neurons showed high variance, ranging from 0.24 to
0.60 spines/μm in wildtype mice and 0.20 to 0.60 spines/
μm in P301S Tau mice. Overall, we found a reduction
in the mean spine density of P301S Tau mice by 17%
(0.34 ± 0.04 compared to 0.41 ± 0.01 spines/μm in wild-
type mice, Figure 1d). By relocalizing and repeatedly im-
aging the same dendritic elements every 3–4 days for a
period of two weeks (Figure 1c-c’), we observed further
aggravation of total spine loss in P301S Tau mice during
disease progression: The relative spine density declined
to 0.94 ± 0.15 of the initial value, while remaining un-
changed in wildtype mice (1.01 ± 0.13; Figure 1e).
Tau transgene expression affects spine kinetics
High-resolution, long-term in vivo imaging enables very
detailed analysis of spine kinetics (Figure 1c-c’). By care-
fully following the fate of single spines, the densities of
stable, gained, and lost spines can be determined for
each consecutive imaging session, providing a measure-
ment of synaptic plasticity. We detected no significant
change in the densities of persistent spines (i. e. stable
for at least one week; Figure 1f ) and lost spines (i. e. dis-
appearing from one to the consecutive imaging session;
Figure 1g) in P301S Tau mice. However, while in wild-
type mice the permanent loss and gain of spines was
well-balanced (0.083 ± 0.012 vs. 0.087 ± 0.015 spines/μm,
respectively; Figure 1g-h), the spine turnover in P301S
Tau mice was shifted: The density of gained spines (i. e.
newly emerging from one to the consecutive imaging
session) was reduced (0.058 ± 0.008 spines/μm), compared
to wildtype mice (Figure 1h). Therefore, we could attribute
the constant loss of total spines to a diminished formation
of new spines caused by tau transgene expression.
Homozygous P301S Tau mice show age-dependent
neurodegeneration – especially in the brainstem [14],
but also in superficial cortical layers, where mainly
GABAergic interneurons are affected [21]. In order to
determine whether YFP-expressing cortical neurons get
lost, we followed the fate of layer V neurons’ apical
dendritic trees as well as layer II/III neuronal somata in
4-month-old P301S Tau mice. However, in a time period
of up to 6 weeks we did not detect the disappearance of
any dendritic branches or the loss of a single neuron
(analysis of 199 cells in 5 mice; data not shown).
Morphological spine alterations in P301S tau mice
Since dendritic spine function and morphology are strongly
correlated, we performed three-dimensional reconstruc-
tions of the in vivo imaged dendritic spines to compare
morphological parameters (Figure 2a-a’). Thereby, we
found the spines of P301S Tau mice to be strongly enlarged
in spine head volume (0.15 ± 0.05 μm3 compared to 0.08 ±
0.01 μm3 in wildtype; Figure 2b), accompanied by a smaller
increase in spine length (2.04 ± 0.14 μm compared to
1.69 ± 0.13 μm in wildtype; Figure 2c). Moreover, we classi-
fied the spines according to their length, maximum head
width, mean and minimum neck width into thin, stubby,
and mushroom spines. In P301S Tau mice, the fraction of
thin spines was strongly reduced (15.39 ± 10.43 compared
to 28.23 ± 7.42 spines/μm in wildtype), while we measured
a gain in mushroom spines (58.63 ± 16.96 compared to
39.58 ± 7.92 spines/μm in wildtype). The stubby spine frac-
tion, however, was not significantly changed (Figure 2d).
Cortical spine impairments in the absence of NFTs
In search for the causative pathological process under-
lying the described spine alterations in P301S Tau mice,
we focused on tau-pathology in YFP-expressing cortical
layer V neurons, the apical tufted dendrites of which we
imaged. In the transgenic mice both YFP and the mutant
human tau are expressed in neuronal subsets under the
control of the murine thy1-promoter. Expression pat-
terns of the transgenes can vary nevertheless, depending
on stochastic factors upon transgene insertion. To verify
if the dendrites imaged in vivo belonged to neurons ex-
pressing the human tau transgene, we performed immu-
nohistochemical labelling for human tau on brain slices
(antibody HT7; Figure 3a). Correlating the HT7-staining
with the YFP-expression (Figure 3a’), we found most of
the YFP-positive layer V neurons to show at least weak
somatic HT7 immunoreactivity (Figure 3a”). Despite the
broad expression of both proteins in the neocortex, it is
not possible to verify that all of the analyzed neurons
did express the tau transgene.
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Homozygous P301S Tau mice develop severe tau-
pathology with abundant filaments of hyperphosphory-
lated tau in the cerebral cortex already at young ages
[14,21]. Hence, we expected many of the YFP-expressing
layer V neurons to contain pre-tangle or tangle-like tau-
aggregates. In search for a fluorescent, brain-permeable
dye for in vivo labelling of these tau-deposits, we tested the
amyloid-binding Congo red derivative FSB ((trans,trans)-1-
fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene)
[29,30], which stains filamentous tau in the spinal cord and
Figure 2 Tau transgene expression affects dendritic spine morphology. a-a’ In vivo imaged dendritic spines (a maximum intensity projection) were
reconstructed (a’, 3D wireframe graphics) and classified into mushroom (red), stubby (green), and thin spines (blue) based on morphological parameters
using Imaris software. Scale bar: 2 μm. b-d In P301S Tau mice, the spine head volume was enlarged (b) and the spine length was increased (c), causing a
shift in the fractions of morphological spine classes (d). Presented are means ± SD of 3–4 mice; 130–167 spines on 10 dendrites per group; 32–45 spines
on 2–4 dendrites per mouse. Unpaired t test of log-transformed data (b), unpaired t test (c, d); * p < 0.05.
Figure 3 YFP-expressing layer V neurons are free of hyperphosphorylated tau. a-a” Immunohistochemical labeling of human tau (antibody
HT7, magenta, a) in the somatosensory cortex of a 4-month-old P301S Tau x YFP-H mouse. One cell filled with densely accumulated somatodendritic
tau is marked by an asterix. YFP-expressing layer V pyramidal neurons (green, a’) bearing the tau transgene show white cytosol labeling on the merged
image (a”; inset). b-b” Staining of hyperphosphorylated tau (antibody AT8, magenta, b) in the somatosensory cortex of a 4-month-old P301S Tau x
YFP-H mouse revealed only very few YFP-expressing layer V neurons (green; b’) to contain AT8-positive tau (white cell in b”). c-d Pie charts of
the fractions of YFP-expressing (YFP+) layer V neurons containing (AT8+) or lacking (AT8-) AT8-positive hyperphosphorylated tau in 4- (c) and
6-month-old (d) P301S Tau mice. Presented are means ± SD of 5–6 mice per group; 1983–2433 cells in 0.32-0.39 mm3 tissue. a-a” and b-b”
show maximum intensity projections of 50 μm z-stacks. Scale bars: 50 μm; inset: 30 μm.
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retina of P301S Tau mice, as shown earlier by other groups
and us [19,31,32]. Applying the same method we did, how-
ever, not succeed in labelling any intracellular tau filaments
in the cerebral cortex with FSB, detectable by in vivo im-
aging. Analysis of brain sections from FSB-injected mice
revealed many labelled cells in the brain stem though,
serving as a positive control. To further exclude the pres-
ence of NFTs in superficial cortical layers, we also tested
thioflavin S. This well-established amyloid-binding fluoro-
phore marks NFTs, such as in the brain of the rTg4510
tauopathy mouse model [9,33]. Since fluorescence spectra
of YFP and thioflavin S largely overlap, we used P301S Tau
mice lacking the YFP-transgene to apply thioflavin S ac-
cording to the published protocol [33]. Again, no specific
signal of the dye could be detected. Even 6-month-old
mice, at the stage when the animals die as a conse-
quence of the tau-pathology in the brain stem, were bare
of FSB- or thioflavin S-labelled cells in the accessible cor-
tical regions.
In default of an in vivo dye, we stained brain sections
for hyperphosphorylated tau using the antibody AT8
(Figuire 3b-b”). To our surprise, we found AT8-positive
tau only in a marginal fraction of YFP-expressing layer V
neurons in 4-month-old P301S Tau mice (0.12 ± 0.13%,
i.e. 3 of 2433 YFP + cells were AT8+; furthermore, 19
AT8+ cells did not express YFP (data not shown);
Figure 3c), and even in 6-month-old mice (1.69 ± 2.87%,
i.e. 34 of 1983 YFP + cells were AT8+; furthermore, 146
AT8+ cells did not express YFP (data not shown);
Figure 3d). Hence, we conclude that the neurons im-
aged in vivo most likely did not contain detectable
amounts of somatodendritic hyperphosphorylated tau
nor NFTs which could account for the observed spine
abnormalities.
Immunohistochemical stainings do not reveal tau in
cortical spines
Since there is recent evidence that mislocalization of
hyperphosphorylated tau to dendritic spines leads to
synaptic impairments [5], we next aimed to look for
tau in spines of cortical layer V neurons. Quantita-
tive biochemical methods such as protein-detection in
synaptosome- and PSD-fractions cannot detect alterations
in specific populations of neurons and are therefore un-
able to to distinguish broad systemic effects from more
subtle changes in neuronal subpopulations. Therefore, we
decided to perform immunohistochemical stainings for
tau on fixed brain slices of the cortical region analyzed
in vivo using the phosphorylation-dependent antibodies
AT8, AT100, and AT180 (Figure 4a-f).
We found AT8-positive hyperphosphorylated tau in
the somatodendritic and axonal compartments of several
neurons, as well as in neuritic dystrophies and neuropil
threads, but never in dendritic spines (Figure 4a-c”’). The
sparse labeling with AT100 and AT180 was usually re-
stricted to the soma and the main shaft of the arising
apical dendrite (Figure 4d-e), in a few cases also staining
higher-order distal dendritic branches in a punctate pat-
tern (Figure 4f). Unlike the phospho-tau stains, a large
number of neurons were labelled with the human tau
specific antibody HT7, congruent to the pan-neuronal ex-
pression of the transgene (Figure 3a). Only a few cells,
however, showed neuritic staining and in none of those
dendritic spines were stained.
Also after application of an alternative brain tissue fix-
ation technique using Bouin solution, which is supposed
to improve tau detection [12], (phospho-)tau could not
be observed in cortical dendritic spines. These results
were furthermore affirmed by DAB-stainings of con-
ventional paraffin sections, thus avoiding impairments
of antibody penetration due to section thickness. The
usage of enzyme-mediated antibody detection provides
strong signal enhancement, enabling tau localization
even in very fine structures like axons or thin dendritic
branches (Figure 4c’, c”’). By analyzing YFP-negative
cells (Figure 4c-j), we also excluded detractions of
antibody-binding by the presence of YFP in the post-
synaptic compartment. Yet, when analyzing different
brain regions like hippocampal CA3 (Figure 4g-j), AT8-
positive tau was clearly localized in neuronal spiny protru-
sions (inset Figure 4g). AT100- and AT180-labeling was
again less pronounced (Figure 4h-j), resembling the cortical
staining pattern. These findings hint at distinctive patho-
logical mechanisms, leading to brain region and neuronal
subtype specific tau mislocalization in tauopathies.
Discussion and conclusions
Dendritic spine abnormalities in tauopathy mouse models
The generation of dozens of tau transgenic mouse models
during the past years (reviewed in [34,35]) has facilitated
studying the potential role of tau in neurodegenerative dis-
eases (reviewed in [2,15]). However, with regard to synap-
tic density and dendritic spine morphology, inconsistent
effects of tau on synapses have been described, strongly
depending on the tauopathy model, the stage of the dis-
ease and the brain region analyzed [9,10,12,13]. All these
approaches were performed ex vivo, therefore missing kin-
etic spine data which can only be obtained by in vivo im-
aging as presented in our study.
Dendritic spines are not rigid structures but rather
bear a strong potential for morphological plasticity, thus
enabling neurons to modify their synaptic interconnec-
tions, the correlates of learning and memory [36]. While
the majority of spines is stable, a small fraction is per-
manently retracted or newly formed, even in the adult
brain [20]. Underlying changes in dendritic actin fila-
ments, modifying spine morphology, can occur on time
scales from seconds to hours [37]. Changes in the total
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number of spines such as a reduced spine density can
therefore result from either a loss of persistent spines, a
diminished fraction of new spines or an enhanced frac-
tion of retracted spines.
We measured a reduced spine density on apical tuft
dendrites of cortical layer V pyramidal neurons in 4-
month-old homozygous P301S Tau mice which further
decreased during the two weeks imaging period. Obtain-
ing kinetic data on single spine level, this was attributed
to a diminished density of gained spines, while the stable
(respectively persistent) and lost spine densities were
largely unaffected compared to wildtype mice. The
remaining spines underwent morphological reorganization:
They were longer and the head volume was strongly en-
larged, thus increasing the mushroom spine fraction at the
cost of the thin spines.
Numerous studies have shown that spine volume is
proportional to the size of the postsynaptic density
and the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid) receptor content (reviewed in [38]). Thus,
we propose that the observed spine remodelling displays a
compensatory mechanism for the loss of total spine num-
ber, thereby strengthening the remaining synaptic contacts.
Moreover, the decrease in gained spines is morphologically
reflected in the diminished fraction of thin spines, which
commonly correspond to non-synaptic transient precur-
sors of the larger established spines [39,40].
Previous studies on tauopathy mouse models have ob-
tained divergent results with regard to dendritic spines:
While in most models, the spine density was found to
be reduced [8-10], in others an increased [12] or un-
changed spine density [13] was observed. Direct compari-
son of the results is hindered by both genetic differences
of the mouse models used as well as specific properties of
the diverse neuronal populations analyzed. However, detri-
mental effects of abnormal tau were found in most stud-
ies, thereby causing a loss of dendritic spines. Our study
adds the important finding that expression of P301S mu-
tant human tau impairs spine turnover and morphology,
leading to a net loss of spines, accompanied by structural
reorganization.
Mislocalization of hyperphosphorylated tau to spines
It was reported recently that tau localization to dendritic
spines mediates synaptic dysfunction in FTDP-17 and
AD mouse models [5,6]. This was shown mainly by ana-
lyzing cultured hippocampal neurons of mice expressing
P301L mutated, truncated, or wildtype human tau (lines
Figure 4 Failure to detect tau in cortical dendritic spines by means of immunohistochemistry. Immunohistochemical labeling of
hyperphosphorylated tau (antibodies AT8, AT100, and AT180) in cortical layer V pyramidal neurons (a-f) and hippocampal CA3 neurons (g-j).
a-a” YFP-expressing neuron, filled with somatodendritic AT8-positive tau. The marked section of the apical dendrite (dashed rectangle in a”) is shown
in higher magnification in b-b”, demonstrating that the protruding YFP-positive dendritic spines (exemplarily marked by arrowheads) are bare of
hyperphosphorylated tau. c Example of a YFP-negative layer V neuron (c’-c”’, magnifications of the regions marked by dashed rectangles),
containing AT8-positive tau in its soma, axon (arrows in c’), basal dendrites (arrowheads in c’), apical dendritic shaft (c”), and higher-order distal
dendritic braches (arrowheads in c”’). An adjacent AT8-positive layer II/III neuron shows a similar punctate pattern of hyperphosphorylated tau in its
dendritic filaments (arrows in c”’), not to be mistaken for emanating spines. AT8-labeling is also found irregularly in the neuropil, for example in
neuritic dystrophies (asterisks in c”’). Different from the cortex, in hippocampal CA3 neurons, AT8-positive hyperphosphorylated tau was frequently
found in spiny protrusions (inset in g, arrows). Images show maximum intensity projections. In c-j, images were inverted for contrast enhancement.
Scale bars: 2 μm (b), 5 μm (c” & insets d, f & g), 10 μm (a, c’, c”’, e, h-j), 20 μm (c, d, f & g).
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rTg4510, pR5, Δtau74, and rTg21221). Pre- and postsyn-
aptic accumulations of hyperphosphorylated tau in the
hippocampus have also been shown for other tau trans-
genic mice (lines Tet-hTauP301L, 3xTg-AD, and PS19)
by means of electron microscopy [10,41,42]. Moreover, tau
was found to be associated to PSD95 in forebrain extracts
of rTg4510 and rTg21221 mice [40] and present in a few
dendritic spines of cortical neurons in rTg4510 mice [8].
When we investigated brain slices of P301S Tau mice
utilizing immunohistochemistry, hyperphosphorylated
tau could also clearly be located in dendritic spiny pro-
trusions of CA3 hippocampal neurons. However, we
never detected tau in dendritic spines of pyramidal neu-
rons in the cortical regions accessible for in vivo imaging.
The protein was even absent from spines of neurons in
which the somatodendritic compartment was almost com-
pletely filled with filamentous hyperphosphorylated tau.
The brain region specific mislocalization of hyperpho-
sphorylated tau to dendritic spines in the tauopathy
mouse model analyzed here is supported by very similar
findings in AD patients. There, only the thorny excres-
cences of CA3 hippocampal neurons contain hyperpho-
sphorylated tau, but not dendritic spines in other fields
of the hippocampal formation or the adjacent cortex
[23,24]. Unlike dendritic spines of cortical pyramidal
neurons, which have an actin-based cytoskeleton, the
CA3 thorny excrescences occasionally contain microtu-
bules [43,44]. This explains the presence of microtubule-
associated proteins like tau inside the spiny protrusions.
In conclusion, we suggest different mechanisms under-
lying synaptic impairment in tauopathies, depending on
specific characteristics of the affected neuronal popu-
lations. Moreover, these accumulations of hyperpho-
sphorylated tau in hippocampal postsynapses could
also cause dysfunctions of the local or further inter-
connected neuronal networks. Thus, impaired hippocam-
pal signaling might contribute indirectly to cortical spine
pathology.
Axonal pathology and local network dysfunction causing
spine impairments
Methodical restrictions make it nearly impossible to syn-
chronously follow the fate of single dendritic spines and
their presynaptic counterparts (i. e. axonal boutons)
in vivo. Hence, with our kinetic data we cannot clarify if
the loss of spines is a primary or secondary event,
caused by axonal pathology which is known to be very
prominent in tauopathies [45-47]. Given the lack of tau
transgene expression in a fraction of YFP-positive layer
V neurons makes it even more likely that presynaptic fail-
ure partially accounts for the dendritic spine impairments.
Moreover, a severe neuron loss in superficial cortical
layers, mainly affecting GABAergic interneurons, was re-
ported for homozygous P301S Tau mice already at the
age of 3 months [21]. Since those inhibitory interneu-
rons also form connections with pyramidal cells [48], a
decline in inhibition might lead to a compensatory re-
duction of excitatory synapses. Neurodegeneration in
P301S Tau mice, which could only partially be correlated
to intracellular tau-deposits, is also accompanied by in-
flammatory responses [17]. Microglia and astrocytes are
known to be critically involved in healthy brain homeo-
stasis and synaptic maintenance [49-51]. Therefore, the
induction of inflammatory processes can have significant
implications on dendritic spine plasticity, thus prevent-
ing the emergence of new spines or causing morpho-
logical alterations. Summarized, the observed changes in
dendritic spines might be an indirect effect, caused by
axonal pathology or local network dysfunction.
In search for the toxic tau species
We demonstrated in this study, that dendritic spine loss
and remodelling in cortical neurons of P301S Tau mice
occur in the absence of hyperphosphorylated tau accu-
mulation. This is in line with other studies showing that
tau-aggregates and even NFTs are not sufficient to cause
cognitive decline or neurodegeneration: In a reversible
tauopathy mouse model, memory function recovered
after tau transgene suppression despite continuing NFT
build-up [52]. Furthermore, structural and functional
neuronal changes in different tauopathy mice are inde-
pendent of the presence of NFTs [9,10], and accumula-
tion of insoluble tau does not necessarily affect spine
density and morphology [53]. On the other hand, there
is strong evidence for the existence of neurotoxic prefi-
brillar tau dimers and higher order oligomeric aggregates
in tauopathies such as AD [54-56]. Also, a dendritic
function of tau monomers was suggested to mediate
excitotoxicity in AD mouse models [6]. Therefore, we
argue for prefibrillar tau as the toxic species in tau-
dependent neurodegenerative diseases. Further studies
will be needed to clarify the specific pathogenic mechan-
ism and to finally find ways of disease prevention, arrest,
or even cure.
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Abstract
Pathological alternations of tau protein play a significant role in the emergence
and progression of neurodegenerative disorders. Tauopathies are characterized
by the detachment of tau protein from microtubules and by subsequent aberrant
hyperphophorylation, localization and aggregation. The exact nature of tau
species causing neuronal malfunction and degeneration is still unknown. Here,
we took advantage of the possibility to experimentally induce the formation of
neurofibrillary tangles in a portion of frontal cortex neurons of P301S mice that
normally don’t show prominent fibrillary tau aggregation. By using in vivo two
photon microscopy we compared the activity of tangle-bearing neurons with the
activity of their tangle-free neighbors. Our results reveal a clear reduction of
activity in P301S cortical neurons independent of NFT presence. These results
clearly point to the toxic role of soluble and hyperphosphorylated tau present in
the majority of these neurons.
Introduction
The microtubule-associated protein tau modulates the extent and the rate of
microtubule assembly. Pathological tau protein modifications are critically in-
volved in the pathogenesis of numerous nervous system disorders, collectively
known as tauopathies [84]. Tauopathies, including Alzheimers disease (AD) and
frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-
17), are characterized by tau hyperphosphorylation, detachment of tau from
axonal microtubules and subsequent misfolding and aggregation. Pathological
aggregates can be observed as neurofibrilary tangles (NFTs) located in neuronal
cell bodies and as neuropil threads in neuronal processes. The exact nature of
neurotoxic tau species inducing malfunction of neurons is still not well under-
stood [92]. The classical view implies that NFTs are deleterious for neurons.
This is corroborated by numerous studies which showed that the number and
extent of NFT spread throughout the brain is positively correlated with the pro-
gression of neurodegeneration, neuronal death and cognitive decline in AD pa-
tients (reviewed by [85]). On the other hand, studies in transgenic mouse models
performed with single cell resolution challenged this view. For example, no link
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could be established between the presence of NFTs and structural and functional
degeneration observed in pyramidal neurons of the frontal cortex [230]. In addi-
tion, studies coming from the Hyman lab suggested that NFT-bearing neurons
can survive prolonged periods of time and that they are functionally integrated
in neuronal circuits even in the late stages of the disease [231, 190, 232].
Recent studies showed that the injection of brain extracts containing fibrillary
tau or the injection of synthetic tau fibrils into brains of tau transgenic mice can
induce the formation and spread of NFTs [224, 227]. It was suggested that
tau fibrils serve as seeds to induce templated tau aggregation. Furthermore,
tau fibrils are most likely the species of tau that spread throughout the brain.
These findings opened new avenues to study the impact of tau aggregates on
neuronal structure and function. In this study, we wanted to take advantage
of this new possibility and induced NFT formation in the neurons and circuits
which normally are not affected by this type of tau aggregates.
To investigate effects of various pathological tau species on the neuronal
network functioning, we combined tau seeding with in vivo two-photon calcium
imaging in awake P301S head-fixed mice [214, 233, 227, 228]. This approach
enabled us to study the functional consequences of NFT formation in intact
neuronal circuits and to directly compare performance of NFT-bearing neurons
with NFT-free neurons. Our results suggest that soluble, hyperphosphorylated
tau species are responsible for the observed reduction in neuronal activity of
cortical layer 2/3 neurons in P301S mice. Tangle formation induced by templated
misfolding and aggregation of tau protein didn’t induce additional deleterious
effects in our assay.
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Material and Methods
Animals
We used homozygous transgenic mice expressing human mutant P301S tau (383
aa four- repeat isoform of human tau) under the control of the Thy1.2 promoter
[214]. Tau homozygosity was determined by real time PCR. For control animals
we used mice of C57BL/6J strain (WT). All procedures were performed in ac-
cordance with an animal protocol approved by Government of Upper Bavaria
(ref number GZ: 55.2-1-54-2532-163-13).
Stereotaxic Tau-PFF and virus injection
Two months old WT or P301S mice were anesthetized with an intraperitoneal
injection of ketaminexylazine (ketamine 140 mg kg-1, xylazine 10 mg kg-1). In
addition, dexamethasone (6 mg kg-1) was injected intraperitoneally to prevent
the development of cerebral oedema. Mice were then placed on a heating blanket
and stabilized in a stereotaxic frame. Pre-aggregated Tau formed fibrils (Tau-
PFFs) were prepared as previously described [228]. Tau-PFFs were briefly son-
icated and mixed with AAV1.hSyn1.mRuby2.GSG.P2A.GCaMP6s.WPRE.SV4
virus (Penn Vector Core, USA) before injection. Unilateral stereotaxic injection
(right hemisphere) was performed in frontal cortex (A/P, + 2.0 mm; L, +1.4
mm, D/V, -0.7 mm). Total injected volume was 5 μL (final Tau PFFs concen-
tration 333 μM, final virus titer 0.33 x 1013 GC ml-1). Vehicle without Tau-PFFs
(5 μL) was injected in the control group.
Cranial window implantation
Cranial window implantation was performed as previously described [201]. After
stereotaxic Tau-PFFs and virus injection, a round craniotomy was made using
a dental drill (Schick-Technikmaster C1; Pluraden), and immediately covered
with a round coverslip (3 mm). The coverslip was sealed to the skull using den-
tal acrylic (Cyano-Veneer fast; Schein). A custom made small metal bar was
cemented next to the coverslip to allow head-fixation during training and imag-
ing sessions. After surgery, mice received subcutaneous doses of the analgesic
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carprofen (7.5 mg kg-1) and the antibiotic cefotaxime (5 mg kg-1). Mice with a
cranial window implanted were housed individually in cages.
Imaging in awake, head-fixed mice
Imaging was performed in awake, head-fixed mice as described previously [233].
Mice were trained to head-fixation at least for seven days prior to imaging. On
the first day of training, mice were handled to habituate to the researcher and to
the experimental setup. An individual holding tube was assigned to each mouse,
which they were allowed to explore. On the next day, in addition to habituation,
mice would be occasionally head-fixed after passing through the holding tube for
a brief period of time (10 s – 30 s). In following days, periods of head-fixation
were gradually increased up to 1 hour at the end of training. Care was taken for
the mice to feel comfortable in the holding tube and individual adjustments were
made for each mouse if necessary. During head-fixation, mice typically showed
long episodes of quiet wakefulness (quiet) interrupted by brief episodes of inten-
sive whisking and movement (active). Therefore, we used whisking movement
as an indicator of behavioral state (quiet vs. active).
Imaging started at least 21 days after surgery to allow mice to recover and cra-
nial windows to clear. Before each imaging session, mice were head-fixed and
placed under the microscope for 5 min to habituate. Imaging was performed in
the dark without any stimuli. In vivo time-lapse image series of spontaneous ac-
tivity of layer 2/3 frontal cortex neurons were acquired using the La Vision Trim
Scope (La Vision BioTec GmbH, Germany) equipped with tunable Ti:sapphire
two-photon lasers (Coherent Chameleon, Coherent USA and Mai Tai, Spectra
Physics USA). The setup was controlled using La Vision Imspector software (La
Vision BioTec GmbH, Germany). For recording calcium transients from layer
2/3 neurons, the laser was tuned to 940 nm which enabled simultaneous excita-
tion of mRuby2 and GCaMP6s.
In order to visualize NFTs in vivo, we injected FSB i.p. 24 h – 48 h prior to
imaging [234, 191]. Excited at 700 – 750 nm by the two-photon laser, FSB pro-
vided robust and bright NFT labeling. Laser power was kept under 80 mW at all
times, measured at the back-focal plane of the objective. All time-lapse movies
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were taken at the frame rate of > 10 Hz. For simultaneous imaging of NFTs
and cortical layer 2/3 neurons labeled with GCaMP6s/mRuby2, Mai Tai tuned
to 700-750 nm and Chameleon tuned to 940 nm were used in an alternate laser
scan protocol. Emitted fluorescence light was split at 495 nm and 560 nm and
detected by photomultiplier tubes. A web camera was installed and controlled
by La Vison Imspector software which allowed synchronous recordings of mouse
behavior and calcium transients at the same frame rate.
Data processing and image analysis
Collected images were processed and analyzed using custom written codes in
MATLAB and ImageJ software. Typical recordings consisted of three image-
series. The first image series, recorded by two photon microscopy on the red
channel (> 560 nm), represented cell bodies labeled with mRuby2 (calcium in-
sensitive). The second series recorded calcium changes reported by fluorescence
changes of GCaMP6s in the neuronal cytoplasm (green channel 495 – 560 nm).
The third – behavioral – time series was recorded by the camera. The behavior
was classified as active and quiet behavioral states, using a MATLAB custom
written code based on time-series recordings of whisker and body movements.
Two-photon calcium imaging data was analyzed using a custom written MAT-
LAB code. In brief, individual images from a single time series were aligned
to each other in the x-y plane. Image registration parameters (x/y shift) were
estimated using a Fourier transform based approach [235] on image data from
the mRuby2 (structural) channel [236]. Regions of interest (ROIs) were manu-
ally identified using custom written software in MATLAB. For each ROI, a raw
GCaMP6s fluorescence time series was constructed by averaging the pixel values
within the region of interest for each individual imaging frame. Time series were
corrected for contamination by local neuropil fluorescence and for changes in
fluorescence caused by movement along the z-axis (in/out of plane movement)
using the following method: local neuropil fluorescence was calculated by aver-
aging all pixel values in an approximately 30 μm ring around the ROI, excluding
other ROIs. The effect of z-movement on the fluorescence intensity of an ROI
was determined from the mRuby2 fluorescence within the ROI. The contribution
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of the local neuropil signal (Fneuropil) and z-motion (Fmotion) to the fluorescence
within the ROI (FROIraw) was estimated using linear regression (equation 1).
Finally, the median of the corrected time series (FROIcorrected) was re-adjusted to
the median of the original time series (FROIraw).
Equation 1:
FROIraw = ROIcorrected + a · Fneuropil + b · Fmotion
The relative fluorescence change over baseline, ∆F/F , was calculated according
to equation 2, where Ft is the absolute fluorescence at imaging frame t. Baseline
fluorescence F0t was calculated using a sliding window approach by – for each
frame – averaging the lowest 50% fluorescence values in a 30 second sliding win-
dow before imaging frame t [237].
Equation 2:
∆Ft =
Ft − F0t
F0t
Transient detection was performed using following criteria: > 3.5 SD, rising time
0.2 s, decay time 0.5 s, inter-peak interval > 0.7 s. Correlations in time series of
∆F/F calcium activity were calculated using the Pearson correlation coefficient
on z-scored segments.
Statistics
Two-way analysis of variance (ANOVA), followed by Bonferroni’s multiple com-
parison test, and Student’s t-tests were used. Statistical analysis were performed
with GraphPad Prism software Version 5.04 (GraphPad Software Inc., La Jolla,
CA, USA). P-values are reported and outlined as follows: *P < 0.05, **P < 0.01
and ***P < 0.001. Mean with S.E.M. are indicated.
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Results
Injection of Tau-PFFs induces rapid formation of neurofibrillary tan-
gles in P301S mice
Using immunohistochemistry, we didn’t observe NFT formation in the frontal
cortex of WT mice which had been stereotactically inoculated with vehicle or
Tau-PFFs (Figure 2.16 A and B). Similarly, histological analysis revealed no
formation of NFTs in P301S mice injected with vehicle (Figure 2.16 C).
A B C D
E
Phospho-Tau (AT8)
Tangles (FSB)
histology
WT Tau-PFFs P301S vehicle P301S Tau-PFFsWT vehicle
Figure 2.16. Seeding of Tau PFFs causes local formation of NFTs.(A-D) Frontal cortex
of mice tree weeks after injection at two months of age. (A) WT injected with vehicle; (B) WT
injected with Tau-PFFs; (C) P301S injected with vehicle; (D) P301S injected with Tau-PFFs.
Staining: FSB (white) and AT8 (magenta). Scale bar = 20 μm. (E) Sagital brain section of the
homozygous P301S mouse injected with Tau-PFFs, also shown in detail in D. Scale bar = 500 μm.
However, an injection of Tau-PFFs in P301S mice caused rapid and robust
formation of NFTs in the frontal cortex (Figure 2.16 D and E), which were
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hyperphosphorylated (AT8 positive) and expressed a β-sheet-rich amyloid struc-
ture (FSB positive). Morphologically, these intracellular aggregates displayed a
”flame-like” shape, which is characteristic for NFTs.
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Figure 2.17. Chronic two-photon calcium imaging in the tauopathy model. (A) AAV1
transduced neurons are labelled with mRuby2 (red) and GCaMP6s (green). NFTs are labeled with
FSB (white). The same neuronal population can be relocated over time (3 weeks post-injection
(left) vs 4 weeks post-injection (right)) Images were made by averaging > 50 images acquired at
> 10 Hz. (B) Schematic of a head-fixed mouse in the experimental setup with the camera for
recording of behavior. Scale bar = 50 μm. (C) Schematic of the experimental protocol. (D) Left:
density of tangles over time. Black circles represent mean values ± S.E.M. Gray circles represent
individual fields of view. Right: percentage of fields of view in which changes of NFT density was
observed.
We next wanted to detect NFTs in vivo using a cranial window preparation.
In our experiments, it typically takes about three weeks after surgery for the cra-
nial window to become clear and suitable for in vivo imaging. At this time-point
and using i.p. injections of FSB dye, NFTs are easily detectable in the frontal
cortex of P301S mice injected with Tau-PFFs (Figure 2.17 A). This provided an
excellent opportunity to investigate the functional consequences of NFT forma-
tion on the single neuron level using two-photon in vivo calcium imaging (Figure
2.17 B). We were able to record over time from identical neuronal populations
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in order to follow individual neurons (Figure 2.17 A and B). Furthermore, using
FSB staining we could easily differentiate between tangle-bearing neurons and
their tanglefree neighbors. Our experimental design (Figure 2.17 C) allowed us
to record from 4580 neurons over 3 or more time points in a total of 23 mice.
In order to investigate how fast NFTs form in our model and if there is for-
mation of novel NFTs over time, we used i.p. injections of FSB to label all NFTs
formed upon a given time-point. We performed this experiment in a separate
cohort of mice which we followed up to 10 weeks after Tau-PFFs injection, in or-
der to compare the density and presence of NFTs in same area over time (Figure
2.17 D). To our surprise, in vivo two-photon imaging revealed that NFTs form
already within one week after injection. Our results show that NFT density does
not change significantly over time after that (Figure 2.17 D, left panel). In rare
cases, we could observe formation of novel NFTs (7 out of 53 areas (13.2% of
total area); imaged in 9 mice, total 8 new NFTs; Figure 2.17 D, right panel).
All events of newly formed NFTs occurred in the first three weeks after injec-
tion, i.e. when functional imaging is still not possible due to limited clarity of
the cranial window. Furthermore, no NFT detected using in vivo two-photon
imaging disappeared over the imaging period.
Neuronal activity is reduced in P301S mice independently of the pres-
ence of NFTs
To investigate the functional consequences of NFT formation, we used two-
photon calcium imaging in awake, head-fixed mice. We were able to simul-
taneously record calcium transients from 50 – 150 neurons in one field of view
(Figure 2.18 A and B, left panel) at the single-neuron level. Three fluorescent
channels were recorded simultaneously: mRuby2 (red), GCaMP6s (green) and
FSB (blue). Transients were furthermore assigned to occur either during active
or quiet behavioral states, by correlation with the whisking behavior of mice
during the experiment (Figure 2.18 A and B, right panel).
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Figure 2.18. Recording of neuronal activity in awake mice. (A): Representative in vivo
recordings from WT mice injected with vehicle. (B) representative recordings from P301S mice
injected with Tau PFFs. Left panel: AAV1 transduced neurons are labelled with mRuby2 (red)
and GCaMP6s (green). NFTs are labeled with FSB (white). Images were taken by averaging
> 50 images acquired at > 10 Hz using a two-photon microscope. Scale bar = 50 μm. Right
panel: traces (blue) extracted from annotated ROIs (black) during quiet and active (grey shade)
behavioral states classified based on changes in whisking movement (gray trace in the bottom).
The results showed that during both quiet and active behavioral states, neu-
rons in P301S transgenic mice injected with Tau-PFFs show a clear reduction
of activity, as measured by the number of calcium transients per minute (Figure
2.19 A). Two-way ANOVA analysis showed a significant effect between phe-
notypes (WT vs. P301S; F(1,19) = 15,61, p < 0,001). The effects between the
treatment groups (vehicle vs. Tau-PFFs) and the interaction within groups were
not significant: F(1,19) = 0,05, P = 0,83 and F(1,19) = 0.16, P = 0,69, respectively.
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Figure 2.19. Neuronal activity is reduced in P301S mice independently NFT presence (A)
Mean frequency of calcium transients during quiet and active states. All neurons detectable in
three or more imaging time-points were included in the analysis. WT injected with vehicle (dark
green), WT injected with Tau PFFs (light green) P301S injected with vehicle (light red), P301S
injected with Tau-PFFs (dark red). The P301S group seeded with Tau-PFFs is further divided into
tangle-free (red circles) and tangle-bearing neurons (red triangles). Symbols represent individual
mice, n = 5-7 mice per group, as illustrated; black lines represent mean value ± SEM. ***, P <
0.001 WT vs. P301S, two-way ANOVA. (B) Cumulative frequency plots of the data shown in the
upper panel.
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Closer analysis revealed no difference between tangle bearing neurons and
their tangle-free neighbors during quiet awakefulness (Figure 2.19 A, red cir-
cles vs. red triangles, left panel). Very similar results were obtained when we
analyzed activity during active phases. Again, only the phenotype effect was
significant (F(1,19) = 27,79, p < 0,0001). The effect of treatment (vehicle vs.
Tau-PFFs) and the interaction were not significant: F(1,19) = 0.6454, P = 0.4317
and F(1,19) = 0.01604, P = 0.9006. Similar to the quiet state, no difference in
transient frequency between tangle bearing neurons and their tangle-free neigh-
bors was observed during the active state (Figure 2.19 A, red circles vs. red
triangles, right panel). To present the frequency distribution of individual neu-
rons, we plotted the results as cumulative frequency graphs. In both quiet (left
panel) and active (right panel) states, the curves of WT mice are clearly shifted
to the left compared to the curves of P301S mice (Figure 2.19 B). The injection
of vehicle or Tau-PFFs had no effect on the frequency distribution in neither
phenotype cohort. Again, no difference between tangle-bearing and tanglefree
neurons was observed.
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Discussion
In our study, we aimed to assess the impact of various pathological tau species
on neuronal functioning. We therefore combined injection of Tau- PFFs with
chronic in vivo two-photon calcium microscopy in a mouse model overexpress-
ing human Tau with the P301S mutation. This approach enabled us to directly
compare the effects of soluble, hyperphosphorylated tau with impact of NFT for-
mation on the activity of individual neurons and neuronal circuits. By recording
ongoing cortical activity in same neuronal population over prolonged time peri-
ods, we were furthermore able to partially mimic pathologic conditions in which
changes gradually take place over the course of disease.
P301S mice are a well characterized mouse model exhibiting some essential
features of a human tauopathy and were used in this study [214]. One reason for
deliberately chosing this mouse model was the fact that these mice do not show
formation on NFTs in the frontal cortex and only a subset of frontal cortex
neurons contain substantial amounts of soluble hyperphosphorylated tau [2].
However, we demonstrate that injection of Tau-PFFs into the brains of these
mice causes rapid formation of NFTs in the frontal cortex which could readily
be detected using FSB dye [234, 191].
In this study, we used synthetic, pre-aggregated Tau fragments (Tau-PFFs),
containing the four repeat domain of Tau with the P301L mutation [228]. There-
fore, there is the possibility that observed tau-aggregates represent simply pas-
sive uptake of injected fibrils and are not the product of templated misfolding
and aggregation of endogenous tau. Two lines of evidence argue against such
a possibility. The aggregates are strongly stained with the anti-Tau Phospho-
S202/T205 antibody (AT8). The AT8 epitope is not present on Tau-PFFs used
for injection and therefore the aggregates that we observed are made, at least
partially, from full-length endogenous tau. In addition, WT mice do not show
any accumulation of tau upon injection of Tau-PFFs further opposing the passive
uptake possibility.
In order to investigate the formation of novel NFTs in the frontal cortex,
we continuously performed in vivo imaging of the mice up to 10 weeks after
Tau-PFF injection. Interestingly, we didn’t observe profound de novo formation
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of NFTs, suggesting that mechanisms of local spreading are not present in our
model. Basically all the NFTs were formed within first week after Tau-PFF
injection. We believe that the rare cases in which we could observe appearance
of NFTs in our images are rather due to accumulation of FSB upon repeated
injections and/or due to improved clarity of cranial window. Up to date, no
study followed formation of NFTs using chronic in vivo imaging. Previous in
vivo studies mainly used histological analysis to assess the level of NFT spreading
upon injection of seeding material (Tau-PFFs or brain homogenates containing
the tau fibrils). In all this studies relatively slow progression (> 6 months)
of NFT formation was shown and mainly in anatomically connected regions
[224, 227, 229]. Therefore, it is possible that our mice too, would develop novel
NFTs after a prolonged period of time. This however is not feasible in the
homozygous P301S mice used in our study, as they develop severe motor deficits
and have to be sacrificed due to ethical reasons already with 6 months of age.
These results also raise an important question of careful titration of the injected
Tau-PFF dose and appropriate choice of mouse recipient line in order to best
mimic the seeding and spreading observed in human patients.
Our in vivo recordings indicate clear overall reduction in spontaneous activity
of layer 2/3 neurons in P301S mice compared to WT mice. In P301S mice, which
overexpress a mutated human tau isoform, a subset of cortical neurons contains
substantial amounts of soluble hyperphosphorylated tau [2]. Interestingly, af-
ter injection of Tau-PFFs and subsequent formation of NFTs, neuronal circuits
showed similar spontaneous activity rates as the circuits without NFTs. Specif-
ically on the single neuron level, the tangle-bearing neurons had very similar
transient frequencies in both quiet and active phases as the tangle-free neurons.
This indicates that formation of NFTs in neurons do not induce additional effects
in neuronal functioning. Of course, we cannot exclude that subtle structural and
functional changes might take place which a cannot be recorded in our assay.
Numerous studies have aimed to elucidate the effect of NFT formation on
neuronal activity. Of particular interest for our work are those studies who inves-
tigated this matter on the single-neuron level and that differentiated between the
tangle-bearing and tangle-free neurons. Studies coming from the Lübke lab in-
vestigated this in detail in cortical neurons in acute slice preparation [230]. Their
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results indicated that structural and functional changes in tau mutant mice are
not linked to the presence of NFTs. However, they also reported increased ac-
tivity of neurons in transgenic mice in response to stimulation. An in vivo study
from the Hyman lab showed that tangle-bearing neurons are performing equally
well as the tangle-free neurons [232]. Both groups of neurons were demonstrated
to preserve their resting calcium levels and neuronal tuning and show similar
values as the neurons in the WT control group. Finally, an important recent in
vivo study investigated the ongoing activity in cortical neurons in intact circuits
[238]. Although the authors do not differentiate between cortical neurons based
on NFT presence, they find overall reduction in spontaneous activity, confirming
a disruptive role of pathological tau.
Taken together our results point to the pathological role of tau species which
are present before the formation of NFTs. The source for these protein species
is mislocalized tau protein in the somatodendritic compartment which becomes
misfolded and pathologically phosphorylated. This leads to formation of soluble
oligomers and prefibrillar tau. In addition, it is reasonable to assume that toxic
species could also involve small tau fibrils which still do not reach the critical size
and concentration to form NFTs. NFT formation, on the other hand, might be
the part of a disease off pathway as proposed by Bradley Hyman and coauthors
[239, 232, 67]. Taken together these and our results could have an implication in
the choice of the right therapeutic strategy in treating tauopathy patients. The
results of this study advise caution in approaches aimed to dissolve or to prevent
formation of tau aggregates and rather support the development of therapies
focused on eliminating toxic soluble tau species.
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3.1 In vivo two-photon imaging in the neocor-
tex of the mouse
In contrast to the human neocortex, which is folded into a complex landscape
of gyri and sulci, the surface of the mouse neocortex is smooth. This feature
and its exposed position on the brain surface make it ideal for chronic structural
investigations using in vivo two-photon microscopy, as two-photon lasers may
penetrate tissue to a maximum of 1000 μm [201]. The mouse cortex is further-
more organized into six layers with different cell types and laterally into a map
of functionally distinct regions, which have been mapped into a 3D brain atlas
[240]. Hence the study of structural alterations in physiologic and pathological
conditions can be performed in a site-directed manner. The microscopy of liv-
ing tissue used in this work holds two advantages over ex vivo studies and was
essential for the questions addressed: (i) fine cellular structures like dendritic
spines can be monitored in their physiological environment. For neuroscientists
and for the studies presented in this thesis, this has particular value, as neurons
are part of a vast and diverse neuronal and non-neuronal network, contributing
to their structure and function; (ii) individual structures can be monitored over
extended periods of time, which allows making statements about their devel-
opment in physiological and pathological conditions. In the present work, this
enabled valuable data on the dynamics of NFT development or on progressive
structural changes in synucleinopathy and tauopathy mouse models.
The limitations of this technique involve its great complexity. In vivo ex-
periments are time-consuming as well as technically advanced and financially
expensive, which often limits the practicable sample size of mice involved in the
experiment. Moreover, the maximal penetration depth of the two-photon laser
determines the structures that can be accessed at all, which typically are located
on the brain surface. The midbrain and the substantia nigra central to PD re-
search cannot be accessed and the hippocampus, involved as it is in learning and
memory and therefore of interest to dementia researchers, can only be imaged
in vivo by removing the overlaying cortex [241, 242].
It is of particular importance to avoid physical and psychological stress for
84
3.1 In vivo two-photon imaging in the neocortex of the mouse
the experimental animals, partly but not solely because chronic stress has been
shown to have negative influence on synaptic plasticity and spine density [243].
Care should also be exercised by the choice of anesthesia like Ketamin/Xylazin
or Isofluorane used in mice for in vivo imaging, which naturally also influence the
nervous system. Ketamin/Xylazin has been shown to affect the turnover of den-
dritic spines in young neurons [244] and the survival of developing GABAergic
interneurons as well as dendritic tree growth [245]. The alternative isofluoran-
based anesthesia might increase tau phosphorylation and amyloid pathology in
AD mouse models [246, 247]. Yet other studies could not show an effect of anes-
thesia on the development and dynamics of dendritic spines [248]. In any case
of anesthetizing mice, it is important to ensure the maintenance of their body
temperature. Hypothermia in mice is originally an adaptation to hibernation
[249] and induces biochemical changes such as reduced phosphorylation of pro-
teins due to inhibition of kinases. As the phosphorylation state of tau and α-syn
proteins affects their conformation and their pathogenicity, hypothermia should
therefore be avoided [250].
Imaging of awake mice circumvents the restrictions entailed by anesthesia,
but requires the mouse to be well-trained and habituated to the environment
of the microscope and especially to head-fixation. The obtainment of stable
microscopic images is only possible if the mouse is physically quiet during the
imaging session. On the plus side stands the possibility to obtain functional
images of network activity unaffected by anesthetic effects. In the summarized
studies for this thesis, in vivo two-photon microscopy was used to obtain both
structural and functional data. By interbreeding transgenic mouse lines model-
ing α-synucleinopathy and tauopathy with the fluorescent reporter lines GFP-M
or YFP-H, respectively, a subset of entire layer V cortical pyramidal neurons of
the neocortex were labeled with eGFP or YFP, enabling the structural imag-
ing of apical dendrites over time. Functional imaging of network activity was
performed in a tauopathy model using virus-mediated expression of the Ca2+
indicator GCaMP6s. Being mindful of the points mentioned above, imaging ses-
sions awake and under anesthesia did not persist for longer than one hour and
hypothermia was avoided.
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3.2 Seeding of pathogenic proteins
From in vitro biophysical studies it is known that fibril formation follows a nucle-
ated polymerization mechanism. After a nucleation phase, in which multimer-
ization of the protein is energetically unfavorable, cooperative oligomer growth
and fibril formation occur through rapid monomer addition [28] and produces
typical amyloid inclusions [251]. This process can be initiated (seeded) by the
introduction of pathogenic protein fibrils (the seed) into a biological system,
which may be ranging in complexity from cell-based assays to in vivo brain tis-
sue, and is thought to be the underlying mechanism of spreading of α-syn or tau
pathology along neural axes in the brain (reviewed by [252, 109]). In the present
work, the seeding of both α-synuclein and tau was used to complement exper-
iments with transgenic mouse models. The intention of this was to: (i) study
the potential spread of pathogenic proteins across brain regions, (ii) induce the
formation of nature LB-like and NFT-like inclusions and study their structural
and functional consequences and (iii) gain information about which species of
α-syn or tau might be responsible for the observed changes.
3.2.1 alpha-synuclein
The templated misfolding and propagation of α-synuclein is an intriguing part
of its nature and has relevance for the pathogenesis of α-synucleinopathies. It
can be experimentally mimicked by the inoculation of either brain homogenates
containing misfolded α-syn species [217] or of in vitro preformed fibrils [253, 133,
223] into cell culture and animal models.
The exact way by which misfolded species spread from cell to cell is not en-
tirely clarified yet, but several options have been described. Mediating α-syn
release, direct penetration of cellular membranes has been shown [254] as well as
the release in clear vesicles [255] or via exosomes in a calcium-dependent man-
ner [256]. α-syn oligomers present in the extracellular space were also observed
to be taken up by neurons via trans-synaptic dissemination and transported
via retrograde axonal transport to the soma [257]. Other uptake mechanisms
include endocytosis and membrane-receptor mediated access [255]. Using mi-
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crofluidic chambers to separate aggregate-developing donor cells and synaptically
connected näıve acceptor neurons, it was shown that PFFs can be transported
in both the anterograde and retrograde directions but that synaptic contact is
not required for transmission [258, 134].
For our study on the impact of α-syn on cortical synapses [1], α-syn PFFs were
injected into the dorsal striatum of experimental mice. The striatum is an im-
portant connection between the cortex and the midbrain, and is directly involved
in the circuit-level changes that affect the direct and the indirect pathways in
PD (reviewed by [259]). Seeding of α-syn PFFs into the mouse striatum has ben
described previously [223]. In our study, progressive intraneuronal aggregation
of endogenous α-syn was detected in the neocortex as early as 30 days post-
injection of PFFs. Until 9 months post-injection, α-syn aggregates condensed
and matured to fibrillary structures [260]. 5 months after seeding, the ipsilateral
cortex — particularly in layer IV — and the amygdala were the most prominently
affected brain regions. α-syn aggregates were also detected in the contralateral
cortex and the substantia nigra. From previous data tracing the projections
from and to the dorsal striatum, the topographical pattern of α-syn inclusions
observed here can be in part ascribed to retrograde and anterograde spreading
[261]. Histochemically, the α-syn aggregates possessed several features charac-
teristic for Lewy bodies in the human disease. They were hyper-phosphorylated
[262] at Ser129 and could be stained with Thioflavin S, a fluorescent marker for
amyloidogenic structures [39]. Finally, they were positive for ubiquitin [263],
which represents a cellular tag marking them for degradation. There was no
evidence for seeded α-syn aggregate formation in mice lacking endogenous α-syn
(SNCA-KO) and experiments using fluorescently tagged α-syn PFFs indicated
that inclusions did not simply consist of PFFs taken up by cells, but had formed
from endogenous α-syn. This confirms that α-syn can undergo templated con-
version and aggregation, as it was previously shown by others.
3.2.2 Tau
Similar to α-syn, tau protein can undergo templated misfolding, also by its inter-
action with various co-factors [67]. Likewise, experimentally seeding tau pathol-
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ogy has been described in various cellular and in vivo systems [224, 227, 228, 264].
The identification of cellular mechanisms for tau spreading revealed several
variances. The trans-synaptic pathway for movement of tau between cells, as
suggested by Braak et al. [71] was confirmed by Calafate et al. Their study
explored tau propagation using a microfluidic chamber and demonstrated that
both synaptic connectivity and synaptic activity increases tau-propagation [265].
Furthermore, tau has been described to be directly secreted into the medium via
exosomes and then taken up by co-cultured cells [266, 267, 268]. Uptake mech-
anisms include fluid phase endocytosis, macropinocytosis and bulk endocytosis
[136, 137] Once inside cells, misfolded tau can be transported anterogradely as
well as retrogradely and mislocalizes from the axon to the somatodendritic com-
partment [264].
In our study on the impact of tau on network activity, tau PFFs were injected
directly into the cortex of P301S mice, where they rapidly triggered intracellular
aggregation of tau. These inclusions displayed a flame-like shape, characteristic
for human NFTs present in AD brains. They were also hyper-phosphorylated
[269] as demonstrated by IHC using the AT8 antibody, which recognizes the
phosphorylation at Ser202/Thr205. By their positivity for FSB, a small and
blood-brain-barrier permeating fluorescent molecule, in vivo [191] the amyloid
nature of the tau inclusions was confirmed. In accordance with existing data,
the seeding of PFFs into wild-type mouse brain did not lead to the formation of
amyloid inclusions. A recent study demonstrated that unique pathological tau
conformers from AD brains are able to transmit tau pathology in nontransgenic
mice, but PFFs are not [226]. These findings highlight important differences
between artificially generated tau fibrils and ones that develop within AD brains.
In contrast to other studies, the development of NFT-like inclusions was
restricted to the site of injection in our experiments. Considering the time-frame
of three weeks between seeding and in vivo imaging, it is possible that this was
too short for the relatively slow progression of NFT formation in anatomically
connected regions. Other studies usually assessed tau spreading after longer
periods of time (> 6 months) [224, 227, 229]. The main scientific question of our
study, however, was to study local network dysfunction linked to the presence
of various tau species rather than tau spreading.
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3.2.3 Mechanistic considerations and potential pitfalls of
experimental seeding
The method of inoculating pathogenic proteins to model the spread of pathogenic
proteins in neurodegenerative diseases has created significant excitement and in-
terest among researchers in the field. It undoubtedly has some advantages over
— or in combination with — transgenic models in the search for novel thera-
peutic strategies. Using seeding as a method allows the mapping of connected
neuroanatomical pathways by which the induced proteinopathy spreads. Accord-
ingly, seeding approaches can be very useful for assessing whether pathology is
able to spread from the periphery into the CNS, an important notion considering
that the earliest features of PD may relate to pathology outside of the brain,
like the gut [270]. On the front of therapeutics research, tackling the clearance
of α-syn or tau during the process of cell-to-cell transfer remains a promising
approach (reviewed by [211, 252]). There are however some restrictions that
should be considered as well.
In order to experimentally induce proteinopathies using PFFs, usually an
excessive amount of fibrillary protein is injected into the tissue, overwhelming
the natural barriers that physiologically prevent the induction and spread of
pathology. The use of transgenic mice for seeding studies likewise represents an
artificial enhancement of susceptibility towards a bolus insult of aggregated pro-
tein. The amount of protein injected is far higher than the protein concentrations
that could be locally encountered in a physiological situation and might lead to
exaggerated or false-positive findings. The intracerebral injection of PFFs in a
stereotactic procedure also presents an insult to cells and brain tissue, which
might artificially promote cellular uptake and could lead to proteostatic pertur-
bations. Cellular degradation machineries, like the autophagy-lysosomal system
or the ubiquitin-proteosome system, might become dysbalanced by misfolded
protein species and thus contribute to the spread of pathology. Furthermore,
the activation of gliosis might also facilitate the spread of pathology in both α-
syn and tau seeding models. Astrocytes have been shown to be actively involved
in the spread of α-syn pathology and the induction of inflammatory cellular
damage mediated by microglia might also be a considerable factor (reviewed by
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[109]). Similarly, microglial involvement is also known to aid the propagation of
tau [271].
Other than that, one should consider the variances of homotypic versus het-
erotypic seeding. Homotypic or self-seeding suggests that conformational tem-
plating requires the presence of sequence-specific substrates, able to form the
typical cross β-sheet conformation. It is quite clear that this process occurs
during the spread of α-syn pathology, supported by findings in cell lines stably
overexpressing α-syn lacking the NAC domain, in which PFFs fail to trigger the
formation of inclusions [272, 133]. It was also reported that tau follows templated
misfolding, depending on the biophysical properties of the seeding material [141].
The phenomenon of one amyloidogenic protein seeding the aggregation of an-
other is referred to as heterotypic seeding. Indeed, α-syn and tau have been
shown to synergistically promote the fibrillization of each other in vitro [273]
and in cell culture [274] and might be also relevant in vivo.
3.3 Dendritic spines in mouse models of alpha-
synucleinopathy and tauopathy
Spines are experience dependent dynamic structures and a certain turnover and
rearrangement of morphology can be observed even in the adult brain [275].
This enables neurons to modify their synaptic interconnections, which are the
correlates for learning and memory [167]. The structural changes are based on
reorganization of actin filaments within spines and can occur within seconds to
hours [276]. An observed loss of spines can hence be due to e.g. the loss of
persistent spines, a reduced number of newly formed spines or a general increase
in the number of retracted spines. Relevant for this work is the fact that synaptic
spine degeneration belongs to the early structural correlates of dementia [168,
169]. For that reason, the chronic study of synaptic plasticity using in vivo
microscopy can give important insights about the pathophysiology of diseases
like AD and PD. Several previous publications have addressed spine pathology
in animal models of α-synucleinopathies and tauopathies and in human patients
and are summarized hereafter.
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The first explicit proof for dendritic spine alterations in α-synucleinopathies
was obtained from toxin-induced models of parkinsonism. Both 6-hydroxydopa-
mine (6-OHDA) treated rats as well as 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) treated monkeys showed a 20 % reduction in striatal spine
density [277, 278]. Some authors report that D2 receptor striatopallidal neurons
in reserpine and 6-OHDA-treated mice selectively lose spines [279], while others
found spine loss on both direct and indirect pathway neurons in 6-OHDA or
MPTP-treated models [280]. In a mouse model overexpressing the human A53T
α-syn mutation, spine loss has been observed in the striatum and in the hip-
pocampus [281]. In contrast, another study failed to detect striatal spine loss in
A53T mice, despite a decrease in the number of SNpc neurons [282]. α-syn was
also demonstrated to have negative impact on newly generated neurons of the
hippocampus [283] and the olfactory bulb [284], particularly on their dendrite
outgrowth and spine development. Finally, in brains of Parkinson’s patients, the
degree of spine loss correlated with the level of dopaminergic denervation of the
striatum and striatal spine loss was also present in DLB brains [285, 286].
On the tauopathy front, knowledge about the effect of tau on synapses is
inconsistent, strongly depending on the tauopathy model, the stage of disease
progression and the brain region analyzed. Mice carrying the MAPT mutation
P301L display impaired dendritic tree development and reduced cortical spine
density independent of NFT presence [287, 230]. Spine loss was also present
prior to NFT development in the hippocampus of mice expressing human P301S
mutant Tau under the prion promotor [288]. In another study, spine density was
found unchanged in cortical layer III neurons [289] while spine volume decreased
in mice expressing all six human isoforms of tau instead of the murine protein.
Even an age dependent increase in spine density in layer III cortical neurons
was reported for mice expressing human P301L tau or WT tau, with no effect
on the hippocampus [290]. In the light of these inconsistent findings coming
from studies using various models and approaches, it is difficult to draw general
conclusions about how the (over-)expression of (mutant) tau or α-syn impairs
dendritic spine plasticity. The aim of this work was therefore to shed some more
light on the pathologic process of synapse loss in the respective neurodegenerative
diseases.
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3.3.1 Transgenic overexpression of alpha-synuclein and
mutant tau causes changes in dendritic spine plas-
ticity
In order to study the α-syn-mediated alterations in spine plasticity over ex-
tended time periods, data on spine dynamics was obtained from mice overex-
pressing WT human α-syn under the PDGFβ promotor at three ages. Young
(3-month-old) mice showed a progressive loss of spines due to a reduced spine for-
mation, whereas older (6 months) and aged (12 months) mice compensated the
reduced overall density of spines with an increased daily turnover ratio (dTOR).
Concerning spine morphology, the progressive spine loss in young h-α-syn mice
was reflected in the diminished fraction of thin spines, which are known to par-
tially correspond to non-synaptic and transient precursors of the larger persistent
spines [291, 292]. In older mice (6- and 12-month-old), further spine loss was
counterbalanced by an elevation in the dTOR, which was in turn matched by an
increase in the fraction of thin spines at the cost of mushroom spines.
In our study on spines in tau transgenic mice [2], we aimed to add the dimen-
sion of spine kinetics over time to the existing knowledge, as all previous studies
were based on ex vivo data. Chronic in vivo imaging of apical dendrites in the
cortex of 4-month-old mice overexpressing tau protein with the P301S mutation
(termed P301S mice) showed reduced and progressively decreasing density of
dendritic spines. Data on spine kinetics showed that the observed spine loss was
caused by a reduction in the fraction of gained spines in P301S mice compared to
controls. The density fractions of lost and persistent spines remained unaffected.
Concerning the morphology of the remaining spines, P301S mice showed a trend
towards an increased spine volume, which correlated with the increase in the
fraction of mushroom spines at the cost of the thin spine fraction. As mentioned
above, thin spines are considered to correspond to developing or immature spines
and this is reflected in our study in the decrease of the gained spine fraction in
P301S mice. It is important to note, that the neurons imaged in vivo did not
contain NFTs, but a majority of these cells were found to overexpress soluble
and unphosphorylated tau in the subsequent ex vivo analysis.
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3.3.2 Abnormal spine density, morphology and dendritic
shape after alpha-synuclein seeding
The seeding of pathogenic preformed fibrils (PFFs) contrasts with classical trans-
genic mouse models for the study of neurodegenerative diseases and represents
a fairly recent advance in the field. Nevertheless, it has generated great interest
in the field of neurodegenerative disease research and a wealth of studies have
addressed the routes and mechanisms of pathologic protein spread (reviewed by
[293, 252]). The impact of seeded α-syn inclusions on the strucure of dendrites
and dendritic spines, however, was unknown and for this reason was one of the
aims of our study [1]. Based on the knowledge that preformed fibrils (PFFs)
of α-syn can induce spread of LB-like α-syn aggregates [223] in WT mice, PFFs
were injected into the striatum of GFP-M reporter mice bearing no additional
disease-related transgene.
The analysis of spine density and morphology 5 months post-injection showed
dendritic spine loss in layer V pyramidal neurons of the neocortex as well as a
redistribution in the morphology towards less thin spines. Importantly, the ob-
served spine loss was independent of a spatial proximity of the respective dendrite
towards a LB-like inclusion, which indicates a dysfunction of the neuronal net-
work rather than to a local toxic effect of α-syn inclusions. The morphological
change towards a decreased fraction of thin spines also indicates that less imma-
ture and developing spines are present [291, 292]. How the exact dynamics of
spines are changed, however, could be the subject of a chronic in vivo imaging
study.
Another interesting observation of the study on the α-syn seeding model was
the presence of dystrophic dendrites. These have been described in mouse models
of prion-disease [202] and AD [294]. Additionally, varicosities in axons have been
reported to be induced by α-syn seeding [295]. Here, the degeneration of the
respective cell body and the related axonal transport deficits could contribute
to the dystrophic deformation of dendrites. In fact, it has been shown that
seeded aggregates in neurons mature over time and lead to the degeneration of
the respective cell body [260].
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3.3.3 Proposed mechanisms for alpha-synuclein and tau-
mediated spine alterations
Synapses are complex structures, consisting of several compartments structurally
belonging to distinct neurons or glia. Synaptic degeneration can be based on con-
tributions of all components and the dissection of temporal and spatial mecha-
nisms of these pathological processes remains a challenge.
With α-syn being a presynaptic protein, it seems likely that a presynaptic
pathology is responsible for the neurodegenerative effect and in the case of our
study, spine loss. In fact, it was shown that presynaptic microaggregates of
α-syn are present in the cortical and subcortical gray matter of DLB patients
and that they were linked to dendritic spine loss [39]. Mechanistically, α-syn
was demonstrated to inhibit neurotransmitter release by reducing the size of the
presynaptic vesicle recycling pool [296]. Together with the functional role α-syn
plays in SNARE-driven vesicle fusion for neurotransmitter release [297, 298],
its role in regulating the cytoskeleton [299, 300] would certainly affect synaptic
plasticity.
Relevant for the loss of synapses might also be the cascade of postsynaptic
events induced by chronically elevated influx of Ca2+ ions, which recruits and
saturates the postsynaptic membrane with AMPA receptors, which causes a
decline in the ability to induce LTP and leads to overall excitotoxicity [301, 302].
However, as spine dynamics were not disturbed in the same way across the
cohorts, the mechanisms involved in spine alterations might not be uniform
throughout the course of disease.
One part of our study in P301S transgenic mice was to assess whether den-
dritic spine degeneration is linked to the presence of hyper-phosphorylated tau
within spines. However, no hyper-phosphorylated Tau could be detected within
spines of the cortex in P301S mice, not even in those cells in which the soma-
todendritic compartment was strongly positive for phospho-tau. In contrast to
this, we and others could observe hyper-phosphorylated tau in spines in the hip-
pocampus of P301S mice [2], other tauopathy and AD mouse models [288, 303]
and postmortem AD brains [304, 305]. The disparate subcellular localization of
tau could be explained by differential composition of the spine cytoskeleton in
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the cortex and the hippocampus. Whereas in cortical spines it is actin-based,
CA3 hippocampal postsynapses contain microtubules [306], which can associate
with tau and therefore may also explain the presence of phospho-tau.
Furthermore, the observed spine impairments could be caused by presynap-
tic or axonal pathology and local network dysfunction. Even though a direct
follow up of both connected pre- and postsynaptic structures is scarcely achiev-
able in vivo, several points indicate that these factors might play a role in spine
impairments in both our tau and the α-syn models. The fact that a subset of
eYFP-positive layer V neurons does not express the P301S tau mutant transgene
is such an indicator. Furthermore, we also did not observe the presence of α-syn
in dendrites of eGFP-positive layer V neurons. Instead, α-syn showed a promi-
nent presynaptic localization, which is well known from previously published
literature (reviewed by [307]) and was confirmed by co-staining with a VGLUT1
antibody, a marker of glutamatergic presynapses.
As another factor that might be relevant for the observed spine alterations in
the P301S model, axonal pathology is known to be prominent in tauopathies [308,
309, 310]. The P301S mouse model has also previously been shown to develop
axonopathy and deposits of hyper-phosphorylated tau in the optic nerve before
fibrillary tau was present in retinal ganglion cells [311]. On the neuronal network
level, homozygous P301S mice were shown to exhibit astrogliosis and death of
layer II/III cortical neurons at 3 months of age, with a particular vulnerability
of GABAergic interneurons [312]. The degeneration of cortical interneurons
could disinhibit the network, thereby causing overexcitation and degeneration
of dendritic spines. A similar mechanism of dendritic spine degeneration might
in fact also be true for the α-syn seeding model. In the cortex of α- syn seeded
mice, the accumulation of fibrillary phospho-syn was observed most strongly
in neurons of the layer IV, which are predominantly interneurons and project
intracortically to other cells like layer II/III pyramidal neurons [259]. From our
current data, the exact functional consequence on these cells is not clarified and
remains the subject of study. However, it seems likely that the dysfunction of
interneurons might also lead to a disinhibition of the cortical network.
Finally, the involvement of microglia as the primary immune cells of the brain,
is another biological factor that could promote pathological spine loss. Microglial
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activation is known to be present in PD and AD brains and both protective
and detrimental contributions have been attributed (reviewed by [313, 314]).
Interestingly, microglia have also been described to facilitate spine formation
[315] as well as to mediate spine loss in AD [168]. From our dendritic spine
study including the seeding of α-syn PFFs, no unequivocal statement on the
involvement of microglia can be made at this point and could be the objective
of future investigation.
3.4 Network alterations due to aberrant expres-
sion of tau
In vivo recordings of network activity in P301S mice, described in the manusript
by Marinković et al., aimed to elucidate the functional changes that are linked
to the presence of various pathological tau species. A combination of tau seeding
and tau P301S transgenic mice were used to trigger the formation of NFTs in
the frontal cortex, an area in which usually no NFTs develop in this model.
P301S transgenic mice overexpress human mutant tau which is predomi-
nantly soluble and in the frontal cortex of these mice. In vivo network analysis
showed a clear overall reduction in spontaneous neuronal activity in these mice
compared to WT controls. Interestingly, this effect was independent of the pres-
ence of NFTs after seeding, which indicates that formation of NFTs in neurons
does not induce additional effects in neuronal functioning. This is in line with
several studies demonstrating that tangle-bearing neurons are functionally not
different from tangle-free neurons [232, 230]. However, there is also support for
the disruptive role of pathological tau in the activity of cortical neurons [238]
The results of this study on network activity moreover connect to the findings
of Hoffmann et al. [2], where it was previously discussed that local network
alterations might give rise to the structural changes which can be observed in
dendritic spine density and morphology. Our new results indicate that this in
fact might be the case, as an alteration in synaptic input is known to affect
synaptic plasticity (reviewed by [150]).
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In neurodegenerative proteinopathies, monomeric proteins traverse several in-
termediate stages, before they end up in their pathologic state; mature Lewy
bodies, neurofibrillary tangles, amyloid plaques or other types of insoluble de-
posits. Up to date, there is still considerable debate about which species of
protein, whether misfolded monomers, oligomers, protofibrils or fibrils pose the
greatest threat to neuronal homeostasis. Some evidence for the tau and α-syn
proteins indicates that NFTs and LBs might actually represent a mechanism of
cells to sequester smaller and more toxic oligomers into less harmful accumulates
(reviewed by [316, 317]).
There is a general consensus in the field that assigns the aggregation of α-syn
a main pathogenic role, but uncertainty remains about the nature of neurotoxic
forms. A prominent concept states that especially α-syn oligomers have such
a potential. For example, the proteins with the E64K mutation fibrillize less
readily than the WT protein [318] and the presence of oligomers, rather than
mature fibrils, proved to correlate best with neurotoxicity in cellular systems and
in vivo [319, 320]. Protofibrillar oligomers were also shown to alter membrane
permeability, increasing Ca2+ influx from the extracellular to the intracellular
space which causes neurotoxicity [321]. α-syn oligomers can also prove toxic by
disrupting microtubules [322], damaging mitochondria [323] or causing lysosomal
leakage [324]. It is further under debate, whether it is the process of fibril
formation, rather than the α-syn fibrils themselves, that has the greater impact
on α-syn neurotoxicity [317].
Some uncertainty also remains for the exact nature for neurotoxic tau species.
Although, the number and extent of NFTs spread throughout the brain is pos-
itively correlated with the progression of neurodegeneration and cognitive de-
cline in AD patients (reviewed by [85]), other studies challenged this view. For
example, the presence of NFTs was not linked to structural and functional de-
generation in a mouse model for tauopathy [230] and NFT bearing neurons
were shown to survive and stay functionally intact even in phenotypically late
stages [190, 325]. In a reversible tauopathy mouse model, the suppression of the
MAPT -transgene causes an improvement in cognitive performance, despite pro-
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gressive NFT formation [326]. Furthermore, the presence of NFTs was found not
to cause structural and functional changes in neurons in different mouse mod-
els [230, 288] or changes in dendritic spine density and morphology [327]. The
maldistribution of mitochondria was additionally found to depended on soluble,
non-fibrillary tau protein in tauopathy mouse models [328]. On the other hand,
there are some studies supporting the toxicity of higher-order tau aggregates,
like prefibrillar oligomers [329, 330]. From our present data on structural and
functional alterations in the P301S model and from tau seeding however, there
is stronger support for the toxicity of soluble oligomers rather than NFTs.
While numerous studies have addressed the molecular mechanism behind the
toxicity of proteins like tau and α-syn, it remains to be clarified whether a toxic
gain-of-function, a loss-of-function or both is responsible for the degeneration of
synapses and neurons in diseases like AD and PD. Future research unraveling
the disease mechanisms will add to the present knowledge about the potential
points of intervention, leading to the development of effective treatments.
The combined studies in this thesis demonstrate the impact of potentially
toxic and misfolded proteins involved in neurodegenerative diseases on structural
plasticity of synapses and on cortical network activity. Chronic two-photon imag-
ing in live mice enables the study of brain tissue in a time-resolved manner during
the progression of pathology. The present studies on spine dynamics in mouse
models of alpha-synucleinopathy and tauopathy provide a link to the pathophysi-
ology underlying dementia which is associated with both α-synucleinopathies like
Parkinson’s disease and tauopathies like frontotemporal dementia or Alzheimer’s
disease. Especially in combination with site-directed seeding of pathogenic pro-
tein species, these chronic imaging studies enable both the study of disease pro-
gression and the evaluation of potential drug candidates and their impact on
spine pathology in vivo.
In conclusion, studies in animal models as presented in this work can be of
advantage for the understanding of the very complex facets of neurodegenerative
diseases. Piece by piece, they create knowledge about the mechanisms of synaptic
and neuronal death, which may translate to patients to improve clinical practice
for better diagnosis and therapy.
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[61] Burré, J. et al. α-Synuclein promotes SNARE-complex assembly in vivo and in vitro.
Science 329, 1663–1667 (2010).
[62] Burre, J., Sharma, M. & Sudhof, T. C. Systematic Mutagenesis of α-Synuclein Reveals
Distinct Sequence Requirements for Physiological and Pathological Activities. Journal
of Neuroscience 32, 15227–15242 (2012).
[63] Vargas, K. J. et al. Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis.
Journal of Neuroscience 34, 9364–9376 (2014).
[64] Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O. M. & Südhof, T. C. α-
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Deutschland, Österreich Und Der Schweiz Auf Die Alterung Der Gesellschaft Vorbereiten
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401, 273–294 (1931).
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